var title_f35_29_36304="Erythromycin: Drug information";
var content_f35_29_36304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Erythromycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12624528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26419?source=see_link\">",
"       Erythromycin (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/6/25705?source=see_link\">",
"       Erythromycin (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/28/31171?source=see_link\">",
"       Erythromycin (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9418 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36304=[""].join("\n");
var outline_f35_29_36304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26419?source=related_link\">",
"      Erythromycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/6/25705?source=related_link\">",
"      Erythromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/28/31171?source=related_link\">",
"      Erythromycin (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_29_36305="Inferior wall left ventricular aneurysm apical long axis echo";
var content_f35_29_36305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/72045/aplailva_conv.mp4?title=Inferior+wall+left+ventricular+aneurysm+apical+long+axis+echo\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricular aneurym",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 240px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical long axis view from a 2-D echocardiogram shows an aneurysm of the inferior wall of the left ventricle. The left ventricle is diffusely hypokinetic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36305=[""].join("\n");
var outline_f35_29_36305=null;
var title_f35_29_36306="Amyloid AA IF";
var content_f35_29_36306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunofluorescence microscopy revealing secondary amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 258px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAECAXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5xhv5HYByzHGOTkVLcyNJtXbtFGmrFE26XnvUupSq6boU+Uc5xwK89257JHmu3NaKK8iRoqsSC3c1ZjbZACOcnn2rKG6dtzHAHpVm4Z4YAvTfzVShsipQ2XU6Zr2zvNKdZtqSxjCj1rnV+b7oJNVIbhjIFbkE46VuRxxJANufNzzn0rH2aoadzL2fstO5NpqCC2ad41fdwoPrWpaQRrFJPd5jcDhccGsSO7eK5iCkMEOQD2NX3ma/ulEhIj/iIHSuarGTd2YTi73IvnvZSsKkei0lzoV3v3SxsCa7jwxb21nbTXG1ZFHAYrnFJ5r6nuW2GVjyfauN42UZtQWiMXiHF2itDjLLw1cTTAbdo/vN0rstG8MWUMMrXl2coM4Xoa0tMS6n0WaJLZQyHAbHUmufe7vome0CbnJ5zWE8RWxF4qVrETqznpcbCdJku3REQ44ANLfW7WkoEQ228nQ+h70yz8J3RvVuJGWNF5YscYp/jHUbcWiQ2TBmQ/M47kVaalUjCm+bv5CaTaUXe5atZNLWB0vYXckcMO1YFwsTlltgR82cdgKyU1RnTbMSCBgMKuabFLNBNJalmZeSMcGulYd0byb/AMjX2Thq2WbXNpfq1xGHkI4PY5rn/FNu/wBqMpA2ntXTJbSTWhuD8znk452/WucvhLcSmOTJGetb4aX7zmvtua0JWnfsc/jnPFSrcSqu0O2KvX1lFGoEZ/eAcj3rNVSxwOTXqRkpq56MZKaubWgaRdamZHgUvjrVvVoVtLURsuJwcEHtW34FNzZWU0se3b0OaxtRJurqd5iN5LY9M153tZTryT+FHDKo5VmuiMbzWjtywGMjBFUK6ZI7ebR2RVzPnpis7+xLryfMx8tddOtBXvodNOrFXvoUrCF7i6jiQkMxxxW1NZS2NzH5ybhnPsaoW9tNZzLN91l5FW7nUJ7hlad923p2qarlKXu7E1JOUk47G0tzdJqS3NuqQAAAKOgqn4huri8lWWYKV6blHeqzXLyxKVBGzgKKFYyWzqed3P41zRp8slJrbQ51CzTfQn0mMSWzh5Me2axNQtxFcOVBZQenrVmRTAVPmc8EgVordW9xbrGIlMvHbitU3TlzLVM0TcJcy2ZT0OC5SKSeMfIOxqveyNJOxb6V01wbawtFlt33q64ZM8g1ytxulnDRjgk5Aooz9pJzaCnP2k3ItTrAtikkZP2isy4uJ5ECyk7eoHatC2hEgKs21x2NF5Es6onG4enWtYSUXZ6mkJKL1MermlwJPPtkHFX10QtamUPgjnmqVsJIGODwfStHUU4tRZo6sZJqLLGq2CrO32cgqOtZboUOGq/PIY8sJDu9fWqMz+Y2T6U6XNazHS5rWZYsXjj3GVMgkYNdPd31oujKkci5HOB61j232aTS2WXAlAyDj9K52RjkgMcZ6Vm6Kryu9LMj2Sry7WZbe4M4+bBOetU5iC/FMBIBwaACSABXbGKjsdsYKOwlFTNbyKm5lwOtRgEnAFNNMpNPYbW1ZXEc1iIZCFZenvQ2mRHS/PjYmUYJFZq20wIby3C564rFuNVb7GMpQqrfYmKKzFSRgHqatJYsyKQ64IzVdH2BgQOeOajpO72ZLu+puae0cchWfmNhg8VrapJaQaQkFuUdmOSe9ZJtuo3fpUZEKKd8hJHWuKUFOSlc4XFSaZBDHn5tvyDrTbx5L67/AHaHA+VRTZJXuiIol2oPSrdsy24X5TuHUmt3eOvU3bcdepHZ6bO9zsVCzgZxjpV65DwfIxyw4JHY1r6Y6PZXNxtkjmYbQV6YrDlilywJzk9zXOqjqTal0MPaOctegtjEZJix5Heuq0qwmuFMcUQWPGWbHJrDsYXI2qpzx0HWvV/B2t6baW0dtdWzl0GWYjrXn5jiJ043grmFeV9DE8LOLC5azvLdpY3bCj9K9b0LwVpZcvCphWUZ2kj5fwqhLZaLeAXGmIwmxuDnnmub8Xa3cwXBjileGaNQMqfvV8vWqVMbO1JuLe//AAxgpxhK8lc6XxItvoUDQWmyUgndhe9eU2Gt2n9q4uFCkMSWbsK1UvdW1GxxKWB/vnvWdZaVoq35TUZ2yOXI4ruwlCNCEo1Xd+Rno5NyKuvale6nfvDprsYDxx3Fcjc2U8d0YZGLHHT/AOvXoWva1oemRsmlkEgcYHJ/GvOrjUrm7uXliTBPtXs4Dncfdjyx89zehzfZWhDY2pluTDIVXnBJ7VcvUl0xStrMdjddprLWeRGJ3HJ65psrvLIMsfYelek4SlK7eh1uLb12NfSb+5jPllyiucEn+dR3IKyEswbn5SKpxqyDJJJPYnpVm0Yxz/vVGzOcGs3BJuSJcUnzI19LtbG6vkk1JSsJTD47H1rN1TQ4v7ZeHTyGQH5WrasIEuI5FQgyDJAz1FYl7E0Fx+6LwkccGsKU5e0dpdNuhlTm+eyZNfW8+jxJDHMfMf7ydqn0DQpb3zZWOXAJH1qncncUa5uPMkIxz2rYtNWWLS0t7IhJ933weSPSipKooWju92OTkoabvqZEu2KZo0ibzcHJA4psmo3UFv5MiKR1zmt2ytL9JLm4CqwQZYg9KxtSuVnLKQFJ4+UdacJKcrWvYUXzPlauZc92swy4IPoKdZLDOVi2N5pbrnjFLe6dKtuZDC0a4ySazILmS2l8wjB7YrtjFTj7jOuMVKPunf3dlaabpscwZWkPUZ6Vy3mG5ucxjaPT1qtcaibmJQ7kt6E1a0aXyLyN2XKHg8cVzwoypRbk7sxjSlBNy3IpYhMWAViw71HZBoZsjIPpiur1q1s4JopbJsiRcsv92su+s5YlEzRlUPQ4op4hTj6ihWUlYrXcSSyBmcgMMkVe8NafanUYl1HcIH4yBVzwna6feXUq6pN5QCZQk4GRXTWmraUblrEQxEICBKw+9XJiMTKKdKCb0M51HD3Uc14z0K3sESayDGNv4s8VyfluVyvGK9A8UXVpdtDaW6ExRj/lnzXOwWcAt5fP3LIDwMVphK8lSXtNxUKrUPeOeJuCCMsfatPRdLe/mCXEyRL6scU9bVtw24z25raGjRtaLKsrCXGSR3/Gt62IUVZO1zapWUYnMyaeUDEMjkE5UntWaLdWu1RjsQ10MNtIs0siEYXj5qyp4TLKd4xk8Gt6dRu6ua06jvuaFxpNstpu87JxniuYMBYMApODyQO9a80LRYU5KGrOmXdvb7lmTcCCKqE5U4t/EOnOVNNrU5tbOZ8lFyB3xUtjH5V3H5i5+YcfjXQwanHbtJGsYKE5BxWPfFpJmlCbVPpxW0asptxkrI3jWlN8rVkdH4qMMWmxrHbhZCAc/hXIWSqWG8HBOK0zJc3CAXAaSMD8qbFamKRGcZVugNZ0V7GHI3qZ0rUoOLepHMk1sREsmVfkAd6nnlvLaNROBsboCOtWLiNmuBHEu4jj5fzp/wBhu9QbdiR/K657UnNaOViedaORhXIaQ7sbSTkUlalzaFMGcEYPQdcVcSayCKPKbgY7Vo61krK5o61krK5R1G8kMpVThfas/BbJ5PGamulLTYAzxQylYxhfm5BwKqCUUkioWilYsaWcOeBzxmpbrJfcRjPSp9Ejj89I5QMOQM+la+uaTFFfRw2zeYSATjmuadaMatmc06qVSwzS57kWSqFHlD2oEOWaSUceh6V2GnXenWHh57SW03XLAncTz0rjJJpHlIXpnpXBSqOpKVo2/U5Yy55Pl0N7RZFTUIS0aFSPl78+9amszzPFLNBDtC8F8VxUN7JBMccMDkg12dzryT+F0tQ6s7PuZQOfxrnxFGUakZJX6GdWm1Zmh4c1+4tbPaW3ZGct29qRvM1CSa4fL8856CsHQbO81CWOC1iZyXyFHevTR4UvNL0Zmvh5UjIQEPqa87FSpYee65mZTg1eSOCg12SCX7OxBhTPFYFzFNfasZovmBIya6ZtCWysria5ILsSQfT2rB07SNXA+1wW8otiThscGu6jOkuacGl09S6bSu0N8QeG5EhE8YIOORVbS7dLO0ke5ADEfKCcZrpJdWlNuyXUTMcYJArkdQne6uCqg4/uitqEqtSPJPYqnKc1yPYxpx++bAIBPFWre0lcgxqzHHQVp6LpEup6pBagYZ2wPWvpTw18MdNtrGEXpjDAZLcAmozPOaOASU9WzvjGdTSmrnzra6BeKiXJh3qecYzis7U8GcttKk9a+vNY8M6Vp/hu5jtUCvsyGPOa+VvElltv5EOR8x7VyZTm6zCUna1jnqxnRrKFR9LmFa3EsTnyz8o7981enuFu1JO4Snt2NZzxyKRsBA71o6X9nSRvtXGRkGvbqJL31uVNL4kZlzDIT0+6OldB4b0tp4bhnhLMiZUHiq7XduZGCqGVuAcYp2nahdafeh4XcxE8jrkelZVZVJ03GOjIlKUouOwyK6vrOaSCKZk8z76npVCK4aDUg7AOAckEe9dLr8umrJFd2cgleUZeM9VNc3Nbm4kaQjbnkfSijJTXM1a4UpX1asafiKaa9svNtgSh5NcM5Ysd3UcV2VuJzbPaxOGZ/l21kT6HcBmfy2IXnIHWujCzjSTg2bYacaV4sy7FVaZQ4+XP3sV3uj29o9/DZEh4piMye+K4+OExOFZec9K1Y3a3jQFcN94c4IoxSdVWTHX9/Y3tRs4bLWxBav56qRxjv6Vo+Kr2aXSkieJETGQF7VlaZDeLKL1E83B5zzUeqPcXN2Y5EJbOSg5Febyc1SN3fl6nBy3lGL1sYPIORWnotgLyRi0qRhRn5u/0q+2mzSzKHhEW0c+1WrSxVJsIm5icD3repiE42T1Np1rqy3L9rBHboVtkUse55ZvpT08KatqUMk1vA+xcZyuK9o+Gvw5htEi1PU8vOyArEV+Vc+tekwadFCJFkRWQ9OABivjsVxFGjUcaK5rdTvpZTUaUpOzf4Hzzb/Ced9GjuJpGSZhuCgfzrlrrwpqke+JCSi8DB6/hX1bdWzXEexgUTpwO1VoPDunQy+bHGGYnqwzXJS4krRu6mo55XOc/3b93zPj290O+txgxTBh/s8GsS4t5oHaGZCpXkgivtnUfD+ms6zTQKEQ5OOK8N+Lvh3TZ5pLvSyY5OpBGK93LOIY4qoqco2v1OTEU54O3tGnf+rnjjWQuIMx/dXndWYtk0khjQZcngVoxE28rxzhlB4IpBFJG+6Ig4OQwr6iM5RurhGTj1M6S0a3lKS/fzxjmobqNym124/lV++aWeXfJzIDzkVTuFIA3dPat4Sbs3ubQk9G9y1oV+tojxXMalWGNx60uqIzWoKoF43DHpQJLL7IAVYTL36iqrXLFGAk++MbT2qFG8+dKxNrz5khmgaqdNvRK6CRSMHNddJqcdpp8s7DC3A4C9jXn0iFHKmtuC+NxZLHOoO3gYFPE4eM2p29SsRRU7SNWx+w/YpLyeRXYDAjJyaRBaFFO0dPas+7toZYFjRDEyrli3essWU2BhjiojSUrvmsRGmpXbdjSh09nieVsAAUgtFMQVcFzVu8eaG32OrJgVQsJSsjSE5xziqTlJOVwTk02BiaKNXBIYd66bRLaf+zJr0AyyA4PfArnZrkTFEA2Rg10lprMumWKR2eNrcMCOtYYnncUktWZ1uZxtbVmalxK9yxlJDN2NWdU0m50yziviy/vPmVe4FUbi48+4Mz8d6o6jqlzelVmkLInCg9qcac5SXLouoRhJtW07lcu0s5IyST1rpNDh5VQMyPwB14q14Q0WynsZb/U5PLt14AAySa7HTbDRPsj39hcmWSP5FRlxya5cZjYxvBJ6abaXJr1FZxXQ9S+CHhq3tba4v5Wje7+6q5BKe9dL8SNMkk0SS6jY74lyR61a+Geix6V4cglIJuLkb5GP6Cupu7eO6tpIJlDRupUg1+ZYnGSeNda97P8j24YH2mC9m9JNX+e6PnzS7L/AISeG3N1GUt4eXwMZxXRXesIIo9O0qyV7eH5C2OlT/E0r4O8OlNOC7pc5x2HrXn/AMNtWXUNR8pJm82QEsrHqa96EHiaLxKXuLZfqeBOEoSdJfP1J/Gujvbae92YgueSVHWvNozDBGzhcyP69a9z+JGoW+n6GlvIUaVj93PI/Cvn/UJGe6JQALntXtZNOdaj7xkoWm4LY6X4dtKniWO6WMyFDnbjIxXpuoaX4p1zVVurK8dbJGHBfAUZrzTwFrJ0e8a4aDfGwK89zXZW/wAQLu9vorCGNo4XcbsDA61jmNKvKu50orRbvXQ2bjzJO7t0PRNUv5LG2ihvplmSNMPg5zxXiGt3GmXl9NK5fmT5Vx/WvVtS0yC/tXEs5A6bfX8a4m18HWst7KtxIRbJliR1rhyyVGgpSk3fyMaknOpzSOS1dbCOyjeyZjKeXBAwK4zUAS7jnOa9U1Twpa2TY84rE54B561yuteGpbHfOUMltnG8V9FgsXS2TvfuVRqRi9TkrJiHCsPbPpWzpkwCyWzpmZuEOe9QSx+ZHtgiMaZ78k04wTpEkhQiVcEHvXfUamtTonJS3HX+mXVsV+0xeWTyTio4Fl2LHJlU67h1ArRu9Tl1W1SOYuZkGD/jWZLdyrGIZFA2ntUQc5RtJakRcnoy1qEMcTh7aVygAYMeCDUkGuSxRMjbW3LgnAOavabp41LTJpbVGPkr82W6VzlvZS3MrRwoXZevPFTDkqJxn9kUYp3jPoPeWEjzFG6Q+tQSO0jlnOTXVaV4ZM8So4Kse56CszWNGaxvEhBzuOM9jVQxFJz5E9S41IKXKWtK1qay057e32MHxnIzg+1dR4ftpbKCXV9QhDOw/d7h37VQk8IfYdPgu5JgBJyQxxiptLlvtVuINPV3dVYKgzxXmV506sXKlt1ZhL3240/ieg/zjcSyXF4GO4YyhwBW/wDD+2hm14xOqcrwXAIX869D0P4d2Nnp1xPq+ZFVCfxri/Bt1b6f4pltfKUwvJhHI56148sdDE0qsaH2V8vkaLDuhUhGfXofQtgWNrHvHzbRn8qe5Yvswu0jNQ2ksbKI9wEkYGVz0qaQyBhsCle5J6V8J1Psm7xuggLEHeMc9KeSqjkgCoIGnMj7gnl54POaZcDfdIADwME9qfLdkKdoJr0J5AJgyFcoRw3UV458VLKO3vgJW2xvxXpus64mkGISx+YW6qnUCvMfiZJZavLFcyTMFjIIU9favYyeE4V1J/Czwc6qUqsFFP3k1c8Z1jR447t0u2C5G5JB0IrlryFraUojlk7EGvbLuzsbgCS5tPOk4G3kALj+dULjwbFdqJRaGGJzhFUcg/jX21DNIwS9oeTSqOOj1PIHm3xbWHzetV5V8xcN2GBXuB+FVnJCGLzFieqjIC1y3iH4dSWqN9jd2YDOCuOK66GcYWpLli7HR7WMN1Y8peJwdoB5qvEjQyI+clexrWvYJ7SdkmVlYcYPUVI6289kd6ss6jhhzur21V0XVM6lUsvJlvw5oieJBcOzBGhXIwPvGlsBY2WsBb4gLH2C9ce1VNC1a60W7ae2XDYxzWXrt9JqN+9xMoVm9BWCpVKlSUW/ca08iVCUqlk/dsdD461e0v7xJrKNFCqFO0YBrnBqTAAeX+v/ANan6VBZyo7XTkMvQDvUDpb7j9fWt6NKnSj7JJuxdOEKa5LXsdn8QLyG/wBauJLQKlsCFRRxwBiuSRTk4zgVfvkcznJOCa6bwnoMF5aTz3IO1Bn61yqpDCUFfZGCmqNPU46IfOoPIzWvPFKkCFh8oqWDShNrn2eLITdxntWt4sIs1+zIoJUYLdjxSqV1KpGMeupE6t5RSOaKllkyQFC9az403P681oHKWbs3Jbg062gVI5GPpkHpW6lypmyly3O70ewXU/CaWttKol5Z171o+FvDctnDIzxl9pySeAKwvAP2uG6FzAMRRHLE9xXsnh6+tNYUxzQrFFkZdeB718tmNeph3KMdYt3ZxSi3JxT3PUPBmoR3+gWzRAL5aiMge1X9Znnt7F3tYzJKeAKzEk0/QNF3WbKYzyuDnca8g8V/EfVZdR8i0IWFT06ZNfF4bA1MZVbpL3b9T6Cvjlh6KpSd5tdDa+JN7pws7a21dGeSQEsVOdp9K89tLTTbG+W7snSKNec7scVk+MdRvL2aFrht8r/wjoorNtLCXUVlPnLGkYz9a+xwmB9jQSc7J79j5uUnOTnsN8Y61JrutOyO0gGFXHetfw54M+02El5qJaOJQCM8Zpnh/wAPNb3YlkCqynJz3rZ8aeJ5BYrY2kS9MEgYxXVUrS93DYXbuNzSjyw3OX1IQNOkNkPlXjHbHrV7STMs22Bgh4BYjJrPtUFtoUuoyJuk3bf/AK1N8N+JYIrxPtUG47h0NbTpylTkoK9gjBvRdDvPEkeo6Xo9u0TySSSjO4dAK6vwhptzq3hKUyIySFRkuOfwrV07xTo2oaPbx3NiqxKMF3GQPpXoEC29zoP/ABLwoheL5Cox2r43F46pCCpyhZ33PSw2Bp1faOMrq3zPJLnwnFqEC2lzc+VFEeWq1rNhocOmQ2lrKLgYxtBzXOeO9W1KAR6dbsRNI2CBwa7f4e+AjY6St5qBk+2SLkRseAPSuitKVGlGtWqddEuvmcuHoPFKUKcdOrPK7vwwY7kOAttAf79c5r9jLYSFXKsnTcOldx8Un1D+0I7OO1YKzYUqDzV+bwvDfaVFBdzKtyiA7D96vYo4104wqVXpI44xbXMtkzxyOzIY3EbgD603VLKSOJXkQZkGVOelaniC2OlX72wU7fU03UHE2nJkhgoGDXtxqtuMlszVTekkSafpN7beHpr23mxGRhgGwaxdKvZ9OuZXhUsG4J7Cm2msXsFlLZRO3ly8Fa6rw/YyR6Y0d5afJIN29hj9aVRuipOrZ3f4GlT3OZy2ZljWpkG0nBPJIPNSatfJcx2qQxlpkO5iepqm6R2mssZU+RPuioHuS9+8luMFuBmhUotqUV5mainZr1N3Vten1qOCHYsSxqFwPUd66n4U2Rm8UWkeM7TzWB4a0iS9lS2t4gZ5jtB6nmvc/Bfw5OjFbua5ZLtR8gjPT65FeFmuMoYajKgnZtOx3ZfQlOqqkY3indnodxBHJZSROgaNlwV9RXjniDTtO03xXZXFvCViRhuQH3rvb3UtU03f50EkkJ+VZCOlcReYvL8q/wC8mLbuP8K+Zy6EqXM2/da6M1zPExqzg4q0k+q/AseK7jVrDxEL7TJZDFIc7V+7tr0fQ5p73TYZb1sO4yRjFc7oxWQw29wjGTGCAvTnua6+K2i2oVHC9h0rkxlVOMabVmuvc78upSXNK94t7eu5M21I+eFAxx2qupjhBYEkcnLHpVlsY5HH0rH1+5jhtS5ZQuOcnFcdKPO+Xud2Kqeyg6nY5jXbxb+4l2xMY1JBbH9a8tvGim17e3mPFC33c5ANehalrmkLYkSNcKAMnysfP9TXDXl9HPdwWel2bRRySAsxBJbJr6nARlBNcrSPkK/vVVJSu/1Z2vhnTzq0r3EUCrEvTcMZNdkdJDxqJdpwPlUDge9TeGrNNO0tEbuuTxWvGOmwdRkn0rwMRipTm3HZbH0eHwEI01F79TIaCKyt/mchD8uQM9anls7Gayc+SJPlIzjnpSXrh7vySCoY/Nxmrc7xxQec7bUA78AVg5PR9TSMIe+mlZaanzj8VfDFg8Ml3C4jmXO7cuPw968UjYq+0HgHgHgivo74ravpF7YTwwyDeQQfrXz1d26LaGQjDBtoPc1+n5FVnLD2q3+Z83h5KMpQTur6dhl3JKAkjhWQjGRVTVljktopIyNwHzU9S4iMbZ2np9apXaNsYc59K9+nGzR2wVmiK1tHmjaRW2heaqnk81ZtZmjilC9Kq11K93c6le7uejDRGmn2uwDAfnW7o9wum2cttEquzcA1j6jqv+khrU42jFUdL1IxNLLMMknIY+tfOzp1K0Pf27HiWnKOpq6crfa5G2lXds5Iqp4sjz855xx9aZeao1ukcyON5OcGrmpXMOqaSZ3URyBegHGaIqUKkajWmwJOMlNnNXLRHSkjiXMpbJ9a2/A+hya5fJZwxmRyRn0A9TWdodvHPdeXIBtIxX0r8N/CNlpumpJax4uXjzIwOc89KwzfMo4Gi0viex2Rjzy9miLTPCGn+H9MWOZIppZSA7A/KvrV6DQLe6jlk0lsBB90DANW/GN8kFrFbRqPNAAZBya1vDUdzFaQpAIo0lXLMeo9q+GqYit7P20pat9S4UqdWq6dtF2OOv7a6ttOD5ZnCFQvZa5lPDsNhY/2hqEga4kG6Mf3eeter61JB9neJAm1D82RyTXjXjW+mW38pxtHOz6V35fUqV/dWl3qcWKpqi7RdzhfE+pQPfP87E561zkms+WSkWQvqDVO+V3uX3bs54qv5JXhl575r72jhqcIJPU2pUIqKudFpPiK7gmLPJkEY+atPTryLVZyshJcnJHc1x5UEDNdp4Nk0rS2+03RMk5GEAPeufF04U4OcI+95E1acErmpo6RzPeaVP8ANbSHOPRqzbjw5b6ff7txYfwirMs6x3TXUbgMzE4FbltpcXiJoZReJbhCNwLYxXmyqyovnbtF7+pzRcm1+J2+j6Glr4EaeTBlYchsgj6V0/ww1tD4Te385TJbZC+wrjrnVbZoo9EhufM2rtB/vGqnhWyvND1CfKtFCfvFj1H0r52tQdajP2r1b5kddHFeyrOVPZq3/BJ7zw9qWo+JYtUCNNbJMCeOnPSveJPltGwDwnQVx3g25WNJZY5la1bnbnvXaRsJIww6MM14uYYidWcYSWkdEe3lVGMKLUXueP32r/2jfXkPkLm1bcCyckV50NSubjxAZJ5SmJMdccele2a1ocdhf3F6ULxy9QK8U8fWsMuoiSzUxkNn0zX0OVzpVW4xWjW/bufN16cqNSKq79f8x3xB0+CSxNxGD5gGd3tXm3nM1sY1fgHp6V7XIY9Y8KiQRx+Zs2vj1FeMzWrWt9KHjIXd0Ir3sqq80HTlvFip2jOUH6ozkzBOrtyVb867+18RR3emxQvuATA3f1rip3S5RwqgSL6d62vB/wBkcPDfHBPTdxXdi4RnDnktUbVVzxu1sX/FsWnxWsX2GVZZHGS4681mWGniGISOwJIAAB5Fa3iLT7GEwrAxxjJwc8U63gja2jAPzk8+wrlhV5aKSb+ZhGXutLudV8PNTGk6pHciHzmKMkf+y3rXo2ieNZ21SRNXmEXGE+X5QfSqfwn8M291arf3MfyxttRT3PUmug8WeB47+Y3FmqoVG4jOCa+QxuIwtbEyhUWu1z1KdHF0qUa1PVa6evUu3erC/tfKMyOW5AQHkfSvPdWv4dBaV7MBr9hksTjZ/nNdBYWcmmW0jOkodEIHBPNebw6Ve6/rcpAdmDElepNVgaFNOV37i/E48TVnVnH+Z/kdb4P8cTyzrBdOkbvwXI617NaOHgRlcMuBgivPbHwtZW+nRGa18uTbg5XkmmpJqejTIYpmMHUxzDAIrz8ZTo4qd6Hu/qephcXLCLlrK679j0K882S3JtnAbGRx1rI1LTGv9N2SsPN28g/0p2h6tNd2ZluIo0XsYzmtKOeNwOd5Udu1eauei7dUz0akaOKj7z0aPN9Q8HTm2KqvKg55xxWZ4c02603WIGuIhJEr85XsPevR9du/Kg3WyO2QchBk/lXK2XiSRP8Aj7smDK3DHoB7169LEV6tJpq6Z4dSlRw9dcsrW18jt0u4LqNQWEZyAMmtDGEyGAHrXjPiHW7251IJplxFJg52jj8K66zv9T1PToIo/wB25ADDH9a462XypxjJuyf4Ho4fNFPmfLd/mWNUvGk1fbDcgRkgZ/Grup6xb2WlPJesjxqpIAPLYFUW8MzraEt+8nZsnacYrgfiJY6vaQxR3MSLbM2FKnOO1dGHw9HE1IwUtjir1sRh4ybjrL7tTiPH+pw6vdCWCJU39BgZArlNTt9OuNEC25BnT7w969Ak8J/a3VHOHC4x0Irz/wAQ6c+h3s1sDlW5565r7bA1KbUadN6xPIh7rt1vc4svumUf3SRU1wqyISFw/bHSomTbNnBznPTtW3pdna3Ntd+bKI5kj3Ju/iPpX0FSaglI9OclFXMO208Tq+ZFQgdD3qg1ooYgseK02jMkqBSQW4yK1BoKAfNK2e9W6/s/ie43W5N3uV4AJ7uNGJCM3X0qzrEEEMm2zctCDgbuuarWcbNcbVGW6Vo29mi3MkNxnLD5a5ZyUZXvt0MJS5Wc/MWyM5AzXRC5jfw/5eNrLx9ayblUDMhX5geaskr/AGYQp53D8aupaaj6lVPeSI7mSO2ht2gYrMRlmB6GvZPgr4wvFF9DeXZwkY2BvQdhXhzN+9VMds5rvfhTaxy6nc3ErgJCmSufvCvPzbD06mEkqi/q423TXMnqj2O9s/PZtTaQsJGz15xW1/a9rYWUZuG78gHkVh39/b3Gl2ENlIgMrBDjnYc9DXLeNAkd2IoHZo0bazA8H/PFfG08P9YahU03+5HM6rotuHX/AIdno0Fxb3mnXesTgfZ1BVcnnFec+IWs9cJmWQrHGpAzxtIrsNNglh8KJbsmbaYevA7k15T4yW0tkZLG4b5Mqwz1NdOW0U6rUXrey9BYiTlyr+rmBdWMG7zWZQcZDVzupSRbztO5vWmSXMsjbTKxXPc1o6J4cuNXvFiiGQcfMBmvs4pUFzVZaI1hDk1kzOsLOW9lCqCF6k+1asWliK4UYZgDy1dprOmx+F7CK0MSSXLYYuOoFaOjxWGu2zOsPltGvzZ4ya4KuZNx9pFe4ZzrSle2xyw07iFwpw/WtmPRlDbreZlcjhWON1UNR1W3ttSS2icFE4yOla0lnHqcUbR3yRyIQwjz972rlqzqJJydkzn1evQoDTrpQDFBMZwcgqDkH61u2Eupx2phvY7geYp+dwcj8663wvrFxbyC1eKBX4QGTkj3ruZrzT7p/supGMvHyGUCvFxWYzjLllTujrp4eNWPxfeeZ6Nb32h6RcTQq7+bjDN0Ar2XwbftqXh2znddrFApGc9OKy2/srWtPms4wY4k4U5xmug0W0isdLt4IABGigDFeDj8Uq8byjaV/wALHuZZQdKpJqV4tK33jNfgW40uZWyDjg+9eFa74X1K4bz2OLZiRvB/pXtfi6YxaRIQ+3IPNeZx6r/begyafbzKt7b5YY/jFdWVzqUo88Nr6+RwZuoTrv8AmUfv1/yOF8PpdaXdva3CyfZ3JwzDH0qn45sYkjLL98jIOOTUlz4j1Cyl+zCEPcKcZYVBf2WtX+68vAm5VHyZAwPQCvqaanGqqs2lfz3PFlqlLt1PPIg0Mxbr1/CrKDfIGjBVxzmrd8/DL5YXJxmp7K0kijgkUqfM556CvblV05mdfPdXZLBC/AlJbuSa6zwno0+qXsMMKMdzZ6VhXSNkOEATpkDjNezfAy0P2S5upFBf7qGvCzTFuhh3VW5pgcP9aq8jdluz0PQrA6dZwWVuCIoRhm/vN3/CteOJUzjPJqQAKKWvzycnJ8zPsIQ5UUr20ElrOsJ8t3U/MBmvM7C9vPC1xcyfYIzHK3Ln73WvWa5zxhoR1TSpo7ZlSTacA9K7MJWjF+zqfDK1zzMwws9K9DSUV0M3RfFVtdLI122MvjBPAroJ9Ptb9UlkQSgD5fpXkOh27wWssNxuaVG2Ng9cV2vhbV7xIpIvLDRJwu5sYrpxeD9m3Oi9jkwuOjU/d11fTT/gnU2WmtBEVZgB/CqenoaztTBtwrxlgRwQTVxtdtrayWa9nijcjkA5xWLJqn9rxNIsarFnAJPUVyUoVHJyktDoxM6Sgo0n739blxJ4oLWWeAgzbMlCa50a/b3TmDULKNVPyl4+K0pbDDh45NyMMYFZPiXSPJsy6OI3YhtorroRpOXLLd9TzsROqlzJe6t18zkxbWMOt3EsqMYFIABP9a9h0WxgtbGBo92NoI565ryIouoSvbi4giD/AHMn7p969hspVsNOgjuHBaOJQSBweK0zVtqCvr2N8lUVCUp7K1mWg7Bd7ZDA8io7q3tNUjaK5hEqj+8vSmPcymPzkCPGwGVzVu2dXiDIpUY6YrxneHvI9qNqnuPVef5nm/iPw6bDWVlspHMboSVJyR7e9eb6t4K1fxDPeXbrDDDGdod2xzX0VHHDOQZYgXyT8wzmvPfjOhTw6sFm5jZnBZU43civfy3MavtY0o/E9Ls+fxmAp0Yuutui9Wj5l8YeHL3QLoLdruBwySLyprDDeWWb+8On4V7P4/s/tfgq0ZG3/ZhtYPyRx614u3yooYAmv0HLsU8TRvLdaMwpSveL6fl0LCr5qxIgG/pk1E73KsRv6HHWrcNsXVGRscZ6VA/32ycnPWuxSV7FJpuxYhkNpfLJ2ByR7Grspee/WePcBnNZiHzJVEh4PGa6WGFbVMQqZEdRz6Vz1moWfUxqvls+pm6zp5S+VwQFmAYH09aq6pB9mhWIEMSN2R9K7LS/DbajA81xOVUcIMdawPEGjS2Rbdliv8XWsaOKhKSp82qIhV1SbOZlR22uo9s16L4I0m7s9CuNQjkQ+aNu3uK4jSrGS6uhDyATnPXArvtB1D7BFPZtkqnQZ4zSzKcnT9nD5+heJnpyoisrm5sogof99uLEg9K6DTJbe/0k28hb7QW6k859aqWOm3CaYb9oGdZCcHGRVvSYY7OWC5lbExOduP0NeNXnGSbW6fTucje6ZY/s3xjcacbayaWSyT+IHkCtK7+HiW2gWg1S7RZ7nlRjnNdd4e8SeSERiApJDAY/lSeJruPWNRimmOyC3XEYz1PrXkPG4hVFBJRW90tWdPLS9lzXvI8C8SeEZrLVEtrANcFum0V6V8M/Amo2+ntq97N9mhhBbaw5OPWsPxR4ti0e9C2Ue66B3bz0Nc7N8QPEd7p89n9qcWszfMi17tSOOxmHUI2Se7e7HRm5QvNX7evQ7f7TDrevkzlJUnbYhI9P5CrXiLTk0DTntrMAyyZyUGMCua+HPhfXb3U7WdbWcWgYFmZTjFet/ELQ2tbFLgKrKx2H/Z968rE1aeHxMKEZXXb0JnhZKg6i111PDotHt2k869yG6gE1t+HrO1m1GJoGdjGwIUVV1nRp726iiSXyyBV2x0uXw8oLXBGeRzzXpVaqnT+P3n0OdSslJs665Kz3MjKhSdSOG9qyNR8SRWLvDfOBcAZUgdPQZrEutflS/jZHLAfe4603U10/XXWTbidRhsnrXJTwqi17Ve7+RKb3Z0Og660disovFVpM5VvWul8P+PzZTql5LvgPGO1eUSXdvYW5gUBmU4Fbtz4Zur7TLa4spVkLqCQT0qcRgqEv4uikb0q9SlJTpux6R4x8VDVIVh0ch1Ycgc/561zWj2UGiSNdzZa8kHft9KyvC2mXWgrNNeAN+tTadq0Gt62Le6ZIQh+QseCf8a5o4eNKEqdLWC3fccqk6tXnTvJ/h6FHXZLe2le/ulDSscg46VgaNra6hdziWb92RtjQDJY123i/whcajE6Wzo2wZKq3WvNtK8P3ek6vHJNGcRuDg/WvTwkqFWi3ze8ZU4Ru41NOxT1qMpevA4IOeBiq1lvikActgHgE103j6Jpb+K8SNI1bsoxzWXJB9x3ZSTjgV6VKqpUot9Qpz9xJk8McrlI8k7jkDtXv3wm0+eDTlLfLEMsMHqT/AE614jaBpbuF8AcjvXv/AMNJH/soGTAHdjxz6V81xBUl7CyPVyi3tryOxvQjW7JI+wHvmufm8XaTp84t7m4ww4JrU1+aGLT5GlbG5SFx614tqMNkNSe5uVaWXORluK+fwOEhiE+e9uljtzHHzw1ZRhbXc9xh1K0lgWaOeNo2GQwPFDXNvdRMsNwjH2Oa8astetrS3JkcJEWwyL6fjXoOgLplvpyahZsZty5DE5//AFVOIwLoK7v5aF0cyeIbVkl1PNvGmpNpPiWRlR1gZuSB1rV8Na1LcWMs0kKxxg/KWHDitTxfe6Tq5Qbf9IPG3bnNcpc5gk8jLtBGuCvpXtQ5a9GMZRtI+fb9jOSi7rWz6f0jR8VSXV/p5S0hAVuQ6c/yqnot/qtoPstxE7KiBkKjPFdn4PghmSKWymAjccqVzkV08lraWUkuY1+dfmyK4542NJOhyXsdtLAylF1XK1/8tDyy08Wz21z5ksTPEpI2kYxTNZ8WHVRsWVVUjjB5Fdj4j8K2F/EWgnEbuM+WT3rza7+H+ombZCpIOSCDwPxrsw08HVftH7rOSrSxEP3M9V5aiwS2NlrduJw80jsNpPAPPrXurQrLp4NvGOVBVe2MV8rao13peppDNuLWr9Gr2CLxTJqGmWX2K7EDbFYruxn1xTzXATl7OcH8+h14HFU6WHlGWt2ekWkEiWKpdAdeQK0YxhcYI+tZFheW0ttEi3atJgAknv71YuLtrTTZbh23kA7cc18vKMpO3W59DCpCmr9Et99jRxjoK5TxdpmnarbGa8vBDHFy3PIAqbS/FMF/bNgbJ1O1lI4zXk3xR8W22nz3VvbyeY0gwRnpXo5dga9SvyRupI83MsbSlTUYpSvt69P+CcT8TPF8Dq2l6MpSwTILE5L/AInrXlsCliWbB54qTUrs3d07fwk9OtLtXZtBwexr9UwmFhhaSpxPNpQ5I3e73O1tLayl0NZg6xyrFjHdq49wC7YYdfer2kyMJCjglQOmKie0+duGHNZ0o+zlJN3uZR9ybu9wWBWjO4bGBxitjTYZGMeJMIeCAelZtwjCJnJ6/nmltI7qBVmVjhu3rRP347il7y3O2gv5tKBhljkbJwhzxWfeySfbnjmbzA67sdgSKk0/URf2iWzcTryGP8qoi9MOqt/aA3KBt9xXmwptSempzJO9itYwS2lyXbhWyBjtUllZXd3rbJFvd3I4HetOb7NPfxxWcm7zADyehr1v4d6FFoNs+o6pDG0pOVcnO1f8axxuYfVqbm1eTWiNqUXUlrod34H8Px2vg+1s76MSMVywYdK4TWvCrnUpJ1jCxpyEYYwBXoPhfxVYarBOIplV4mICO2CR7VFq88d/50NrKouHGORgfn618RSxFejWk5Kzb1PYxlChVpQlF6pfeeM688VvLDLGGSQkqyjjI9atWFu99C0glkJK9znimeIvC12Xkkln3SA5yTnHPSsexkuNK1eGIzfu5iFb0FfTRUalP93K7R4Chryvc0L7wCmrXqO5I/ve/vXZ+EfhpYRKHv441g6qG6n3r0Pw1p1tb2wljBZmHJYfyrlfidDqdqY76yvBHCvBj6V4v9qV8VL6vGfKj2Xgo4Wiq1Rcy7dDvdOiht7dYLcr5aD5QBjArz74zS3H2CKOHcY8ZOOinsans9W1mbwl9uszEsv3cNwWx3rnIdW1G90e7l1oINikfMeSfaubB4adKr7V2dnbzKzDGxq0PYpNaJ+VtzxefW7i31NZDI5dOOTSx+ILy8uWYyByeSG5qKS0TUb6WVYjuyTtHTNWtN8Py+aZHdIh0+c4r75+wjG8lrY8dcvLruZ76jdPegyR7hnsK9X0rwza3OhnUrRGFz5RJXOecdcVP4V8NWl9Ag8mIyL/ABqc7q75LK20uL7IJEiLpt47fWvnsxzOLap0lZr8johQ54O6su582Q6fqEtzIXhMkYbnI6V1mla9qGjKtqPLZMdGGTitptQh07Xbu2kdXtl5Y9yc1XvbbQdRuJVS8MV2AWVc8MPSu6piFWsqsPd9DlU3ZNGL4o8XXNxbFIQEHfb3rjrW4uZ5WmTgrzx61p6rpcyXRiU5Vmxknir9lY2+mW5E4WSTuScAfT1rvp+xoU7QW4RlFR5urDw74q1K0vt0krbejck8V0t5c3GuyqbXBUYLMVrkIZLYyt5iny85yp6e1dno2uadFarHaRlZxx8x4NceLgoy9pThqOVppX6HLeN5pgkdtIuAgyMiubsp/wB7Ghyfeui8bTzXV1vkTYp74rM0W1W42nAwgySa78O1DDq4qXwXZv2EwhXf5W7cMD2FeoeBNUNzoklnIAvOV55/D2rh9J0WTV5RFp0buyLksF4Fd14G8MsLjyZN6tHzI+MflXz2Z1KLpvmeq1OrBxqOfLFfFp8jttddofDRWdW3bRsZe31ryDXPKt4jcTSuezAnFe26jZjyYYZpCYMbenPArn/EngDTNZ01kgd4Xxwc8H614mX4ylQaVTZs7swwVavNypq/Klp1PELDWrG5leB169yOldL4Z1DUNOnktreVZLZx8q5/lXGax4WOhX7x+aHIOMr0FW9KvJbaW3McuDG2AR255r6qvQp1YXpap9zyISSacGem22kGW9WeXO185B7VcvvCc+oWshhIJQ5yD94VXstd0+XS1XzX+0K3zGus8P6rbmGN43Z1kOxxnG0+v4181Xq4il7yWx6FDDUKj9nJ/wBO36/mZ/g3TCEj8ouiQna3YlvWulkgtTdgM8juT0JwCavxWEEYbyU8sOcsB3NOFnEhUooBHc8mvJq4j2k3M9yng3CKi0tN/wDgHN67odxeYFnCqN/fLEVzb+Etdh3qurPGXI/doeG/GvTJVMgCxuFweTSzRq0REhz71pTx9SmlFW+6/wCZlPK6UnKabv6nkU/gBNcNzJdyOLmM4ZuME1kxfDibT7pphMfs8Ryq5xk11HiTxV/wjl6II5CxdsuWrj9Y+JlpvnW33zTMuAoHy17+HeYVFaHws8Gf1eMbQvdXT9TD1fXNQ0rVfsqQARnnknce2c1Db+Orq2t3S4aV1XkYPQ9aztJ8S/2jrbNepErOQFz0Wl+JctjGka6e6F3Ulwo5Br244aDqRoVaerW5ypSikn10HSfExksX8lXNy+c7ugrzXWdQnvrvzp5C7ueSarKCJeRnnpUktpcSlXjhcpk9FNe/hsHQwrbgrXO6NKEJcxUlj8pVcHpU0TlkDEdTT0USKVmG0/1qHLwYRl+nvXZe+nU2vc77wBY20t/ay3jZhdtrdyDXuI+GWkSgSB4sP835183aFfvayqFbABDY9ea9MTxpLsX9+446AmvlM3wuKnVUqM7HO50ofxoc34HmsuHaRHHyjkGnNfJD5SpjCDnPeor5tkuT/H3rMAIlAYnOa9+FNTWpEYcy1NPTrp7bUDMB0+atfVb621q/h8hPKdhtY+9c7FA0jSEZ54FW7G2aaX93wwweOKipThzc/VClGN7ncaZ4XNtbGfcpuFYAEN05r37RtL00+GbS31G6R1ZAzZcD8K+Yjqt1E4gllkzkYAPAxXV6Pq91JCiPIzKPlXn/ADxXzWaYGviEpSns7hQr+xblOPNfue3T+HdJs9NNxaOigj924PX0qsdTtbPSjNeOGbdsVV+8Wqg2u6edAtxLPtkhXJT+8azNL8QaUm1tSiIkUgqAvD189GhUkm5pyszqnXgp2p2jdfIim1a21CKXzI3KcjO05X0zWReaPp+rNbLHP5U6EkyOetbGv+J7I2032eBEEnbb1rzAa2y3TpED8pJUH1r18Hh6k05QTjY8+bXNpqe9+F/EVjpsC2Oo3sfmqvyv2IHrXN/FPXYNTihisbqN4lYZwa8zhi1DUJWleMBW6EHFZeqafNblC83k5bPJ54p4fKKUK/tOf3jpq46pVpKhPY9cjvZ20WO0tW2rGgJ3c44rkFs9V1W8mVlZraPngYDGtv4UajZ3TzWt5IrysBs3nAOK9M8MWqvLep5UaQh8J0zXFWxDwEpx5df8yqWDeJlHXdP8DyHQbS303SdQa9tSlyGwoK/eFed6pcXFzqB8tvKiJ4Unt6V9C+NLO1VJpDtiwCAT3rxzTdD0ua/kkupmkCkkAHGTn1r1MtxkZqVead38zlqQdOryy6I7nwXpOppYpdWl5thKAsoPQ4qS+19PtAtL7eZWbZvU8k9M10nhrTbAaMlmZJUMp+XB4Argfifoz2OoQjTn3Se31rzqE4YnEuE9H00sbV4OEYyXwvfX+rGf4h0GZJZGaOU7uQ4GQRXIyWNxaqtz9nkVl+6+CK73RrrxE9sWaESqBgFh0HvW0dZW10podasY3iIJwo5Jr04YurR9yyl6M51GMb62OE0CP+04JpLphHIgzz/EKxby9Ms0qSsJI1OFNWta8UWYkli022MKsMdelcrbE3MwXcBzk16tChJ3qTVl0XYShzPmtZBc3GJmWJT6DFaWmSXVvJG72zRk8qxXrVm2tYEVpI8eYvqO9Jc+I5XRInKsIuFOK2lJ1FywjfuXzX0itSz4j1CTUrKOSUBWDbSMVn6RK0SyAHg8cGsqa+mlmaPPDfMeO9XNNbOeucZp+x9nT5eguTlifT/whtEg8MxyhFDyMSW713EcMcbMY0VSxycDrXj3wS17ZC+n3UzYJHlAivZAc81+aZnTnTxU1Lq7n2mElCdGEo9FYx/FLPHphkiBLqR0rlhqNzPZFTMyRkHJHeu6v0iktZI5/uMpHTNcDoEP9qy3lgmUiiJAkIJNPDuPs25L4Ty8fTqSr8tN3clt6bnm3jA26QsI1Lys3BJ5rK0vw7LcxKwGHYAgk46+lexr8MrGRi11dSSZ5wFxzUuqeC47dIX08nMQAHHOa9yOb0oRVOm9e55X9l4mnBylE8rGk3EEfluhyvHA5rs/CZBtGt3wtyvQZwT6Guu0XSIntzHfLm6AyTt4rI1/w28V4lzCxR17r3rlqY6OIbpy0fctYOph0qtrp/gdxpEsktnE02PMxzUy3FvKzxrKjMvBANcPY699ghdfKlYg8hfSsTW/F2nXcos9PjeG4PVgApJPevNhl9SpNpLTv2PVlm0IwVtX26v+up6uucD7uPb0qlquo2tjaPLNInyjIGa8butS1woYrWUB14zISorno4NbuNQJv5pJXz/qIucj3rso5Mm+adRWRzVM6lKPLThq+rLnirytfvJ3SQGZj0IPHtXkt/cQ2csqwgGblWz2NeheNtfvNGi8uLTJbV2XbvkTbn6V4/dO0rPI5OWJZiPevuMpoScLv4eh42HpOUm3t+oqyuZcoTuz94Gup8K+Gb3XtWEUkjLEoDyPnOFrk4J1iMbAdD0r0n4carJPqsqRyeUrJyM8tiu7MJ1KVKUqfbc7ZXT2NTU/hnJb39u2hmS+WQZ4U8fWtuLwNqUFrbym3dFixvAHPXmvZ/BG3+xYvnDPk7iK6AojDGBwa/P63EGIv7OWtuvc745SqlNT59Xr/wADzsfK/jLwoLa4a4tLOSSCUZJVPumvMNbtp4JQJ1KleMEc4r6k+JDwWsFybJ/LcsFIVupPtXz98RINmqPGxORt69cYr6zJMdOsoqZ41O9Ks6e9jlNMLG7RTkg+tbxVsnn+dYVtmKVSVwBjkHrXRrqtkFAaEEgcnHWvaxF+ZOKubV07qyNmLTrPUtMvsAi6hTzo2ByMDqCKxINKE6xuWGc8mltrmezeaIMAXG0n1HpV2cM1shiAVtuWxxXEuem2k9Ht9xz3cdjBuWeJ3WNjtQ4OO9SWtw8V4rRngimKN1w0TJ270yBXW8WMAMT0HpXbZNWZskrWZsI3n3i+aRkgnd6Ve052iY/PnB6DtVez02RJPNkfapGB61teHrG2n1O2judyRs4DN2xXnVqkIxfZHO2r2Rc+1T3G37MGYKcEYyPpXRRtMbOJ57ZwY/mjZR3969a8HW/hyzT7DYwRiZvmO9c7j7Zqv8QYxaQ2q21tGqF+dqjn2r5OWaKpVVKNO3qdlXL+Sh7dTT/zPD9cnutWlgiu9lvt4GBjJrLFobK8wxUup/Gvb9a8Aw6rHbXsY2ME3FBxg4rzfxH4d+zTvNcyFGPRfb3r0sHmNGqlCLt5HJVozov31obsFxPYadCUhjYOu8lh1P1rj/GMT3tjHfzBVbOdqdge9a2g293q5W185jCgwoU4xVfxZohsoMyXDPFkB19KMPy0q6TfvGcr79DnPC0L3Uc32SVUaMbiT3+lXLPxzrmh3qNBcH92fuMeGHpT9Ts4rDRlOnN5cpGd4PNefyfappjvkLMTXrUqNPFuUppOPZmtJvn5ou1j1TxN8Rl8SxpHcwLCmOUQ9TWd4amSJbqZMtGEyuecGvNmjljlXdux61u6RczxMVUNsbrnuKcsupUaXJR0RVWF2531Z6D4Z8R3movcGCUxyQkBYwCSfeu90y3i8R2wa5uI1eIYK7vmJryXU9Ju9NsP7RsHaEzLyAcbs1n+GrvUrW6JLyqTyBnrXmV8DGvF1KElG39MmDim+ZadvM9W8YQ6tpGmRPA5KuflVfTtk15pceLb0XptdVQBWO3Ir17R/EcV5oTWusQA8fIxHf1rzPXdNsNT1IvM6qUPOCB3rDLZRXNCvDbqhVVCM97xf4Gc/hiznkWQ3AWKZdyn1Nc2Lb+ztZKM5KqcqSOtavi/Uo18i1spQVhBC7f8a5N7u4luVeVmL9Oa+hwtOrOHNN6NFUoylqnpqdzZpdalM/2KHdnlgq8VmXWkT3MrwW1sGkU5baMnNbXhC9FjodzKbgpOThUBwSK17zUf+EehjuLEea9yu5lY5Of8muF1qlOo4wXkjN2hLy2+e55dJbT2upCK5Qo2dpBHStGyTFxgsAA2OKj1i/kvr43EwAdj6YqOyYmXOCfrXqy5pQvLexrdyinI9W8DXSWM9u6uFIkGTnnr+lfRMFxG9uJA42jqe1fLVlAYPJmJKsQD15617V4L1K91fSmtIyGMRAZ3P6V8HneG5mqyfqerlWLcFKkld7o61i2pXQ8t/wDQkBDDBG89OvpV+1tLe0TZbRJGvoopkgmt7RVtolkcYAUfKKkt1kC/vWJJ7HHFfOSk2vLse7Tioy1V31f9fkTUlLikrN3NxNo54FRTwJKmGHSpqryXUSbWZxjdtBpxv0M6nJb3jifE0McF6WjGHZclR0rz7WNG+0z+cmUuF+6yjk13XiJmGqM6yrIsg9elZNzL5kIClY3TjJ719JhKkqUU49j4rExUpyktLNnmtxp+uTOzvI7pG4GPWvQfDV/qWnIksVpbmdx5ZypBHv71X1q3lFkWgkKyY3MWOM/SsHw7rlxb386XEM00ceDwCTn1r0KreKpPRWXQijUlRqWva3X8xfixrDa3rFvbXMOyKBfmUj7zYryTV9MRWP2f52J5AFei+JdVttS19JdjxxYw+Riux8P+GtMn0xJbeKNyDkyNgljXdQxay2jBNW02HTdSpJ1d222/vPnGy00zXvkysIgT1bIxXRfD26OkeMYWVlkEZZT6EYxXc+KdFsr/AO0x2kUcdxEclgpGT9fwrzaC3n0DWI2ulZVLfe9u+K9uOKjjaUovdrY3o4hzvbR2PorwN4qFmzQ3c+yN23ZI4FekvrmnxWrStcxhCCd26vBtNl07UdMjNpMZypOCp5X6jrToNE1HUEbM5EanAXOeK+KxOWUqtRzk+Xua0MxrUI+ySvbY6HWZbM3tzq7s1xbW5yikfKT2NeE+LdQbU9Rku3xulbdtHQCvUvF95Bo/gg6fOwaZ22DnGeea8Z1GRd6noAM49q+mySha9T5L0RyUUnPTZfrqyrKf9JBGAMA7c1KfKz/HVYDzLkAdulX/ACYBw0hyOvSvoJaWOyTSsbekQJLIsl0ck84NXLy7Vr7bGhMZG0AVWN1DbWT5bEvp6VFY6pE4TeNrp7da82UJSbnY4XFyu7GZcM39p/OCnI4NTPG7X0Yiz5hPy4p2oOLjUkkGDn7xFXbq3MUsUkWflGTmt3OyXoauS0PQfCWjRqiS6qSDwVB5ql45jtbS6T7D8kbEZxx3rpvBl3b3GgBnUu6KAd3IH1rC8fKs7xskYRVAbHr7V83SqSli2p/8AwkrWN7w14tnGs20NjbrNc8AADAIArudY8R2+qzWsUls+9GBZAeh+teFWWtrpN2l7Gm24jGBg8H1zXUaJ41t7y+WVoBFIPmJL5Ga58Xll5e1hDZbm8K9SNPkT0b1PeL27+x2MdzKRHCByAcnFeYa9av4p1ALEs5QsPurwPStq21yK9tJXlmSSMjays3AHatDwrqNpbyPMjbiflxnivDoxnhE5pe8jrq1I4upGMnaJyEvhifwrrEHlTvtkHOOhPetrxHpFlf6CkTtvmcbjhvuGvQtT0+21uxQP3+ZHHUGsiDws0cbq8yuCODipWY8/LObtJfib1ctnFyjBXi9vI8IOlraGW1vG+Re56EVw+rzpY30q2pUpnrXtvjvRWhsZFdctu2rjua8c8R6O9jI3mDJxkkdB7V9hleJjW96T36HjKPJU5ZnPz6m8jBXAKg8Vu2+s27ac0TRhXC/KQOtVdB06O4mkaRAeON1VNbtHguV2Jwvp0r2JKlUl7PsbSUJPk2NnTPEbh44b2QvAh4U84H+TXrEN34b1DREaKeGK4GPnJAI9RXjuiaFb38Mtxd3HlIDgYGa2T4MuGVf7MlafjoDivLx2Hw1SSXO4tfcKXIrx7nS+KPEmmacjJBN58oXaoU8D/GvK7zWJJckEoWzkk1q3/hfUord7q5R0jRtnzDvXPGykkdlBFehgcPh6cfdlzeZVGFPdu7FtY555dygvjv1wK1bW2SSQlzgoOQeKqWF9JpxbcgZe9Ne+SedpEygPBwK65qcm7bFzUpPTYu3N55DCNGznpjtSTXF0lukj7mj6DJ6CsyKaMXDEgnHOTVm71GSeLygAEPpxU+ys0kheztZJGi8+nPbbwszzkY5PAaobUkyBug4zirnh/Tob+2aJX/fnhRjOa17aG2NqtskYW5RsE+pzXLOrGneKuzGbUHZGs9yDYwl3xJjFdb8M/FUWk6qz6hL5VpOu04GRuxx/KuHZPss0QuYy/lsCV/vD0qvrE9tNORp8UkKswPlu27B56V5NXCwxMHSktH1DD1pUKiq03rc+p9P1M6tKsljKgtkwW4yST29q2B7814j8J/EM/nPZpIMhc7TznAr1O21+EcXxWA5wCx4r4jG4OeHquCWiPqMHjYTgud2b77G3TZN2z5MZ96I5FkQPGwZTyCORT64D0nroRlN0WxznIwcVWMUAtmQbWVR096tnvTPJjx90dMUKViJwvsjB1tbKPTHu5bdVdRkFl5ryddROoaid2QqkkAdK9g1n7PcK1o7kevtXlWq6Q1vdn7KrbScZxjFe9lko8rUt/0PlM0i1VTW22nfuT6xFcz2CMmwRqMlc/erQ8NRp8rRwou5PnABLEVr6P4ckurCEO+ABzir6aTcafp+oyKCjkYQj+6KKmKg4+yT1uEMJUhKVVp2s39yPPtU020ub5ysPG4qOO9XpjJb6W9qZJYIUGRtXAPtU/h+6W91VjLGPl+Z8d8cZrs76wi1KzKoMxYGeOn0rWviXSlGE9kc9HCyqUnKD+R5lJk2ybrWX7S44YDKlfX615l8VreaOK1aTA6jjg16z4g1GfT9StILWMOw/dlMYOK84+M00DSWQDEyldxH8K17uUyl9Yg7aO7MI29omu9vw/q55VaahdWEoktZpIn67lYitRvGGtOG3X8xLDB+bFYjREjJDYFQYJbFfZyo0qjvKKbPV5Iy3RrNfXurTIt3cSy7TxubOKfcL+8Kk7gnAzWZal45N8eQVGc1cDM0LM5+ZuR71MoKLtHYiUbPTYdbRh7ojjB6EVO0WGI3rwccmltUNtbrMVIJ6Y71AzMzFto5OeT/APWqLtvQm7b0NbxG0T35aBgVPPFZUSgyYU/MSB16VZlxbTSCcEnFJp0SySb0IB6gY61EPchbsRH3YHRR6V5MEbyYZ2wR9KtzJJcSLGnzcbcD1qnuulnVbklUHI9K6fwdpUt/q1u6cQ78s3bFeTXqezi6k3scesmi14as77T7a5hmjk8iRM5HGKLDT9Q1uWOGGKWZFYLnGcfU16V4kaPEdjDsCMoAwP1rsfhzpiafoZBjCytIdxI5PpXzNfNXTpuvy+89v8zqw2DeJrezvoup4X408G3NiUaWHy1cjcay7PwmbyYrp0mJFGW9q9/+IHlX9jNYtCpfbkMev4V5f4bhmsknbJjUnBYe1bYPM61TD3bs0Y4ikqFZ0lK6X9fgUdK8JaxDH5MjBYWOC5PFdTf6Xc6f4fMf+qm2ZBz3r0vSjb6po1uw8t5EUEjPSuYnvJtX1q40y5t2EEfMbkYrzXmNWvNuSS5dWdNXAqEVZ3ctib4TXky6UbC9maWdPnUsc8eldvfiX7K5gOJFGRxWX4d0GDS8yqG84rtyT2+laGrS3Mdriyi8yZjtHoo9a8fETjVrucOp9DQjOGF5au9um/keJ/EXXZbS6ihWN5pWOeTwprC8UaRc34s5JztmZAzo/AFehfEfRGtraPUGgWZ1wWwM81hW13a+LNDuY2R1u4x8uRxxX0mFxCjShUprRaNnytelKM5Rl8Sd/kc3qGn2VrBb29tHkqvzSAdD6e9ct4hijFowJGR0Hc+9dNpUTQWEyTswaCXOG6muV8Z3MF+xe3HlnuQcZr2MJze1Ub38zm3lc5nTtReDzYSoK9AK6fRtfvtOCZQrHu3cjqfrWN4G0yPUNeiSSRPJDjcrHlvpX0b4q8HWV94S8u0MQZACpwPyrXNMdh8PVjRqRvzb+R3yoOUZTgttzgdHu5fFPhnUYpDGJQ3yIT0rjYvDn2eaRZ1w6nAYcir101z4GvIbqNvNgk+R4811mp3kT+GxqaQbJHTftYYrlUp0H+6+Cb09TjnZR54+jPEvFNu1pdtHkFTzk8ZrL0mOOW+iSdtsZI3H2qx4h1GTUb95JMDHYVRhhZiDkr6Y619ZSjJUUpOzsehSTVNKW50niCCzWSMWCBR04Oc+9UBarsYknIqS0tpY2VWHzEZUGr9vbPNdLDN8m44xXNzezjy3vYw5nH3Uzo/AEUlvDK6FAH+QMeoz3qPUraXStdkEcjSbG+/jgnFb1xHZ+G1tYgDJHIoMgPPPrUOr3lzfxmNbIiFj5kUhTBI714qqudV1Evdkc9Sbc+ZdNPu/pjLg3N4beaZFKPnDDv7VzupzrDfK4BVcY5rag1ie1sns5EDxhtyFuqH2qheWi31v5ylQR1BrWj7kvfWhCSUr9P8AM1PA73en6xZ3NkVm3zKrY54J6GvVfjEkVtoqSF2jncA7FOMH/wDXXlfw0vIdL8S2v2wBomkXqeAc19Aa54Si8RTSPfS7oGGY8dv88V4Oa1o0MdTqVNkt+/l8j1IYaeIwjhTV3zL5W1/EwvgbeXl14dl+1yNIiOAhY5xx/wDWr0ts4+UZNYvhTQIfDun/AGSA7l3E5rcr5bGVI1sROpBaNn09CLjSjGW9iIoxC/OcjrjvUMl2EuVh8uRif4gOKpXep4vWtoHUuo5XuKtwq8hRz06nPXNYuHL8Rl7ZTdqRSvISzXEiBFdlwNx4rmLS3ubiV8skig5yO1dB4psri6tPLtiglfjJ7CuIFu+h3yPdXbMWGCM4X8q9HCx5qbs9ex4mLtCvaatHv5vU9ItInEVuVkCKB8yrzmrxUMpVgCD1z3rF8OX6XVuoVt2BwQOK2JJVjwXIAPc9K82cWp8rPeozg6XN0ZxEPhl7bxO91uUWzgkxkd/wrb1e6g0zRZl3iN1Tgg4/GoJ9eeXVmi0/bcJENrrGN3P1HSs/xNor60sbGcwFhuaMnnHuK9C7qVIvEOy0PGklSoSjhVfdfJ/mecW9pNqr3V6ryqqNgSE43eteJePtV/tDXZkAZY4CYxuOSSOteq+PPEttotpLYW+oJJMpC7UJ6e4rwa7lMs0jkkl2LEn3r9CyPDybdea06Hj4SmnLmS0X59y2Zo2tiWb5sYC1VtbWS4mGwY75PpUCgk8CtSS+AtEhiGGHU+lfQNOGkep3NOPwkDxmOUQq2SfvYpZGD3Comdo/nT4kYDe+dzdzVhLYoxk2kP2H9ahyS3JcrbjbuUpbKgPzDnNUPOf+9+la2q2TQiFZXUsVz8pziskRZH30/OlScXG6CDTRt66N902RjdVGyDxupiBLA5wK6fxRprJdbm55xlelQ6XZGyn+0Om9ACPm7VxwxEfYqxzxqpU7D77VGuWtopYwrHhic5+tesfCP7I8U0VzFu2ghG7k15VekLdmSdUMpxhR0Wu6+FerS2uorDLAJRMQo46H2rx80p8+EagrEUrcyPSZdL/0pZZ4m2owAI9K6/w/c3MV3Lapb5gGCGzwox3qx4hs2n0wJbMFRcZxS+GGiitvs/nCSbqa+DrV/a0uZns4fDOhiFC9vPv5FHXIodThlgjV2uucsv8ACK5e18NPBG1uC/2aVCfMAyVNenRwRxs7KoBbqcVwviTU1svEVlZQl95fLBemPpVYStUlenT9SMfhYU7Vam7dtP6+8v8AgPQTpJmkF2lwrjHy10T2ivqCT+WAQMbsVxfi3W72y0RJdIQpNFJu2IPvD3rpvB2q3Wr6DDdXts0FweGRhjPvWeIp1WvrEnu7eZ14OpRdsPHpqbSurMVHUdahuJpIpolSFpEc4Zgfu066B8iTy2CSEcMfWs3w5HexQTLfvvG/5GPU1yRS5XLsd86j51T79Sv43vbSy0R2vsmJjt4rh7a903T/AAzcC2jO5mZldO/1r0fXdLj1az8iXGM55rzfxLa/8I1C++3FzakcoOMf5xXp4BwnFU9b3vbueFm0asKkqltGrXPLZdWSKbDIZYmcmQZ5zXNtLZX3iLZGWS3PGx+DVPxHPMdVmurKJ4rcnhc5rJkl23KXO4hwc4x3r9Dw+FSjzJ6tHkUqWibNtLn/AIRvxBDcRqrojE7QeRXoFl8TzLamKVsRADIY4LV47qN693OZpjnpTdavIJ2i+yjaQgDEetXWyyniuX2yu+50Rpy5VFs7Xxp4pttes9ixiKSNtygVp399dXfgaKVm2FECMo6Yrym3uWjcE849a7rR9VFxpbLfvm3TooPLn0qcRgo0IQUFpF3M61HkhZd7nEC2YzHeCMnIFdLp+lSSqWVAUQbunXHerMGmwy3LXM02yPG7kfdHoKqy6nOWaC1d0tzwEz1rpqVpVdIDnUdTSJoabatd6hDHt5YhAfStTWTYaP4qgMrs8cQG8DnH0rDka5ijQQ7lnH3dvBrA23lw8lxMryMGO5jzWEaDqy5pSsrWt6ipq7Ur7HY63qcWq62rW4ma3PQHqK7RtehtraKNbSd5ootsrKuVBwMcV554e8QtZlMW8LSKwO5lzXeaZqIjtbqSeRHubobtiEbVH4d687G0eTli46LbUwqR9nBx6WZyct5DI5eZcMTk4rShuLTyxFGuNy7snnB9KxLe4R9XR5Y0lRpOUboa272PTrXxFHDDIhjlIyoHCH0rarFJ8tntcTh7sV3OfVWW/MhwAhzzyDXungT4lwPpMdjflYrlECpITw1ePeJdMWOaV7bJRTz7Viw3ReNU4Vx79SPSssVgqWY0lz9PwOvCYupRi+R6Pc+jbjxpqUVx5ataKp/5at0IrotG8YQ6iqABFY8Hn7x9hXy5b6tcqfndnwuAGJNbGkeJ/sDJPvkjljO5dp4z2ryMRw9Fx91a+RtRx+Ipy96TaPpTWIpbecXNtbB9xyWA5zWhY6gskSIUZZjxsI5BrzLS/jPZvbLHdWchnxjchBBOOuK1tA8daZc3Esk7CN87gCMbq+fq5diYQ/e03p+J6ccXRhU/dz0fdbHd6hEps5JZXKlVJyTgCvE/FGuWl5fmIP5skancqmup8a/EnSPsL21uXnV1IfaOlfO1jr7aZr0l1sMkZYnafQ17OSZVVlCVSaaa2R52YVIYmty0n7qW/dnq+heMpfDupxqHf7MSPNiJycf416HN8SNNe3lKhXiKnDMcfgRXzJf+JhdXk04iO9znk+1UptQmvUOflHQgGvWq8PU68lOorPqZ0sTiaVL2adl9+/Q1r7xrf2Pia6vdFne3R5C2EOAaqa14/wDEepzLLd6lOXQEIVO3APasi2+y2d2j3BWVTyVPIo1qSzvrzfZqIo8YwOlfQQwtBTT9mnZb2HC0Yxpq7SMe4leV3klcs55JPNRxp5nQEmtq6tLS3sU3EGcnJYNwfas5G5KQDHua74VFJe6jWM01oWba7jt9NntjCrzOcBzyRUEEAjw8wwvWp4RHECXw75yfSnS7ruTy42Ty/wC9Wd7N267kX1Y+CZXlWRkwB91ewrVtr+0hgd5IzLct93J4X8Kdp2luImlYxtEAQzk8D6e9Lb29vdTrHaeUshIRWbAGfU1yVJwlfsjCTjJ2MyOKTUJ9qk+YT8qqMkmrH/CHax/z6n8SBXUppsPhuXzZXLytEeVOCzensKxm8QQFiTazkk9ftLc1EcTVm70F7v8AXmifbTf8JXRf17XI72SPyuUQ8A1Hf6hHdWuLSNlYLtb0rKtNLWSQujhlz8qDrir6PGrtHHFtAbBx3rL2VOFlDoZuMVsN0hxJfW63eNmcFm9K9P0HTsTQXMbAIjYUp2zXnskal12qiqefyr03wjJbzGCxtZ43ZgHbnoa8vM5vk5kSlzSVj2nR0hg0uC3BJV1OS/OSadpOjWunsZIstIRyxNULx47PRUSR1EiKADnn8K5S31u9uPEFvpkMoWJ15cnHAr4WFCpVUnF6bs+ini6dKcIyjd6W8ju5JF0ayZpXeVWkJGewJryr4qvc2HiWx1mzRnVPvAZwRjvXfeKrgW1vZ2SzAyOcEscmsjx4lunhZ5mA2xjB3DBziujL37KrGbV+a69UznzGTqRlCO0LP8NfzH+E9dhv7Brq2h+dNrTI5B49vfrW9q2sS2l2ogi8xNiuMHhgf614B4F8TXFtq32RYy8EzBTt9M16rHIdbVbeyuh9otZSGiZsFk68H2rqxuXKhW95e7+hhQxlT2fJHfT+v67G5rOvRXVosUYaKVxlSeCD6Vylr4yntNXgsrndJHu/M11WsaLHeTx3EpVI413t3JI9K41INOuX807NyHcsueQc1lhI0JQacb/oycVVxEaqlJ2f5pHf6bq0l7qJ8kL5ZH8Rx+Arzn44+JBa3FrY7OGG5m9K6vVZf7GPh+5V0IeUK/YENWN8VtIttXvYpIVWSeMAs2eEp5fGlTxUJyXu2f4aGuNlOWFak/tar5X0+88iu2jh00vNb/LIOGZeoNeb38+bhlRCUB4Ir6Gm06LUNFRdQQmWJcb1G7gdzXj3iSxsYbmUQMGP91RzX2uV4uEpOLWp5VKSpz16nLbBINpxj37VTmChsIPrU88jxuwC4A45FNtbKe6V2gjLKgyx9BX0MfdV29D0E7asrV03h+0kco8it5Qx+NYVtCxlGR3x0rt9Ft5pkQEeXAvVsHAHqa5sZV5YWRlXnZWQt2HvZ1t4UVF6AdK527V4ZJIwpBQ9e1dRfPFJeosBZbWM43gct60niOTTntobbT2UqzZZ2XBH1rho1XBxjbR/h6nJTla2hh6NK0u/LsJQOGxk1sWNrqcGmSS2gzbyZDkgVtaJY6dp2jSyW0wmuH4LBfu1a1G6RNEijikUDbjntXPVxXPO0I6X6k1qi15fI5XRLb7Hew319bF7BGw7EcV20T6VaWl5qFkgmixtTjgEiuKvr+4/strKNiLeT+8v9a6K3s5bfwTHGHj8tjuORyD6fpUYqLnaU3a7tby/zFWfNC79PvOS+1wiSZpoiXfO3HRTV7RltGaWXUCyEodpI5JqrBYSz3Ue2IjnO1hjNd013pN7pjvdIqT267BCx5Y9OK2xFVQSjFN37dC5WUNN/wBDlIblS7pCxliZeSfeqeoW7xndtKjr9RXW21jFd6MbqC0Nv9m+ZmGcMBU+pW9prGmQ3dmUSRcRtEWHPvWCxUYz202ZF+X3l/VzhUmSSNGdQuw7SfUUs6wyum0M0fQlRnFXbvTQzOiMPMU8gGs+Ey2W4PGSBwDXdFqWsdy009UNijmimYWEjGROT61dj8TanbvtZhuA5BXmq8FwTctI0bFSOqDHFW2mtJotn2eQzYOHY44+ppTSb9+Nym+6uZ0uszzTTM2GLdRjvWWWaVjI6AqDjA7VpNZhbkIZSoOeO9VZ4oklKISVY9R/Wumm4L4UXBxWyK0k0XlgRw7X/vVUmlk8ny41IGfmI71b+zhs+W/I6huKiVACPNJXPtXRFxRvHlMwxOT0b8qkit5ZDtVSSK6KCwt5FP71dwGCGOMU1kRVITCt0wvb8aPrN9EDr9EZ8GnEmPzmJJOAnetW30q4dZpPshWKEHez9B/9esxo7pZVlQbiOp9Kvpd3k6CJ5dseeeeprKo5vVNETcmtGZy2clzKRtIUc9Ofz71ZWNrWJlWNSScAjkite3ult1COFO/q59KpPNDBdsYgJFGOvvU+1lJ2toR7SUna2hKljqlxoyzlZDZhtpP4/wD1xUukm20+6Sa5iZwnOzsTWnazXNrYyrc3flwA70gBHzGs7UHlhsA8seJJOQcdu1cym53g9m+hHO27Im1TUIdQ1YzPbu3AZgh4UCr4j8JMMtcNuPJ+U1yirPbxOzFjIyZcDp/nFYDEkknPP0reODU1aMmkuxpGgpKydrHotzp8unyLcWbFd3qKj0e5t7d7r7dHulkB2yA8g0mo6+RcCKQl7cHjIwSPWpbexjurdtQth5oDfOmeQDXFaSh+969Tn1S94o6rqCG2ZUTbkY5qHw1q9xpt9HeRk/IcGtTWtMUyIMKPMHAHGK5uSCazlaJwfLJzXRSVKrTcO5rTcXGy3PUbr4gHUby3jZ2SMAbif5V2WnTRpKt5alZJNoKt1rwjTrWSdWnjJ8vGCvrXS6PqdxpxQ73Kr1ANeRistpqPLR0t0M5e6731PYNLZJ/EUz6xcbnYApuPy/T2re8Sw22rWEdrN+6hJwQG+9Xl+nwzarZR3nmsELFlUmlv/EF1EwjcEmJcZJ4HavEngZTqpwlqvwKWI5YOm1uUL6GHQr6YWy73X7gAzWh8P9ejj1ojUcRu/wByQ8cmovDNx/aWoJJOnmgSKr464re1L4dXFxcT3kREdurnAzz+FdterSSdHEOza3JoqSfPFXsd7d6vBPDE882TGu3CHhveuG1+JLolLTMcRYHCnhvrWno3hK8itPtDShrVjt5bkYqZtImGoFFULDjlj/SvIo+yoSfJK9jfEe2q2c1qzF8RapNe6daxXkTLHbbdhHt0NUPEOu3ieHknsI/MmlbB7kgV1Hie3D6BdQXUPleXgwy9Mj096xdFgkj0yJSgaPIJBHOK6qE6fIpcuz26GFTncmpPt/X4Fr4cXN7e6XHPPCWcZ38cbff9a821rTy/iu6/s21aSHeRtAztr2PwfqFzYzS202nsllcynBAxsX/CqXjHxV4a8PRzW9nCkl6QRthHH4mnh8VUp4qapU7821trefob1IRlTjUUtr6db6aI8M8XeHo7fzJQwRgBuUnGSewFYmkSTWdrcwC33LMuNzcEVq6xdT6tqTzXIf5uUA7Cn6XDGkglnbDA/Lnkmvr4TlCjy1NWZRm1C0ijbaOY8NKQd3QA/pWtd6nHBYC0jQoR1I/iqGe62tJIQQc5HsKy5pVa43yglc8gClyuq7z6E61H7xoW8okCK/yq/GcZxWzL4ZtpNStVs7n7XbuoaR0UjHtXOtdRuGjjbYhGckV1XhTUo3spLOdfMCqWVl4ORWGI9pCPPDTy/X5A7pX7GlqrQ6QsFjpkCuZ+oHLZ965HU47pNRW3uImhyc4PPFP1xrt7gT2iurnowP3fbNYuna3MmrrNe5uJYzjDHrRhsPKMOZau2ve4UqfN733mxe3f+kraOi4UgFjXQ3mkyDTDNFcB41YkBCSOlcvdXkWq6zFI0bRo7BSF7CvR9EsbhnTT9KVjbknIcZznuawxc/Yxi9nuyORtJL4mYlqs+p2MEEiCKRSP3pOMipPF8FhYW8MNhHG5YjfMvNew2HgOYWiCaWDzO+EB/nWZ4n+HFzd226KZJWXkDAFeJTzeg6yvKyOmrgMTFX5Hvdnj+lvqN2v2EXZhtpuo3YGBVTVhpySJZ2CzM6nBlU8Z9a2Ne0m50WQi6tikmOh6H6elM0O3aLTpr24tDPBkkLnoa9lVIpe1jt0t1f6nJzX1fQ5aaC406U/vC5bJJXnH1pbWdrmI+Zhn7g13FzqcNjpi32k29v5m3a6SOGAz2wa521ng1XVJZ5Ps8bsMNAh2c46itoV5Ti5Sja3X/gF62d90UVsWkU/Z5FVz2NVJ9PZZxtuAcdevFbWo6sDAbWGzhhWMYdl+8SPesVZYpD++Zoyx4yP51tSlUau/8wi5Xuh95aLsVmPzL1YNkn8KS10y3l3Gedl3dKa8cj3CxjLFjzk9B60mpxG3IijkY44JB4J9q0TekVIab2vuVL6yeBx5BEgxgnGM0Q2Ls6POgVQeS3+FaNpqunWtiYb22ne4wcNuxg9q5mW5lZmO9gp7A9q3pqpO6eluvc2hGb0/E6nUjpctrutyVkH3hjGT61ieX50n7sALjBJOCaq2iMRKxgLgDJYgnFVLi4uPNOCuOwT0q6VBx91P7yo0mnZM1EWUMwPJHZTniqksgy2AUYHI9qIJ8oojZyz8Ek9K6Hw7o+lXckp1bUJIgVwrpwA3o2exoqTVFOU/wKS5W7nO20igXAliMpdMI277p/yKs6RE4uFO1AQpAZxn8frVzVtEm09JpbaQXNvGcmSI5Cj3rNuriS2eBoJj+9XJKrjBqlJVV7j3Dm517vU0PNYXwBxkNuG7qa6bTLM3cfnXwDMoLKjkdOwFYOlajb6SBcXFtFezzLj5ycJ789TVuXUjeA7ECAAbAvXmuKtGctIqy7nPVi7JIwtSvS081qEESu3HqPxo/sP6H3DitS70AyPseZVuHXO7qBn1IrNOmXCEr5n3eODXVCrGyUJWNVOKSUXYk8RgDWAAAAc8fiKt+CZHW4dVdgpfBAPBoorOt/uvyQS/gHT+Lv8AVRP/ABZ696z9YAa3tiwBJXqfxoorz8N8MPmcq6GfpbEZAJAOcgfWrnaiit5/GypbnpPhUAaDa4A6H+ZrntZ51HUgeQEHH/AxRRXiUf48/X9TKfx/15G94DRFvhtVRmDJwOpyK9pd2MIBYkbT396KK8LOv46PYy34JmVrTNH4fuFjJQADAU4xyawp55T4ajYyuWyOdx9qKK5KXT/EXiOv+FEfjImTw5YGQ7j5gGW5444qPTQPMgXA24HFFFdlP/d16s4qn8WXy/JG58RJZLfw6fIdov3J+4dv8q+cISZdSJlO846tzRRXp8O/wpjx/wDvD9EaN7Gi3MW1FHHYe1Zt1xcnHGEyMUUV79PocMSS3UNbz7gDiLIyO9cvJzKc880UV14fdm1PdiOBnp2ra0pmWzJViDg9DRRVYj4C6nwlnTJHZp1Z2KgNwTx0Ncbbc30xPPzH+tFFPCbzChvL0/zOq8HKG1qAMAee4+tfSvw3ijW1d1RQ+w/MBz1oor5riX4H6HZgv96h8zrFlk+0sN74x0zVvcTEck0UV8I+h9JHY8t+JUaMkZZFJJOcivN9fAi0dfK+TOc7eM80UV9tlv8ABh6nw9f45+p53K7fakG44z0zV2zRftTHaM7euKKK+pfw/I36G3oiI+rwo6qyFh8pGR19Kz9ZVRfTgKAA3HHvRRXLD+J8jJfEvn+hl3DMs0hViDgdDV9iTYqSSSc5ooraXQqXQoXABlhyM/L/AEqncxoqrhFHI6CiiuqnsjemdngJ4Qugg2hgMgcZrhrhV+242jBHpRRXPgvin6/5Co/HL+uiNeeNFWEqig7M8DvjrUtmqmOTKg/hRRVS2IZRt3ZftCqxCtjcAeD9azFA+1sMDG48UUVvS3l/XQ3hu/kWroD7MOOn+NaukKPn4HCrj260UVnV/hmc/hJZHf7S43Nj61YVRtHA6UUVydDmP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in secondary amyloidosis using an anti-AA antiserum. Markedly positive staining is present in the glomeruli. Although not shown, there is also substantial amyloid deposition in the tubules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36306=[""].join("\n");
var outline_f35_29_36306=null;
var title_f35_29_36307="Idursulfase: Drug information";
var content_f35_29_36307=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Idursulfase: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/47/8948?source=see_link\">",
"    see \"Idursulfase: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3151893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elaprase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5376743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Elaprase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3151896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3151943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to pediatric dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3151942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     MPS II: I.V.: Children &ge;5 years: 0.5 mg/kg once weekly",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3151944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Studies did not include patients &ge;65 years.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3151950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elaprase&reg;: 2 mg/mL (5 mL) [extractable volume: 3 mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3151894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3151945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administer using an infusion set containing a 0.2 micron filter. Infuse at an initial rate of 8 mL/hour for the first 15 minutes. If tolerated, may increase rate by 8 mL/hour increments every 15 minutes; maximum infusion rate 100 mL/hour. Solution should be infused over 1-3 hours, but rate may be decreased, temporarily stopped, or discontinued based on patient response. Total infusion time should not exceed 8 hours.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3151936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Stable in NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3151899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Replacement therapy in mucopolysaccharidosis II (MPS II, Hunter syndrome) for improvement of walking capacity",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3151890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Elaprase&reg; may be confused with Elspar&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3151928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (25%), atrial abnormality (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pyrexia (63%), headache (59%), malaise (22%), anxiety (13%), irritability (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (28%), urticaria (16%), pruritic rash (13%), skin disorder (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Abscess (16%), infusion site edema (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (31%), limb pain (28%), chest wall musculoskeletal pain (16%), musculoskeletal dysfunction (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbance (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Wheezing (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Antibody development (51%), infusion reactions (15%), superficial injury (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1(Limited to important or life-threatening): Anaphylaxis, angioedema, cardiac arrhythmia, cyanosis, hypotension, infection, loss of consciousness, pulmonary embolism, respiratory distress, respiratory failure, seizure",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3151923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3151924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Serious and sometimes fatal anaphylactic reactions, as well as delayed reactions (24 hours after initial reaction), have occurred. Use with caution in patients with compromised respiratory function or acute respiratory disease; risk of complications may be increased and additional monitoring may be required. Appropriate medical support should be readily available.",
"     </b>",
"     Patients experiencing initial severe or refractory reactions may need prolonged monitoring. Antihistamines, corticosteroids and/or decreased infusion rates may be used to manage subsequent infusions. Discontinue therapy immediately if severe reaction occurs; use caution with readministration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antibody formation: Development of anti-idursulfase IgG antibodies has been reported in 51% of patients; may increase incidence of infusion-related reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Registry: Patients and healthcare providers are encouraged to participate in the Hunter Outcome Survey, intended to monitor disease progression, patient outcomes, and long-term effects of therapy. For more information, refer to www.elaprase.com or call OnePath",
"     <sup>",
"      sm",
"     </sup>",
"     at 1-866-888-0660.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3151900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3151921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3151922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Elaprase Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/3 mL (3 mL): $3248.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3151948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Monitor for infusion-related and hypersensitivity reactions; pulmonary function, oxygen saturation; blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5378699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Elaprase (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3151937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Idursulfase is a recombinant form of iduronate-2-sulfatase, an enzyme needed to hydrolyze the mucopolysaccharides dermatan sulfate and heparan sulfate in various cells. Accumulation of these polysaccharides can lead to various manifestations of disease, including physical changes, CNS involvement, cardiac, respiratory, and mobility dysfunction. Replacement of this enzyme has been shown to improve walking capacity in patients with a deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3151939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Half-life elimination: 44-48 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8971 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-1FFB8D27E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36307=[""].join("\n");
var outline_f35_29_36307=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708563\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151893\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376743\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151896\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151943\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151942\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151944\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897596\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897597\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151950\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151894\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151945\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151936\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151899\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151890\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151928\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151923\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151924\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299508\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220952\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151900\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151921\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151922\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322949\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151948\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5378699\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151937\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3151939\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8971\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8971|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/47/8948?source=related_link\">",
"      Idursulfase: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_29_36308="Acute diarrhea in adults";
var content_f35_29_36308=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Acute diarrhea in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/29/36308/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36308/contributors\" id=\"au6152\">",
"       Christine A Wanke, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/29/36308/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36308/contributors\" id=\"se1937\">",
"       Stephen B Calderwood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/29/36308/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36308/contributors\" id=\"de1811\">",
"       Elinor L Baron, MD, DTMH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/29/36308?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DIARRHEA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Diarrhea is defined as three or more loose or watery stools per day. Nearly everyone will have an episode of diarrhea at some point during their life, with the average adult experiencing it four times per year. Although most cases of diarrhea resolve within a few days without treatment, it's important to know when to seek help.",
"    </p>",
"    <p>",
"     This topic review discusses the causes and treatments of sudden onset (acute) diarrhea in adults in developed countries. A discussion of acute diarrhea in developing countries and returning travelers is not included here. Diarrhea that lasts for more than 14 days (called chronic diarrhea) and acute diarrhea in children are discussed in separate topic reviews. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/14/7395?source=see_link\">",
"      \"Patient information: Chronic diarrhea in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/1/27?source=see_link\">",
"      \"Patient information: Acute diarrhea in children (Beyond the Basics)\"",
"     </a>",
"     .) A topic review that discusses antibiotic-associated diarrhea is also available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/52/19267?source=see_link\">",
"      \"Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DIARRHEA CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Diarrhea can be caused by infections or a variety of other factors. The cause of diarrhea is not identified in most people, especially those who improve without treatment.",
"    </p>",
"    <p>",
"     Diarrhea caused by infections usually results from eating or drinking contaminated food or water. Signs and symptoms of infection usually begin 12 hours to four days after exposure and resolve within three to seven days. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/30/29156?source=see_link\">",
"      \"Patient information: Food poisoning (food-borne illness) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Diarrhea not related to an infection can occur as a side effect of antibiotics or other drugs, food allergies, gastrointestinal diseases such as inflammatory bowel disease, and other diseases. In addition, there are many less common causes of diarrhea. A summary of the various common causes of diarrhea is available in the table (",
"     <a class=\"graphic graphic_table graphicRef68314 \" href=\"mobipreview.htm?9/9/9372\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      DIARRHEA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     A person with diarrhea may be mildly to severely ill. A person who has mild illness may have a few loose bowel movements but otherwise feels well. By contrast, a person with severe diarrhea may have 20 or more bowel movements per day, happening up to every 20 or 30 minutes. In this situation, a significant amount of water and salts can be lost, seriously increasing the risk of dehydration. Diarrhea may be accompanied by fever (temperature greater than 100.4&ordm;F or 38&ordm;C), abdominal pain, or cramping.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      DIARRHEA HOME CARE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Drink adequate fluids",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have mild to moderate diarrhea, you can usually be treated at home by drinking extra fluids. The fluids should contain water, salt, and sugar. The fluids used for sweat replacement (eg, Gatorade) are not optimal, although they may be sufficient for a person with diarrhea who is not dehydrated and is otherwise healthy. Diluted fruit juices and flavored soft drinks along with salted crackers and broths or soups may also be acceptable.",
"    </p>",
"    <p>",
"     One way to judge hydration is by looking at the color of your urine and monitoring how frequently you urinate. If you urinate infrequently or have urine that is dark yellow, you should drink more fluids. Normally, urine should be light yellow to nearly colorless. If you are well hydrated, you normally pass urine every three to five hours.",
"    </p>",
"    <p>",
"     If you become dehydrated and are unable to take fluids by mouth, a rehydration solution can be given into a vein (intravenous fluids) in a healthcare provider's office or in the emergency department.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is no particular food or group of foods that is best while you have diarrhea. However, adequate nutrition is important during an episode of acute diarrhea. If you do not have an appetite, you can drink only liquids for a short period of time. Boiled starches and cereals (eg, potatoes, noodles, rice, wheat, and oats) with salt are recommended if you have watery diarrhea; crackers, bananas, soup, and boiled vegetables may also be eaten.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Antidiarrheal medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medications to reduce diarrhea are available, and are safe if there is no fever (temperature greater than 100.4&ordm;F or 38&ordm;C) and the stools are not bloody. These medications do not cure the cause of the diarrhea, but help to reduce the frequency of bowel movements.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Loperamide (Imodium&reg;) is available without a prescription; the dose is two tablets (4 mg) initially, then 1 tablet (2 mg) after each unformed stool. No more than 16 mg is recommended per day.",
"      </li>",
"      <li>",
"       Diphenoxylate (Lomotil&reg;) is a prescription medication used to treat diarrhea; its benefit is similar to loperamide, although it can be associated with more bothersome side effects.",
"      </li>",
"      <li>",
"       Bismuth subsalicylate (Pepto-Bismol&reg;, Kaopectate&reg;) has also been used for treatment of acute diarrhea, although it is not as effective as loperamide. Bismuth subsalicylate may be recommended in certain situations, such as if you have fever and bloody diarrhea. However, women who are pregnant should not take bismuth subsalicylate. The dose of bismuth subsalicylate is 30 mL or two tablets every 30 minutes for up to eight doses.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antibiotics are not needed in most cases of acute diarrhea, and they can actually worsen diarrhea or cause further complications if used inappropriately. Antibiotics may be recommended in certain situations, such as if you have the following signs or symptoms:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Moderate to severe traveler's diarrhea",
"      </li>",
"      <li>",
"       More than eight loose stools per day, dehydration, symptoms that continue for more than one week, a weakened immune system, and in those who require hospitalization",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, the decision to use antibiotics must be made carefully after discussing the potential risks and benefits with a healthcare provider who is familiar with the situation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Preventing spread",
"     </span>",
"     &nbsp;&mdash;&nbsp;Adults with diarrhea should be cautious to avoid spreading infection to family, friends, and co-workers. You are considered infectious for as long as diarrhea continues. Microorganisms causing diarrhea are spread from hand to mouth; hand washing, care with diapering, and staying out of work or school are a few ways to prevent infecting family and other contacts.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Hand washing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hand washing is an effective way to prevent the spread of infection. Hands should ideally be wet with water and plain or antibacterial soap and rubbed together for 15 to 30 seconds. Pay special attention to the fingernails, between the fingers, and the wrists. Rinse the hands thoroughly and dry with a single use towel.",
"    </p>",
"    <p>",
"     If a sink is not available, alcohol-based hand rubs are a good alternative for disinfecting hands. Spread the hand rub over the entire surface of hands, fingers, and wrists until dry. Hand rubs may be used several times. Hand rubs are available as a liquid or wipe in small, portable sizes that are easy to carry in a pocket or handbag. When a sink is available and the hands are dirty, wash them with soap and water.",
"    </p>",
"    <p>",
"     Clean the hands after changing a diaper, before and after preparing food and eating, after going to the bathroom, after handling garbage or dirty laundry, after touching animals or pets, and after blowing the nose or sneezing.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      DIARRHEA PREVENTION",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Food safety",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following precautions have been recommended",
"     <strong>",
"      for all consumers",
"     </strong>",
"     by the Food Safety and Inspection Services (",
"     <a class=\"external\" href=\"file://www.fsis.usda.gov/\">",
"      www.fsis.usda.gov",
"     </a>",
"     ) and the Centers for Disease Control and Prevention.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Do not drink raw (unpasteurized) milk or foods that contain unpasteurized milk.",
"      </li>",
"      <li>",
"       Wash raw fruits and vegetables thoroughly before eating.",
"      </li>",
"      <li>",
"       Keep the refrigerator temperature at 40&ordm;F (4.4&ordm;C) or lower; the freezer at 0&ordm;F (-17.8&ordm;C) or lower.",
"      </li>",
"      <li>",
"       Use precooked, perishable, or ready-to-eat food as soon as possible.",
"      </li>",
"      <li>",
"       Keep raw meat, fish, and poultry separate from other food.",
"      </li>",
"      <li>",
"       Wash hands, knives, and cutting boards after handling uncooked food, including produce and raw meat, fish, or poultry.",
"      </li>",
"      <li>",
"       Thoroughly cook raw food from animal sources to a safe internal temperature: ground beef 160&ordm;F (71&ordm;C); chicken 170&ordm;F (77&ordm;C); turkey 180&ordm;F (82&ordm;C); pork 145&ordm;F (63&ordm;C) with a three minute rest time.",
"      </li>",
"      <li>",
"       Seafood should be cooked thoroughly to minimize the risk of food poisoning. Eating raw fish (eg, sushi) poses a risk for a variety of parasitic worms (in addition to the risks associated with organisms carried by food handlers). Freezing kills some, although not all, harmful microorganisms. Raw fish that is labeled \"sushi-grade\" or \"sashimi-grade\" has been frozen.",
"      </li>",
"      <li>",
"       Cook chicken eggs thoroughly, until the yolk is firm.",
"      </li>",
"      <li>",
"       Refrigerate foods promptly. Never leave cooked foods at room temperature for more than two hours (one hour if the room temperature is above",
"       <span class=\"nowrap\">",
"        90&ordm;F/32&ordm;C).",
"       </span>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Food safety for pregnant women or those with a weakened immune system",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following additional recommendations apply to",
"     <strong>",
"      pregnant women",
"     </strong>",
"     and those who have a",
"     <strong>",
"      weakened immune system",
"     </strong>",
"     :",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Do not eat hot dogs, p&acirc;t&eacute;s, luncheon meats, bologna, or other delicatessen meats unless they are reheated until steaming hot; avoid the use of microwave ovens since uneven cooking may occur.",
"      </li>",
"      <li>",
"       Avoid spilling fluids from raw meat and hot dog packages on other foods, utensils, and food preparation surfaces. In addition, wash hands after handling hot dogs, luncheon meats, delicatessen meats, and raw meat, chicken, turkey, or seafood or their juices.",
"      </li>",
"      <li>",
"       Do not eat pre-prepared salads, such as ham salad, chicken salad, egg salad, tuna salad, or seafood salad.",
"      </li>",
"      <li>",
"       Do not eat soft cheeses such as feta, Brie, and Camembert, blue-veined cheeses, or Mexican-style cheeses such as queso blanco, queso fresco, or Panela, unless they have a label that clearly states that the cheese is made from pasteurized milk.",
"      </li>",
"      <li>",
"       Do not eat refrigerated pates or meat spreads. Canned or shelf-stable products may be eaten.",
"      </li>",
"      <li>",
"       Do not eat refrigerated smoked seafood unless it has been cooked. Refrigerated smoked seafood, such as salmon, trout, whitefish, cod, tuna or mackerel, is most often labeled as \"nova-style,\" \"lox,\" \"kippered,\" \"smoked,\" or \"jerky.\" The fish is found in the refrigerator section or sold at deli counters of grocery stores and delicatessens. Canned or shelf-stable smoked seafood may be eaten.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Travelers' diarrhea prevention",
"     </span>",
"     &nbsp;&mdash;&nbsp;Recommendations to prevent travelers' diarrhea are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=see_link\">",
"      \"Patient information: General travel advice (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP FOR DIARRHEA",
"     </span>",
"    </p>",
"    <p>",
"     If your diarrhea is not severe, you do not always need to be seen by a doctor, especially if the diarrhea begins to improve within 48 hours. Self-care measures for this situation are discussed above (see",
"     <a class=\"local\" href=\"#H4\">",
"      'Diarrhea home care'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     However, if you have one or more of the following signs or symptoms, you should be evaluated by a healthcare provider:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Profuse watery diarrhea with signs of dehydration. Early features of dehydration include sluggishness, becoming tired easily, dry mouth and tongue, thirst, muscle cramps, dark-colored urine, urinating infrequently, and dizziness or lightheadedness after standing or sitting up. More severe features include abdominal pain, chest pain, confusion, or difficulty remaining alert.",
"      </li>",
"      <li>",
"       Many small stools containing blood and mucus",
"      </li>",
"      <li>",
"       Bloody or black diarrhea",
"      </li>",
"      <li>",
"       Temperature &ge;38.5&ordm;C (101.3&ordm;F)",
"      </li>",
"      <li>",
"       Passage of &ge;6 unformed stools per 24 hours or illness that lasts more than 48 hours",
"      </li>",
"      <li>",
"       Severe abdominal",
"       <span class=\"nowrap\">",
"        pain/painful",
"       </span>",
"       passage of stool",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In addition, if you have persistent diarrhea following antibiotics, are older than 69 years, have other medical illness or a weakened immune system, you should also consult your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Acute diarrhea is defined as three or more loose or watery stools per day.",
"      </li>",
"      <li>",
"       Diarrhea can be caused by infections or other factors. Sometimes, the cause of diarrhea is not known. Diarrhea caused by an infection usually begins 12 hours to four days after exposure and resolves within three to seven days.",
"      </li>",
"      <li>",
"       A person may have mild to severe diarrhea. Some people with diarrhea also have fever (temperature greater than 100.4&ordm;F or 38&ordm;C), abdominal pain, or cramping.",
"      </li>",
"      <li>",
"       People with mild diarrhea do not usually need to go to the doctor, especially if the diarrhea begins to improve within 48 hours. If you develop any of the following, you should call your doctor or nurse immediately:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Profuse watery diarrhea with sluggishness, becoming tired easily, dry mouth and tongue, thirst, muscle cramps, dark-colored urine, urinating infrequently, and dizziness or lightheadedness after standing or sitting up. More severe features include abdominal pain, chest pain, confusion, or difficulty remaining alert.",
"      </li>",
"      <li>",
"       Passage of many small stools containing blood and mucus",
"      </li>",
"      <li>",
"       Bloody or black diarrhea",
"      </li>",
"      <li>",
"       Temperature &ge;38.5&ordm;C (101.3&ordm;F)",
"      </li>",
"      <li>",
"       Passing 6 or more watery stools per 24 hours or illness that lasts more than 48 hours",
"      </li>",
"      <li>",
"       Severe abdominal pain",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In addition, if you have persistent diarrhea after finishing antibiotics, are older than 69, or have other medical illness or a weakened immune system, you should also consult your doctor or nurse.",
"      </li>",
"      <li>",
"       The most important treatment for diarrhea is to drink fluids that contain water, salt, and sugar. Sports drinks (eg, Gatorade) may be acceptable if you are not dehydrated and are otherwise healthy. Diluted fruit juices and flavored soft drinks along with saltine crackers and broths or soups may also be acceptable.",
"      </li>",
"      <li>",
"       If you have dark yellow colored urine or do not pass urine frequently, you should drink more fluids. The urine should normally be light yellow to clear colored.",
"      </li>",
"      <li>",
"       Medications to reduce diarrhea are available without a prescription, and are safe if there is no fever (temperature greater than 100.4&ordm;F or 38&ordm;C) and the stools are not bloody. These medications do not cure the cause of the diarrhea, but help to reduce the frequency of bowel movements. Common medications include loperamide (Imodium&reg;), diphenoxylate (Lomotil&reg;), and bismuth subsalicylate (Pepto-Bismol&reg; or Kaopectate&reg;).",
"      </li>",
"      <li>",
"       If you do not have an appetite, you can drink only liquids for a short period of time. Boiled starches and cereals (eg, potatoes, noodles, rice, wheat, and oat) with salt are recommended if you have watery diarrhea; crackers, bananas, soup, and boiled vegetables may also be eaten.",
"      </li>",
"      <li>",
"       Antibiotics are not needed for most people with diarrhea.",
"      </li>",
"      <li>",
"       If you have diarrhea, be careful to avoid spreading the infection to family, friends, and co-workers. You are contagious for as long as diarrhea continues. Infections are usually spread from hand to mouth; hand washing, care with diapering, and staying out of work or school are a few ways to prevent infecting family and other contacts.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784941258\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12026559\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/5/9299?source=see_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/34/34338?source=see_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/22/10595?source=see_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/26/11684?source=see_link\">",
"      Patient information: Lactose intolerance (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/47/28402?source=see_link\">",
"      Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=see_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/62/32738?source=see_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/3/10290?source=see_link\">",
"      Patient information: Ischemic bowel disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/24/6530?source=see_link\">",
"      Patient information: Cryptosporidiosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/31/27122?source=see_link\">",
"      Patient information: Salmonellosis (Salmonella) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/3/20530?source=see_link\">",
"      Patient information: Travelers&rsquo; diarrhea (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/63/31730?source=see_link\">",
"      Patient information: E. coli (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/29/28114?source=see_link\">",
"      Patient information: Listeria (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/42/2723?source=see_link\">",
"      Patient information: Campylobacter infection (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12026641\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/14/7395?source=see_link\">",
"      Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/1/27?source=see_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/52/19267?source=see_link\">",
"      Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/30/29156?source=see_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=see_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=see_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/19/19769?source=see_link\">",
"      Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=see_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38535?source=see_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/48/26376?source=see_link\">",
"      Clinical presentation and diagnosis of rotavirus infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13961?source=see_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37960?source=see_link\">",
"      Pathogenic Escherichia coli",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/44/24265?source=see_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26345?source=see_link\">",
"      Epidemiology and causes of acute diarrhea in developed countries",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6313?source=see_link\">",
"      Epidemiology of viral gastroenteritis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43241?source=see_link\">",
"      Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36073?source=see_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18868?source=see_link\">",
"      Prevention and treatment of viral gastroenteritis in adults",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Digestive and Diabetes and Kidney Diseases",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/diarrhea/index.htm\">",
"        file://digestive.niddk.nih.gov/ddiseases/pubs/diarrhea/index.htm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Center for Disease Control and Prevention",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cdc.gov/\">",
"        www.cdc.gov",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Gastroenterology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.acg.gi.org/patients/gihealth/diarrheal.asp\">",
"        www.acg.gi.org/patients/gihealth/diarrheal.asp",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/29/36308/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/29/36308?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36308/abstract/1\">",
"      Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36308/abstract/2\">",
"      Musher DM, Musher BL. Contagious acute gastrointestinal infections. N Engl J Med 2004; 351:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36308/abstract/3\">",
"      DuPont HL. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1997; 92:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36308/abstract/4\">",
"      Thielman NM, Guerrant RL. Clinical practice. Acute infectious diarrhea. N Engl J Med 2004; 350:38.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f35_29_36308=[""].join("\n");
var outline_f35_29_36308=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DIARRHEA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DIARRHEA CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           DIARRHEA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           DIARRHEA HOME CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           DIARRHEA PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHEN TO SEEK HELP FOR DIARRHEA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/9/9372\" title=\"table 1\">",
"           Diarrhea causes PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f35_29_36309="Skull fracture in an abused infant";
var content_f35_29_36309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skull fracture in an abused infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 615px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain radiograph of the skull demonstrates a right parietal skull fracture (arrow) in an abused infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cindy Christian, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36309=[""].join("\n");
var outline_f35_29_36309=null;
var title_f35_29_36310="Parasitic pulmonary infections in HIV-infected patients";
var content_f35_29_36310=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parasitic pulmonary infections in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36310/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36310/contributors\">",
"     Patricia A Tietjen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36310/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36310/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36310/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36310/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/29/36310/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the era of potent antiretroviral therapy, parasitic pulmonary infections were more commonly seen than they are today. However, the clinician still needs to be aware of presenting symptoms and signs of these uncommon infections, which may still be diagnosed in the immunosuppressed patient with untreated or drug-resistant HIV infection.",
"   </p>",
"   <p>",
"    This topic will address pulmonary infections related to Toxoplasma gondii, Strongyloides stercoralis, Cryptosporidium, and Microsporidium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TOXOPLASMOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasma gondii is a ubiquitous intracellular protozoan. Although T. gondii can infect a wide range of vertebrates, feral and domestic cats are the definitive hosts. The organism undergoes its complete life cycle in the cat, resulting in the production of oocytes, which are passed with the feces into soil. Oocytes may remain infective for over one year. If ingested, Toxoplasma can invade tissue and reproduce. The two routes of transmission to humans are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of food or beverages contaminated with sporulated oocytes.",
"     </li>",
"     <li>",
"      Transmission from mother to fetus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no evidence of any other type of human-to-human transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;T. gondii is generally believed to cause subclinical infection in most immunocompetent hosts, but one review found that one-third of the reported cases of active pneumonia were in patients with no underlying immunosuppressive illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/1\">",
"     1",
"    </a>",
"    ]. Of the remaining two-thirds, 61 percent had AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] and 39 percent had other forms of immunosuppression.",
"   </p>",
"   <p>",
"    Most active cases of T. gondii disease are due to reactivation of latent infection. Approximately one-third of adults in the United States are IgG seropositive for T. gondii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/4\">",
"     4",
"    </a>",
"    ]. In HIV-infected individuals who are seropositive for T. gondii, it is estimated that approximately 30 percent will develop toxoplasma encephalitis within two years of the initial diagnosis of AIDS without antiretroviral therapy; another 1 percent who are seronegative will develop primary toxoplasmosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although encephalitis is overwhelmingly the most common manifestation of T. gondii infection in AIDS patients, pneumonitis has become its second most common presentation. The incidence of pneumonitis is unknown, but the number of case reports is increasing. One report estimated the prevalence of T. gondii pneumonia in France to be 5 percent, based upon a prospective study of bronchoalveolar lavage (BAL) specimens in 169 AIDS patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/5\">",
"     5",
"    </a>",
"    ]. Rates in the United States seem to be much lower, which may be due to lower rates of dormant infection or to under-diagnosis. Active pulmonary toxoplasmosis does not usually occur in HIV-infected patients until the CD4+ count falls below 100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasma pneumonitis generally presents with fever, nonproductive cough, and dyspnea. The chest radiographs generally show diffuse bilateral interstitial and alveolar infiltrates. Other abnormalities include single or bilateral pulmonary nodules, cavitary infiltrates, lobar pneumonia, and pleural effusions.",
"   </p>",
"   <p>",
"    Pulmonary toxoplasmosis may be clinically indistinguishable from PCP, tuberculosis, cryptococcosis, or histoplasmosis. Serologic tests for IgG, IgM, IgA, and IgE to T. gondii are available, but the results are usually not helpful in the profoundly immunosuppressed patient. However, the absence of IgG antibody to T. gondii does make the diagnosis much less likely, since most active disease is due to reactivation of latent infection. Reports of gallium scans in patients with T. gondii pneumonitis are rare, but diffuse intense uptake is reported, and serum LDH levels may be markedly elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy with bronchoalveolar lavage (with or without transbronchial biopsy) is the preferred method of diagnosis, but its sensitivity and specificity are unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The diagnosis is confirmed by observing the tachyzoite form of the organism in the BAL fluid or transbronchial biopsy. The most reliable methods of detection are Giemsa staining or",
"    <span class=\"nowrap\">",
"     eosin/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"      methylene blue",
"     </a>",
"    </span>",
"    staining. The tachyzoite is 5 to 7 microns in length and is crescent-shaped. Immunofluorescence staining with a monoclonal antibody, inoculation of mice followed by traditional culture, or polymerase chain reaction (PCR) technology may increase the yield of BAL, but most of these methods are not readily available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If bronchoscopy is not diagnostic, then an open lung biopsy can be performed, either by video-assisted thoracoscopic surgery (VATS) or traditional thoracotomy. Pathologically, a fibrinous exudate can be seen in the bronchi and alveoli, with an inflammatory cell interstitial infiltrate and areas of parenchymal necrosis. The organism may be seen within alveolar macrophages or freely floating within the alveoli. Unfortunately, the diagnosis of Toxoplasma pneumonitis is usually made by postmortem examination of the lungs, because it is often not considered premortem and the special stains that are needed to make the diagnosis are not requested. Even with antemortem diagnosis, one review estimates the mortality to be 40 percent in immunosuppressed hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    is the regimen of choice for treatment of extrapulmonary toxoplasmosis. The same regimen is used for pulmonary toxoplasmosis since there are no controlled studies specifically designed for lung involvement. A 200 mg loading dose of pyrimethamine is given initially and is followed by 50 to 75",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    while sulfadiazine is given at 4 to 6",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/12\">",
"     12",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    calcium (10 to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally) is usually given to reduce the hematologic toxicity of these drugs.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    (at a dose of 600 mg every six hours) can be used in combination with pyrimethamine in patients with sulfa intolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact duration of therapy for Toxoplasma pneumonitis is unknown; however, at least three to six weeks should be given, depending upon the severity of the disease and the response rate.",
"   </p>",
"   <p>",
"    Unfortunately, adverse reactions are common to all of these drugs (",
"    <a class=\"graphic graphic_table graphicRef75331 \" href=\"mobipreview.htm?18/38/19051\">",
"     table 1",
"    </a>",
"    ). Other drugs that may be considered include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    alone or in combination with other agents.",
"   </p>",
"   <p>",
"    Some studies suggest successful treatment outcomes in 50 to 77 percent of patients, although the number of cases of pulmonary toxoplasmosis is small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary prophylaxis or maintenance therapy is prudent because relapses of toxoplasmosis are reported in up to 80 percent of patients after successful therapy (",
"    <a class=\"graphic graphic_figure graphicRef61858 \" href=\"mobipreview.htm?43/43/44734\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lowest relapse rate for Toxoplasma encephalitis is reported with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      (25 to 75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      (1.0 to 1.5 grams four times daily) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      can be used in sulfa intolerant patients. There is, however, a high relapse rate with low doses of clindamycin; as a result, 1200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in divided doses is suggested if tolerated by the patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to guidelines issued from the Centers for Disease Control and Prevention, the United States Public Health Service and the Infectious Diseases Society of America, discontinuation of secondary prophylaxis may be considered if [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient has successfully completed treatment",
"     </li>",
"     <li>",
"      The patient is asymptomatic",
"     </li>",
"     <li>",
"      The CD4 count has been maintained above 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      for six months",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prophylaxis against Toxoplasma encephalitis should be considered in patients with CD4+ counts below 100",
"    <span class=\"nowrap\">",
"     cell/mm3",
"    </span>",
"    and positive T. gondii serology (",
"    <a class=\"graphic graphic_figure graphicRef61858 \" href=\"mobipreview.htm?43/43/44734\">",
"     figure 1",
"    </a>",
"    ).",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    is the recommended first-line prophylactic agent, as it also offers prophylaxis against PCP. Other effective prophylactic drugs include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    as a single agent, pyrimethamine-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , Fansidar, and possibly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Seronegative persons who are not taking a PCP prophylactic agent with known activity against toxoplasmosis should be retested for IgG antibody when their CD4+ count drops below 100",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"    They should receive appropriate prophylaxis if they have seroconverted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/2,17\">",
"     2,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the CD4 count rises above 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for three months, primary prophylaxis for toxoplasmosis may be discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other preventive issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     STRONGYLOIDIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strongyloides stercoralis is an intestinal parasite that has a worldwide distribution but is predominantly found in tropical and subtropical areas as well as the southeastern United States. The primary mode of transmission occurs when larvae from contaminated feces penetrate the skin, although infection can also occur via the fecal-oral route and from sexual transmission. Most infected persons remain either asymptomatic or have low grade abdominal symptoms. Some patients, particularly those who are immunosuppressed, can develop disseminated strongyloidiasis or the hyperinfection syndrome, both of which are considered \"systemic strongyloidiasis\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disseminated strongyloidiasis occurs when the organism, in the larval form, is found outside the usual migration pattern.",
"     </li>",
"     <li>",
"      Hyperinfection is an augmentation of the life cycle, resulting in a heavy infestation of worms in the lungs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surprisingly, there have only been scattered cases of systemic strongyloidiasis in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/20,22,23\">",
"     20,22,23",
"    </a>",
"    ]. The only associated risk factor in the HIV-infected population is previous or current residence in an endemic area. Risk factors for the development of strongyloidiasis in the general population include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Race (white)",
"     </li>",
"     <li>",
"      Gender (male)",
"     </li>",
"     <li>",
"      Use of steroids",
"     </li>",
"     <li>",
"      Hematologic malignancy",
"     </li>",
"     <li>",
"      Prior gastric surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of schistosomiasis or ascariasis may be an additional risk factor that is relevant in rural, underdeveloped countries where these infections are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic strongyloidiasis is manifested by fever, malaise, and gastrointestinal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory symptoms. Eosinophilia is common in immunocompetent patients with chronic Strongyloides, but it may be absent in immunocompromised patients who develop systemic strongyloidiasis. One report suggests that eosinopenia is a poor prognostic indicator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/26\">",
"     26",
"    </a>",
"    ]. Gram negative bacteremia and meningitis may complicate these infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organisms may be identified through examination of wet preparations of stool, sputum, or bronchoalveolar lavage fluid. The diagnosis may also be made serologically, but the tests are not widely available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ELISA has a sensitivity of 85 to 90 percent and a specificity approaching 90 percent. However, there are false positive tests in patients with other parasitic infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serial antibody titers may be followed in patients who have been treated, but there may be difficulty in distinguishing acute from previous infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    is the first-line agent for treatment, and a course of five to seven days has been suggested in immunosuppressed patients with systemic disease. Lifelong suppressive therapy may be indicated for both gastrointestinal and pulmonary infections in patients with relapses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis should be considered in patients from endemic areas, especially those with unexplained eosinophilia.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    may be given either as a single dose (200",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) or in a multidose schedule (200",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day for four days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/28\">",
"     28",
"    </a>",
"    ]. Remissions induced by the multidose regimen of ivermectin have been maintained for up to three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CRYPTOSPORIDIUM AND MICROSPORIDIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidium and Microsporidium are causative agents of gastrointestinal disease in HIV-infected patients. There are a few case reports of pulmonary disease due to these organisms in the early AIDS era, before effective antiretroviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36310/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Fever and cough were the dominant symptoms.",
"   </p>",
"   <p>",
"    Prevention of exposure is presently the preferred method of prophylaxis, particularly in the patient with advanced immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11946490\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to the era of potent antiretroviral therapy, parasitic pulmonary infections were more commonly seen than they are today. However, the clinician needs to be aware of the presenting symptoms and signs of these uncommon infections, which may still occur in the immunosuppressed patient with untreated or drug-resistant HIV infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Toxoplasma pneumonitis generally presents with fever, nonproductive cough, and dyspnea. The chest radiographs generally show diffuse bilateral interstitial and alveolar infiltrates. Pulmonary toxoplasmosis does not usually occur in HIV-infected patients until the CD4+ count falls below 100",
"      <span class=\"nowrap\">",
"       cells/mm3.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchoscopy with bronchoalveolar lavage for examination of tachyzoites is the preferred method of diagnosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      is the regimen of choice for treatment of extrapulmonary toxoplasmosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary prophylaxis or maintenance therapy is important because of the high rate of relapse after successful therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Secondary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary prophylaxis against Toxoplasma encephalitis should be administered to patients with CD4+ counts below 100",
"      <span class=\"nowrap\">",
"       cell/mm3",
"      </span>",
"      and who are seropositive for toxoplasma.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      is the recommended first-line prophylactic agent, as it also effective in preventing Pneumocystis pneumonia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Primary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strongyloides stercoralis is an intestinal parasite that has a worldwide distribution. Most infected persons remain either asymptomatic or have low grade abdominal symptoms. However, AIDS patients are at risk for disseminated strongyloidiasis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Strongyloidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disseminated strongyloidiasis is manifested by fever, malaise, and gastrointestinal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory symptoms. Although eosinophilia is common in immunocompetent patients with chronic strongyloides, this laboratory finding may be absent in immunocompromised patients who develop disseminated disease. Gram negative bacteremia and meningitis may complicate these infections. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The organisms may be identified through examination of wet preparations of stool, sputum, or bronchoalveolar lavage fluid. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"       Ivermectin",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mcg/kg/day)",
"      </span>",
"      is the first-line agent for treatment. After an initial course of 5 to 7 days, lifelong suppressive therapy may be also indicated for both gastrointestinal and pulmonary infections in patients with relapses of infections. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryptosporidium and Microsporidium are causative agents of gastrointestinal disease in HIV-infected patients. There are a few case reports of pulmonary disease due to these organisms in the early AIDS era, before effective antiretroviral therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cryptosporidium and microsporidium'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/1\">",
"      Pomeroy C, Filice GA. Pulmonary toxoplasmosis: a review. Clin Infect Dis 1992; 14:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/2\">",
"      Mariuz P, Bosler EM, Luft BJ. Toxoplasmosis in individuals with AIDS. Infect Dis Clin North Am 1994; 8:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/3\">",
"      Holliman RE. Serological study of the prevalence of toxoplasmosis in asymptomatic patients infected with human immunodeficiency virus. Epidemiol Infect 1990; 105:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/4\">",
"      Evans TG, Schwartzman JD. Pulmonary toxoplasmosis. Semin Respir Infect 1991; 6:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/5\">",
"      Derouin F, Sarfati C, Beauvais B, et al. Prevalence of pulmonary toxoplasmosis in HIV-infected patients. AIDS 1990; 4:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/6\">",
"      Bonilla CA, Rosa UW. Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome: diagnosis by bronchoalveolar lavage. South Med J 1994; 87:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/7\">",
"      Pugin J, Vanhems P, Hirschel B, et al. Extreme elevations of serum lactic dehydrogenase differentiating pulmonary toxoplasmosis from Pneumocystis pneumonia. N Engl J Med 1992; 326:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/8\">",
"      Oksenhendler E, Cadranel J, Sarfati C, et al. Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome. Am J Med 1990; 88:18N.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/9\">",
"      Maguire GP, Tatz J, Giosa R, Ahmed T. Diagnosis of pulmonary toxoplasmosis by bronchoalveolar lavage. N Y State J Med 1986; 86:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/10\">",
"      Derouin F, Sarfati C, Beauvais B, et al. Laboratory diagnosis of pulmonary toxoplasmosis in patients with acquired immunodeficiency syndrome. J Clin Microbiol 1989; 27:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/11\">",
"      Burg JL, Grover CM, Pouletty P, Boothroyd JC. Direct and sensitive detection of a pathogenic protozoan, Toxoplasma gondii, by polymerase chain reaction. J Clin Microbiol 1989; 27:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/12\">",
"      McCabe RE, Oster S. Current recommendations and future prospects in the treatment of toxoplasmosis. Drugs 1989; 38:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/13\">",
"      Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 1992; 116:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/14\">",
"      Lane HC, Laughon BE, Falloon J, et al. NIH conference. Recent advances in the management of AIDS-related opportunistic infections. Ann Intern Med 1994; 120:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/15\">",
"      Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/16\">",
"      Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clin Infect Dis 2005; 40:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/17\">",
"      USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Recomm Rep 1995; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/18\">",
"      Furrer H, Opravil M, Bernasconi E, et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet 2000; 355:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/19\">",
"      Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000; 181:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/20\">",
"      Celedon JC, Mathur-Wagh U, Fox J, et al. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore) 1994; 73:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/21\">",
"      Satoh M, Kiyuna S, Shiroma Y, et al. Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1. Clin Exp Immunol 2003; 133:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/22\">",
"      Lessnau KD, Can S, Talavera W. Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature. Chest 1993; 104:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/23\">",
"      Maayan S, Wormser GP, Widerhorn J, et al. Strongyloides stercoralis hyperinfection in a patient with the acquired immune deficiency syndrome. Am J Med 1987; 83:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/24\">",
"      Davidson RA, Fletcher RH, Chapman LE. Risk factors for strongyloidiasis. A case-control study. Arch Intern Med 1984; 144:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/25\">",
"      Nucci M, Portugal R, Pulcheri W, et al. Strongyloidiasis in patients with hematologic malignancies. Clin Infect Dis 1995; 21:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/26\">",
"      Igra-Siegman Y, Kapila R, Sen P, et al. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis 1981; 3:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/27\">",
"      Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, et al. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004; 5:2615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/28\">",
"      Torres JR, Isturiz R, Murillo J, et al. Efficacy of ivermectin in the treatment of strongyloidiasis complicating AIDS. Clin Infect Dis 1993; 17:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/29\">",
"      Mannheimer SB, Soave R. Protozoal infections in patients with AIDS. Cryptosporidiosis, isosporiasis, cyclosporiasis, and microsporidiosis. Infect Dis Clin North Am 1994; 8:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/30\">",
"      Forgacs P, Tarshis A, Ma P, et al. Intestinal and bronchial cryptosporidiosis in an immunodeficient homosexual man. Ann Intern Med 1983; 99:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36310/abstract/31\">",
"      Weber R, Kuster H, Visvesvara GS, et al. Disseminated microsporidiosis due to Encephalitozoon hellem: pulmonary colonization, microhematuria, and mild conjunctivitis in a patient with AIDS. Clin Infect Dis 1993; 17:415.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3714 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36310=[""].join("\n");
var outline_f35_29_36310=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11946490\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TOXOPLASMOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      STRONGYLOIDIASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CRYPTOSPORIDIUM AND MICROSPORIDIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11946490\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3714\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3714|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/43/44734\" title=\"figure 1\">",
"      Toxoplasmosis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3714|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/38/19051\" title=\"table 1\">",
"      Regimens for toxoplasmosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_29_36311="Acute cholangitis - low power";
var content_f35_29_36311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acute cholangitis (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Portal triads are all enlarged and edematous, including one greatly enlarged triad with many bile ducts that occupies the right side of the image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36311=[""].join("\n");
var outline_f35_29_36311=null;
var title_f35_29_36312="Vasopressin and desmopressin stimulation test";
var content_f35_29_36312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vasopressin and desmopressin stimulation test",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36312/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36312/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36312/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36312/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36312/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/29/36312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arginine-vasopressin (AVP) is the natural human nonapeptide which, in addition to its antidiuretic, vasoconstrictive, glycogenolytic and platelet aggregation actions, plays an important role in the regulation of the ACTH-adrenal axis. AVP and some of its analogs such as porcine 8-lysine-vasopressin (LVP), terlipressin (Triglycyl-lysine-vasopressin), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (1-deamino, 8-D arginine-vasopressin) have been utilized to assess this axis for different purposes including to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Test pituitary ACTH secretion (AVP, LVP)",
"     </li>",
"     <li>",
"      Evaluate the cause or cure of ACTH-dependent Cushing's syndrome (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stimulate ACTH secretion during petrosal sinus sampling (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      alone or in combination with corticotropin-releasing hormone [CRH])",
"     </li>",
"     <li>",
"      Evaluate the presence of aberrant vasopressin receptors in ACTH-independent adrenal Cushing's syndrome (AVP, LVP, terlipressin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the various stimulation tests using vasopressin or its analogs in evaluating the pituitary-adrenal axis. AVP or LVP are now seldom used for the first purpose based on the availability of other tests to evaluate the HPA axis. However, these tests are now used increasingly for the last three purposes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26311?source=see_link\">",
"     \"Corticotropin-releasing hormone stimulation test\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21830?source=see_link\">",
"     \"Insulin-induced hypoglycemia test\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VASOPRESSIN PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;AVP is synthesized in the magnicellular neurons of the supraoptic and paraventricular nuclei and is stored in neurosecretory granules in the axons, which project to the posterior pituitary. In addition, proAVP is co-secreted with CRH from smaller parvicellular neurons in a section of the paraventricular nuclei which project their axons to the median eminence and portal system of the pituitary stalk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/1\">",
"     1",
"    </a>",
"    ]. At this site, AVP promotes the secretion of ACTH via activation of arginine vasopressin receptor 1B (AVPR1B, previously named V1B or V3 receptor) present in corticotropes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/2\">",
"     2",
"    </a>",
"    ]. The AVPR1A receptors in blood vessels mediate the vasoconstrictive effects of AVP; they are also present in adrenocortical cells and mediate the modest in vitro stimulatory effects of AVP on cortisol and aldosterone secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, AVP itself is produced in the adrenal medulla and cortex, suggesting that AVP can exert an",
"    <span class=\"nowrap\">",
"     autocrine/paracrine",
"    </span>",
"    control of adrenal steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cortisol inhibits the secretion of both CRH and AVP from the paraventricular nuclei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/5\">",
"     5",
"    </a>",
"    ]. Adrenal insufficiency decreases this inhibitory effect, leading to a persistent rise in vasopressin release, water retention, and hyponatremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. The AVPR2 receptors on the cortical and medullary collecting kidney tubules mediate the antidiuretic response via the migration of aquaporin-2 water channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/7\">",
"     7",
"    </a>",
"    ]. AVPR2 on vascular endothelium can modulate the release of factor VIII and von Willebrand factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/8\">",
"     8",
"    </a>",
"    ]. Both AVPR1A and AVPR1B activate phospholipase C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ], while the AVPR2 is coupled to adenylyl cyclase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AVP, LVP and terlipressin are expected to bind to all three receptors;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    is a preferential AVPR2 receptor selective agent and has only limited effects on AVPR1A and AVPR1B. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25876?source=see_link\">",
"     \"Hyponatremia and hyperkalemia in adrenal insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TEST PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;To perform a vasopressin stimulation test, an intravenous line is established 30 minutes before the test is begun. Blood samples for measurement of plasma ACTH and serum cortisol are obtained 15 minutes and immediately before and 15, 30, 45, 60, 90, and 120 minutes after the injection of AVP, LVP, terlipressin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. The test is usually performed in the morning with the patient fasting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The standard dose of AVP or LVP is 10 pressor units injected intramuscularly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Terlipressin (1 mg) is injected intravenously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The standard dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      is 10 mcg, given intravenously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    LVP for injection is not available in the United States. Terlipressin is utilized in Europe, but is not available for clinical use in the United States or Canada.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Side Effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;AVP, LVP, and terlipressin have peripheral vasoconstrictive and hypertensive activities and increase platelet aggregation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    is an AVPR2 preferential agonist and lacks the vasoconstrictive, pallor, and abdominal discomfort mediated by the AVPR1A action of the natural vasopressins. However, it shares their effect on platelets. These agents should therefore be avoided in patients with significant hypertensive or atherosclerotic cardiovascular disease.",
"   </p>",
"   <p>",
"    A number of side effects have been observed in healthy individuals receiving vasopressin or its analogs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pallor occurred in six of six men given AVP at a dose of 300",
"      <span class=\"nowrap\">",
"       ng/minute;",
"      </span>",
"      four complained of abdominal discomfort and flatulence and one had severe nausea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study of 18 healthy individuals, 50 percent experienced transient facial flushing after bolus intravenous injection of 10 or 15 mcg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      ; at the higher dose, two of eight individuals had nausea and one did not urinate for more than 36 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effects have also been reported in patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 23 patients with Cushing's syndrome who received LVP, 23 had facial blanching, 22 showed transient increases in blood pressure and heart rate, 11 had dizziness and discomfort, and six experienced abdominal pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Terlipressin has a serum half-life of six hours and has been used in the management of variceal hemorrhage. Complications of AVP analogs used for this indication have included coronary and mesenteric ischemia, hyponatremia, pulmonary vasoconstriction, and skin necrosis from peripheral infusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/20-22\">",
"       20-22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATING ACTH AND CORTISOL RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the normal response to 10 units of AVP or LVP can be less than that to CRH, similar criteria are used for a normal response: an increase of 35 percent or more in plasma ACTH concentrations or an increase of 20 percent or more in serum cortisol concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/23\">",
"     23",
"    </a>",
"    ]. AVP at 3 pressor units was reported to be maximally stimulating when given in combination with 100 mcg of CRH intravenously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/24\">",
"     24",
"    </a>",
"    ]. LVP 1 pressor unit in combination with 100 mcg CRH, both given intravenously, is a maximally stimulating dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/25\">",
"     25",
"    </a>",
"    ]; these combined tests are not utilized routinely in clinical practice.",
"   </p>",
"   <p>",
"    Patients who have taken or are taking glucocorticoids in replacement or pharmacologic doses may have decreased or absent plasma ACTH and serum cortisol responses to vasopressin as well as to CRH. The duration of the effect depends on the daily dose, the time of day the steroid is taken, and the length of time it has been taken. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    therapy may decrease the plasma ACTH and serum cortisol responses to vasopressin&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AVP stimulation test also was used at one time for the differential diagnosis of primary versus secondary adrenal insufficiency. However, since normal pituitary corticotrophs also respond to CRH, a more potent stimulus of ACTH secretion, the CRH stimulation test has replaced the AVP stimulation test for this purpose.",
"   </p>",
"   <p>",
"    It was expected that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    , initially thought to be a selective AVPR2 receptor agent, would not stimulate ACTH and cortisol levels in normal individuals. However, some normal subjects do respond (2 of 15 in one study) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are reports of a greater response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    when it is administered at 1 PM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/17\">",
"     17",
"    </a>",
"    ], rather than 8 AM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/27\">",
"     27",
"    </a>",
"    ], in healthy individuals, suggesting that there might be greater sensitivity to desmopressin later in the day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ACTH-DEPENDENT CUSHING'S SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressin tests have been used in the evaluation of ACTH-dependent Cushing's syndrome. The AVP or LVP tests are now seldom utilized, but the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    test has been utilized more frequently in recent years. The lack of commercial availability of CRH in certain countries and the lower cost of desmopressin have contributed to the interest in its potential usefulness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Identifying the cause",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both AVP and LVP have been used to test pituitary ACTH secretory function in an attempt to establish the cause of hypercortisolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/13,14,19,28-31\">",
"     13,14,19,28-31",
"    </a>",
"    ]. A positive response to any of the agents, ie, an unequivocal rise in the plasma ACTH concentration, supports the diagnosis of ACTH-dependent Cushing's syndrome. However, as many as 25 percent of patients with Cushing's disease do not respond well to AVP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/14,25\">",
"     14,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    has also been used in the differential diagnosis of Cushing's syndrome. At low doses (1",
"    <span class=\"nowrap\">",
"     ng/kg/min),",
"    </span>",
"    desmopressin fails to potentiate the effect of corticotropin-releasing hormone (CRH) on ACTH release in most normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/32\">",
"     32",
"    </a>",
"    ]. At a higher dose (10 mcg IV), it causes an increase in plasma ACTH and serum cortisol concentrations in most patients with Cushing's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/16,33-36\">",
"     16,33-36",
"    </a>",
"    ], suggesting that the test could be used to diagnose this condition. However, subsequent reports that 13 to 60 percent of healthy subjects also respond to desmopressin indicate that it is not sufficiently specific to establish a diagnosis of Cushing's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/16,17,33\">",
"     16,17,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with Cushing's disease, using criteria of a 30 or 50 percent increase in plasma ACTH in response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    , 95 and 81 percent of patients respond, respectively; using the criterion of a greater than 20 percent increase in serum cortisol, 80 to 85 percent of patients respond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/16,34-38\">",
"     16,34-38",
"    </a>",
"    ]. However, in some reports, 8 of 25 (32 percent) of patients with ectopic ACTH syndrome also responded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/16,34-36,39-43\">",
"     16,34-36,39-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    has a relatively low affinity for the AVPR1B receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/10,44\">",
"     10,44",
"    </a>",
"    ] that is found on normal pituitary corticotrophs, on most adenomatous corticotrophs, and on some ACTH-secreting bronchial carcinoid adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/45\">",
"     45",
"    </a>",
"    ]. It was unclear whether this response to desmopressin was mediated by abnormal expression of the AVPR2 on the cells of the corticotroph adenomas and ectopic ACTH producing tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/36\">",
"     36",
"    </a>",
"    ], or by increased expression of the AVPR1B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/42\">",
"     42",
"    </a>",
"    ]. However, a study in patients with Cushing&rsquo;s disease suggests that the ACTH response to desmopressin correlates better with AVPR2 expression levels than to AVPR1B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/46\">",
"     46",
"    </a>",
"    ]. A higher in vivo response to desmopressin than that observed in corticotroph adenoma cultures (compared to high in vitro CRH response) suggested that other unidentified mechanisms to stimulate ACTH release may also be implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/47\">",
"     47",
"    </a>",
"    ]. Responsiveness to desmopressin has been observed in a bronchial carcinoid tumor in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cushing's disease versus Pseudo-Cushing's",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    test has been proposed to distinguish between Cushing's disease and pseudo-Cushing's states. None of eight patients with alcoholic pseudo-Cushing's syndrome showed a response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/48\">",
"     48",
"    </a>",
"    ]. However, desmopressin induced cortisol or ACTH responses in 3 of 20 obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/40\">",
"     40",
"    </a>",
"    ] and in about one-third of depressed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/49\">",
"     49",
"    </a>",
"    ]; as noted above, up to 60 percent of normal individuals also responded. Using an increase in plasma ACTH concentration of less than 6",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    as the criterion for lack of response, 29 of 30 patients with pseudo-Cushing's syndrome were correctly identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a group of 32 patients with mild Cushing's disease compared with 23 with pseudo-Cushing's syndrome, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    test had 90 percent specificity and 81.5 percent sensitivity while the combined",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (2mg over 48 hours) and CRH test had 100 percent sensitivity, but 62.5 percent specificity to distinguish the two etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/50\">",
"     50",
"    </a>",
"    ]. In a second report of 30 patients with Cushing&rsquo;s disease, 18 with pseudo Cushing&rsquo;s and 12 controls, the desmopressin test, using the criteria of basal serum cortisol &gt;331",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    and a rise in plasma ACTH &gt;4",
"    <span class=\"nowrap\">",
"     pmol/L,",
"    </span>",
"    had equally high sensitivity (96 percent) and specificity (100 percent) as a CRH test to discriminate patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Evaluating for cure of Cushing's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 14 patients cured of their Cushing's disease by transsphenoidal microadenomectomy, none responded to CRH or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    immediately after surgery, but five patients who were not cured responded to CRH, desmopressin, or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/52\">",
"     52",
"    </a>",
"    ]. Responsiveness to CRH returned over a period of several months as normal hypothalamic-pituitary-adrenal function was restored, but the response to desmopressin did not return [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 87 patients with presumed Cushing's disease, ACTH responses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    disappeared after transsphenoidal exploration in 50 (57 percent) and cortisol responses disappeared in 57 (70 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/37\">",
"     37",
"    </a>",
"    ]. There was no concordance between the clinical response to surgery and the post-operative response to desmopressin, as 4 of 50 patients without a response had persistent hypercortisolism, and 18 of 37 with a response were in remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general lack of response after tumor resection suggests that either the increased number of corticotrophs in the adenoma or their abnormal response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    is responsible for the plasma ACTH response in most patients with Cushing's disease. While a continued response suggests persistent disease, the test did not consistently predict outcome. In two patients in remission after pituitary surgery, reappearance of desmopressin response occurred between 6 to 24 months before other abnormal tests of Cushing's disease recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/53\">",
"     53",
"    </a>",
"    ]. A group of 22 patients with Cushing's disease underwent a desmopressin test three to six months post-pituitary surgery and were followed for a mean of 4.5 years; an increase of &gt;35 percent in ACTH or of &gt;14 percent in cortisol was predictive of a later recurrence with a positive predictive value of 100 percent for ACTH and 80 percent for cortisol with similarly high sensitivities and specificities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A group of 41 patients who had achieved initial remission after pituitary surgery underwent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    test within 15 to 30 days post-surgery and were followed for 20 to 161 months; 5 of 11 patients who recurred had increases of plasma cortisol after desmopressin &gt;193",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    (7",
"    <span class=\"nowrap\">",
"     mcg/dL),",
"    </span>",
"    but none of the 30 patients who remained in prolonged remission showed an increase in plasma cortisol &gt;193",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Combined with CRH",
"    </span>",
"    &nbsp;&mdash;&nbsp;When AVP or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    is given in combination with CRH, virtually all patients with Cushing's disease have an increase in plasma ACTH concentrations, using the criterion of a 350 percent rise after CRH with desmopressin, or a 35 percent rise after CRH with AVP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/41,56\">",
"     41,56",
"    </a>",
"    ]. However, some patients with ectopic ACTH secretion respond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/41,56,57\">",
"     41,56,57",
"    </a>",
"    ]. Since obese subjects without Cushing's syndrome may have a pronounced response to the combined CRH-AVP stimulation test, it is important to use the test",
"    <strong>",
"     ONLY",
"    </strong>",
"    in the setting of confirmed Cushing's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26311?source=see_link\">",
"     \"Corticotropin-releasing hormone stimulation test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     During petrosal sinus sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRH is not commercially available in certain countries or is more expensive than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    . Desmopressin has therefore been used in place of CRH to perform petrosal sinus sampling in small series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a larger retrospective series of 56 patients with ACTH-dependent Cushing's syndrome (including five of nine patients without central gradient with confirmed ectopic secretion),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    alone was found to amplify the central to peripheral ACTH gradient and to provide sensitivity and specificities similar to reported series using CRH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combined use of CRH and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    during petrosal sinus sampling was initially performed to improve the rate of false negative studies presumably related to patients with corticotroph tumors who are not stimulated by CRH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/57\">",
"     57",
"    </a>",
"    ]. A retrospective analysis of this combined test includes 47 patients with proven Cushing's disease and seven with occult ectopic ACTH-secreting tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/62\">",
"     62",
"    </a>",
"    ]. Of 47 Cushing's disease patients, 46 reached a gradient &gt;2 post-stimulation, while none of the patients with ectopic tumors did, resulting in a sensitivity of 97.9 percent; specificity was 100 percent, diagnostic accuracy 98.2 percent, and the positive and negative predictive values were 100 percent and 87.5 percent, respectively.",
"   </p>",
"   <p>",
"    However, another study reported two patients with ectopic ACTH syndrome who had an IPSS ACTH gradient between two and three after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/63\">",
"     63",
"    </a>",
"    ]. In patients with ectopic ACTH secretion, it is not known whether an ACTH response to desmopressin is derived from the normal corticotropes or the ectopic tumor. Thus it is possible that desmopressin, used alone or in combination with CRH during inferior petrosal sinus sampling for ACTH, may on occasion yield a false-positive diagnosis of Cushing's disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ACTH-INDEPENDENT ADRENAL CUSHING'S SYNDROME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Aberrant vasopressin receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressin-responsive Cushing's syndrome was reported in patients with ACTH-independent bilateral macronodular adrenal hyperplasia (AIMAH) or unilateral adenoma who increase their secretion of cortisol with exogenous AVP, LVP or terlipressin, upright posture or other physiological stimuli of endogenous vasopressin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/64-69\">",
"     64-69",
"    </a>",
"    ]. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/45/730?source=see_link\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"    </a>",
"    .) This exaggerated direct adrenal response to vasopressin in the absence of ACTH stimulation is most often secondary to the increased activity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    expression of AVPR1A receptor-effector system in the adrenal tumors or hyperplasias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/64,65,70\">",
"     64,65,70",
"    </a>",
"    ]. In some of the familial cases of AIMAH, aberrant adrenal vasopressin receptors were identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/66,67,71\">",
"     66,67,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with primary adrenal tumors or hyperplasias, the ACTH-independent nature of the disorder is best established by measuring plasma ACTH concentration. Plasma ACTH is suppressed by excess cortisol in patients with clinical Cushing's syndrome (&lt; 5",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [&lt;1.1",
"    <span class=\"nowrap\">",
"     pmol/L]).",
"    </span>",
"    In patients with sub-clinical Cushing's syndrome (unilateral adenoma or AIMAH) in whom cortisol production is only modest may not have suppressed their ACTH levels fully [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/15,67-69\">",
"     15,67-69",
"    </a>",
"    ]. In these patients, it is necessary to pretreat them with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    2 mg every six hours during 48 hours to suppress endogenous ACTH prior to conducting the vasopressin stimulation test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family members of individuals with AIMAH and aberrant vasopressin response should be screened for early AIMAH with 1 mg overnight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    tests; those who do not suppress their upright plasma cortisol on the following morning below 1.8",
"    <span class=\"nowrap\">",
"     &micro;g/dL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    should have an adrenal CT scan and AVP or terlipressin stimulation test performed under dexamethasone suppression.",
"   </p>",
"   <p>",
"    Similarly, aberrant stimulation of aldosterone was recently reported in patients with primary aldosteronism when vasopressin was administered under suppression of ACTH by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36312/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arginine-vasopressin (AVP) is synthesized in the magnicellular neurons of the supraoptic and paraventricular nuclei which project to the neurohypophysis; it is also co-secreted with CRH from single parvicellular neurons in the paraventricular nuclei which project their axons to the median eminence and portal system. AVP has three distinct receptors, which mediate a number of physiologic effects, including its antidiuretic effect and regulation of ACTH. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Vasopressin physiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    AVP and some of its analogs such as LVP, terlipressin, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    have been utilized to assess this axis for different purposes including to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Test pituitary ACTH secretion (AVP, LVP)",
"     </li>",
"     <li>",
"      Evaluate the cause or cure of ACTH-dependent Cushing's syndrome (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stimulate ACTH secretion during petrosal sinus sampling (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      alone or in combination with corticotropin-releasing hormone [CRH])",
"     </li>",
"     <li>",
"      Evaluate the presence of aberrant vasopressin receptors in ACTH-independent adrenal Cushing's syndrome (AVP, LVP, terlipressin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    test alone, like as the CRH test alone, cannot identify definitively the cause of ACTH-dependent Cushing&rsquo;s syndrome. It can be useful, however, in conjunction with the high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test to suggest a pituitary source of excess ACTH, which will require petrosal venous sinus catheterization for confirmation in the absence of a pituitary tumor larger than 6 mm on MRI. Based on availability, and previous demonstration of efficient stimulation of ACTH, either CRH or desmopressin can be used to perform the petrosal sampling. Further studies will clarify the false positive rate of desmopressin use with the IPSS, and whether the combined CRH and desmopressin tests are sufficiently superior to justify their increased cost.",
"   </p>",
"   <p>",
"    In ACTH-independent Cushing's syndrome, particularly for patients with AIMAH, we recommend a systematic evaluation of aberrant hormone receptors including stimulation with AVP, LVP or terlipressin, depending on availability. This may be particularly useful for early detection of familial forms of AIMAH.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/1\">",
"      Zimmerman EA, Nilaver G, Hou-Yu A, Silverman AJ. Vasopressinergic and oxytocinergic pathways in the central nervous system. Fed Proc 1984; 43:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/2\">",
"      Sugimoto T, Saito M, Mochizuki S, et al. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 1994; 269:27088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/3\">",
"      Perraudin V, Delarue C, Lefebvre H, et al. Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. J Clin Endocrinol Metab 1993; 76:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/4\">",
"      Gallo-Payet N, Guillon G. Regulation of adrenocortical function by vasopressin. Horm Metab Res 1998; 30:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/5\">",
"      Raff H. Glucocorticoid inhibition of neurohypophysial vasopressin secretion. Am J Physiol 1987; 252:R635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/6\">",
"      Zimmerman EA, Ma LY, Nilaver G. Anatomical basis of thirst and vasopressin secretion. Kidney Int Suppl 1987; 21:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/7\">",
"      Deen PM, Verdijk MA, Knoers NV, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994; 264:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/8\">",
"      Bichet DG, Razi M, Lonergan M, et al. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 1988; 318:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/9\">",
"      Thibonnier M, Auzan C, Madhun Z, et al. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 1994; 269:3304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/10\">",
"      de Keyzer Y, Auzan C, Lenne F, et al. Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett 1994; 356:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/11\">",
"      Birnbaumer M, Seibold A, Gilbert S, et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992; 357:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/12\">",
"      Lolait SJ, O'Carroll AM, McBride OW, et al. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992; 357:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/13\">",
"      Tucci JR, Espiner EA, Jagger PI, et al. Vasopressin in the evaluation of pituitary-adrenal function. Ann Intern Med 1968; 69:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/14\">",
"      Raux MC, Binoux M, Luton JP, et al. Studies of ACTH secretion control in 116 cases of Cushing's syndrome. J Clin Endocrinol Metab 1975; 40:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/15\">",
"      Reznik Y, Lefebvre H, Rohmer V, et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study. Clin Endocrinol (Oxf) 2004; 61:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/16\">",
"      Malerbi DA, Mendon&ccedil;a BB, Liberman B, et al. The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1993; 38:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/17\">",
"      Scott LV, Medbak S, Dinan TG. ACTH and cortisol release following intravenous desmopressin: a dose-response study. Clin Endocrinol (Oxf) 1999; 51:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/18\">",
"      Hensen J, Hader O, B&auml;hr V, Oelkers W. Effects of incremental infusions of arginine vasopressin on adrenocorticotropin and cortisol secretion in man. J Clin Endocrinol Metab 1988; 66:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/19\">",
"      Tabarin A, San Galli F, Dezou S, et al. The corticotropin-releasing factor test in the differential diagnosis of Cushing's syndrome: a comparison with the lysine-vasopressin test. Acta Endocrinol (Copenh) 1990; 123:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/20\">",
"      Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004; 32:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/21\">",
"      Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002; 30:2548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/22\">",
"      Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med 2002; 30:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/23\">",
"      Nieman LK, Oldfield EH, Wesley R, et al. A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1993; 77:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/24\">",
"      Arai K, Takebe K. Corticotropin response to combined administration of human corticotropin-releasing hormone and small-dose arginine vasopressin in normal subjects. Metabolism 1991; 40:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/25\">",
"      Favrod-Coune C, Raux-Demay MC, Proeschel MF, et al. Potentiation of the classic ovine corticotrophin releasing hormone stimulation test by the combined administration of small doses of lysine vasopressin. Clin Endocrinol (Oxf) 1993; 38:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/26\">",
"      Michelson D, Galliven E, Hill L, et al. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J Clin Endocrinol Metab 1997; 82:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/27\">",
"      Rado JP, Juhos E. Effect of 1-deamino-5-D-arginine vasopressin (DDAVP) on plasma cortisol (hydrocortisone). J Clin Pharmacol 1976; 16:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/28\">",
"      Webb-Peploe MM, Spathis GS, Reed PI. Cushing's syndrome: use of lysine vasopressin to distinguish overproduction of corticotrophin by pituitary from other causes of adrenal cortical hyperfunction. Lancet 1967; 1:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/29\">",
"      Coslovsky R, Wajchenberg BL, Nogueira O. Hyperresponsiveness to lysine-vasopressin in Cushing's disease. Acta Endocrinol (Copenh) 1974; 75:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/30\">",
"      Krieger DT, Luria M. Plasma ACTH and cortisol responses to TRF, vasopressin or hypoglycemia in cushing's disease and nelson's syndrome. J Clin Endocrinol Metab 1977; 44:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/31\">",
"      Catania A, Cantalamessa L, Orsatti A, et al. Plasma ACTH-response to the corticotropin releasing factor in patients with Cushing's disease. Comparison with the lysine-vasopressin test. Metabolism 1984; 33:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/32\">",
"      Gaillard RC, Riondel AM, Ling N, Muller AF. Corticotropin releasing factor activity of CRF 41 in normal man is potentiated by angiotensin II and vasopressin but not by desmopressin. Life Sci 1988; 43:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/33\">",
"      Scott LV, Medbak S, Dinan TG. Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. Biol Psychiatry 1999; 45:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/34\">",
"      Colombo P, Passini E, Re T, et al. Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess. Clin Endocrinol (Oxf) 1997; 46:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/35\">",
"      Terzolo M, Reimondo G, Al&igrave; A, et al. The limited value of the desmopressin test in the diagnostic approach to Cushing's syndrome. Clin Endocrinol (Oxf) 2001; 54:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/36\">",
"      Tsagarakis S, Tsigos C, Vasiliou V, et al. The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion. J Clin Endocrinol Metab 2002; 87:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/37\">",
"      Losa M, Mortini P, Dylgjeri S, et al. Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease. Clin Endocrinol (Oxf) 2001; 55:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/38\">",
"      Moro M, Putignano P, Losa M, et al. The desmopressin test in the differential diagnosis between Cushing's disease and pseudo-Cushing states. J Clin Endocrinol Metab 2000; 85:3569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/39\">",
"      Sakai Y, Horiba N, Tozawa F, et al. Desmopressin stimulation test for diagnosis of ACTH-dependent Cushing's syndrome. Endocr J 1997; 44:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/40\">",
"      Tsagarakis S, Vasiliou V, Kokkoris P, et al. Assessment of cortisol and ACTH responses to the desmopressin test in patients with Cushing's syndrome and simple obesity. Clin Endocrinol (Oxf) 1999; 51:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/41\">",
"      Newell-Price J, Perry L, Medbak S, et al. A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/42\">",
"      Dahia PL, Ahmed-Shuaib A, Jacobs RA, et al. Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors. J Clin Endocrinol Metab 1996; 81:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/43\">",
"      Arlt W, Dahia PL, Callies F, et al. Ectopic ACTH production by a bronchial carcinoid tumour responsive to desmopressin in vivo and in vitro. Clin Endocrinol (Oxf) 1997; 47:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/44\">",
"      Antoni FA. Novel ligand specificity of pituitary vasopressin receptors in the rat. Neuroendocrinology 1984; 39:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/45\">",
"      Arnaldi G, de Keyzer Y, Gasc JM, et al. Vasopressin receptors modulate the pharmacological phenotypes of Cushing's syndrome. Endocr Res 1998; 24:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/46\">",
"      Wang FF, Tang KT, Yen YS, et al. Plasma corticotrophin response to desmopressin in patients with Cushing's disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumours. Clin Endocrinol (Oxf) 2012; 76:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/47\">",
"      Pecori Giraldi F, Marini E, Torchiana E, et al. Corticotrophin-releasing activity of desmopressin in Cushing's disease: lack of correlation between in vivo and in vitro responsiveness. J Endocrinol 2003; 177:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/48\">",
"      Coiro V, Volpi R, Capretti L, et al. Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome. J Intern Med 2000; 247:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/49\">",
"      Malerbi DA, Fragoso MC, Vieira Filho AH, et al. Cortisol and adrenocorticotropin response to desmopressin in women with Cushing's disease compared with depressive illness. J Clin Endocrinol Metab 1996; 81:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/50\">",
"      Pecori Geraldi, F, Pivonello, R, Ambrogio, AG, et al. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol 2007; 66:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/51\">",
"      Tirabassi G, Papa R, Faloia E, et al. Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing's disease and pseudo-Cushing state: a comparative study. Clin Endocrinol (Oxf) 2011; 75:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/52\">",
"      Colombo P, Dall'Asta C, Barbetta L, et al. Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing's disease. Eur J Endocrinol 2000; 143:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/53\">",
"      Dall'asta C, Barbetta L, Bonavina L, et al. Recurrence of Cushing's disease preceded by the reappearance of ACTH and cortisol responses to desmopressin test. Pituitary 2004; 7:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/54\">",
"      Val&eacute;ro R, Vallette-Kasic S, Conte-Devolx B, et al. The desmopressin test as a predictive factor of outcome after pituitary surgery for Cushing's disease. Eur J Endocrinol 2004; 151:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/55\">",
"      Romanholi DJ, Machado MC, Pereira CC, et al. Role for postoperative cortisol response to desmopressin in predicting the risk for recurrent Cushing's disease. Clin Endocrinol (Oxf) 2008; 69:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/56\">",
"      Dickstein G, DeBold CR, Gaitan D, et al. Plasma corticotropin and cortisol responses to ovine corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease. J Clin Endocrinol Metab 1996; 81:2934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/57\">",
"      Tsagarakis S, Kaskarelis IS, Kokkoris P, et al. The application of a combined stimulation with CRH and desmopressin during bilateral inferior petrosal sinus sampling in patients with Cushing's syndrome. Clin Endocrinol (Oxf) 2000; 52:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/58\">",
"      Pasquali R, Gagliardi L, Vicennati V, et al. ACTH and cortisol response to combined corticotropin releasing hormone-arginine vasopressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome. Int J Obes Relat Metab Disord 1999; 23:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/59\">",
"      Kaltsas GA, Giannulis MG, Newell-Price JD, et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999; 84:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/60\">",
"      Booth GL, Redelmeier DA, Grosman H, et al. Improved diagnostic accuracy of inferior petrosal sinus sampling over imaging for localizing pituitary pathology in patients with Cushing's disease. J Clin Endocrinol Metab 1998; 83:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/61\">",
"      Machado MC, de Sa SV, Domenice S, et al. The role of desmopressin in bilateral and simultaneous inferior petrosal sinus sampling for differential diagnosis of ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2007; 66:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/62\">",
"      Tsagarakis S, Vassiliadi D, Kaskarelis IS, et al. The application of the combined corticotropin-releasing hormone plus desmopressin stimulation during petrosal sinus sampling is both sensitive and specific in differentiating patients with Cushing's disease from patients with the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 2007; 92:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/63\">",
"      Findling JW, Raff H. Newer diagnostic techniques and problems in Cushing's disease. Endocrinol Metab Clin North Am 1999; 28:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/64\">",
"      Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001; 22:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/65\">",
"      Mune T, Murase H, Yamakita N, et al. Eutopic overexpression of vasopressin v1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2002; 87:5706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/66\">",
"      Lee S, Hwang R, Lee J, et al. Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia. Clin Endocrinol (Oxf) 2005; 63:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/67\">",
"      Vezzosi D, Cartier D, R&eacute;gnier C, et al. Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. Eur J Endocrinol 2007; 156:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/68\">",
"      Bourdeau I, D'Amour P, Hamet P, et al. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome. J Clin Endocrinol Metab 2001; 86:5534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/69\">",
"      Tatsuno I, Uchida D, Tanaka T, et al. Vasopressin responsiveness of subclinical Cushing's syndrome due to ACTH-independent macronodular adrenocortical hyperplasia. Clin Endocrinol (Oxf) 2004; 60:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/70\">",
"      Joubert M, Louiset E, Rego JL, et al. Aberrant adrenal sensitivity to vasopressin in adrenal tumours associated with subclinical or overt autonomous hypercortisolism: is this explained by an overexpression of vasopressin receptors? Clin Endocrinol (Oxf) 2008; 68:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/71\">",
"      Gagliardi L, Hotu C, Casey G, et al. Familial vasopressin-sensitive ACTH-independent macronodular adrenal hyperplasia (VPs-AIMAH): clinical studies of three kindreds. Clin Endocrinol (Oxf) 2009; 70:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/72\">",
"      Lampron A, Bourdeau I, Oble S, et al. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. J Clin Endocrinol Metab 2009; 94:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36312/abstract/73\">",
"      Zwermann O, Suttmann Y, Bidlingmaier M, et al. Screening for membrane hormone receptor expression in primary aldosteronism. Eur J Endocrinol 2009; 160:443.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 158 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-A295DD27D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36312=[""].join("\n");
var outline_f35_29_36312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VASOPRESSIN PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TEST PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Side Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATING ACTH AND CORTISOL RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ACTH-DEPENDENT CUSHING'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Identifying the cause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cushing's disease versus Pseudo-Cushing's",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Evaluating for cure of Cushing's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Combined with CRH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      During petrosal sinus sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACTH-INDEPENDENT ADRENAL CUSHING'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Aberrant vasopressin receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26311?source=related_link\">",
"      Corticotropin-releasing hormone stimulation test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/45/730?source=related_link\">",
"      Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25876?source=related_link\">",
"      Hyponatremia and hyperkalemia in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21830?source=related_link\">",
"      Insulin-induced hypoglycemia test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_29_36313="Wiskott-Aldrich syndrome";
var content_f35_29_36313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Wiskott-Aldrich syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36313/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36313/contributors\">",
"     Hans D Ochs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36313/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36313/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/29/36313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24194143\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wiskott-Aldrich syndrome (WAS, MIM #301000) is an X-linked disorder caused by mutations in the gene that encodes the Wiskott-Aldrich syndrome protein (WASp). The originally described features of WAS include susceptibility to infections associated with adaptive and innate immune deficiency, microthrombocytopenia, and eczema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, there is a wide spectrum of disease severity due to",
"    <em>",
"     WAS",
"    </em>",
"    gene mutations, ranging from classic WAS with autoimmunity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    malignancy to a milder form characterized by isolated thrombocytopenia, called X-linked thrombocytopenia (XLT), to X-linked neutropenia (XLN).",
"   </p>",
"   <p>",
"    This topic reviews the epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of WAS and XLT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6866590\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;WAS is a rare disorder with an estimated incidence of approximately 1:100,000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/3\">",
"     3",
"    </a>",
"    ]. Approximately 50 percent of patients with",
"    <em>",
"     WAS",
"    </em>",
"    gene mutations have the WAS phenotype and the other half have the XLT phenotype (",
"    <a class=\"graphic graphic_figure graphicRef66996 \" href=\"mobipreview.htm?7/39/7793\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58264 \" href=\"mobipreview.htm?6/38/6767\">",
"     figure 2",
"    </a>",
"    ).",
"    <em>",
"     WAS",
"    </em>",
"    gene mutations causing X-linked neutropenia are very rare, with &lt;12 patients in four families reported to date. (See",
"    <a class=\"local\" href=\"#H24194157\">",
"     'Clinical phenotypes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22657964\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;WASp plays a crucial role in actin cytoskeleton remodeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/4\">",
"     4",
"    </a>",
"    ]. Its absence impacts the formation of the immunologic synapse, the site of interaction between T cells and antigen presenting cells that depends upon the generation of so-called lipid rafts, which provide a platform to recruit crucial molecules to ensure the stability of the immunologic synapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, T cell function is defective due to abnormal cytoskeletal reorganization leading to impaired migration, adhesion and insufficient interaction with other cells due to abnormal synapse formation. As a result, WASp deficiency also perturbs B cell homeostasis, resulting in the selective depletion of circulating mature B cells, splenic marginal zone precursors and marginal zone B cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The phenomenon of lymphocyte numbers declining over time is possibly due to accelerated cell death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circulating NK cell numbers are normal or increased, but cytotoxicity of WASp-deficient NK cells is impaired as a result of defective immune synapse formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Interleukin-2 (IL-2) can, at least in part, restore cytotoxicity in NK cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/10\">",
"     10",
"    </a>",
"    ] by inducing expression of a functionally related protein, WASp family verprolin-homologous 2 (WAVE2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/11\">",
"     11",
"    </a>",
"    ], making this a possible therapeutic opportunity for WAS patients. Invariant natural killer T (iNKT) cells, thought to be important players in protecting from autoimmunity and in cancer immunosurveillance, are completely absent in WAS and reduced in XLT patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/12\">",
"     12",
"    </a>",
"    ]. In mice, WASp is required for late stage thymic iNKT cell development and egress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    WASp-deficient humans and mice were shown to have regulatory T (Treg) cells that fail to suppress effector cells in vitro and that are incapable of controlling autoimmunity in several mouse models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. While WASp does not seem to be required for the thymic generation of natural Treg cells, it appears to play a crucial role in peripheral homeostasis of these cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/15\">",
"     15",
"    </a>",
"    ]. The suppressive effect of Tregs on effector T cells requires direct cell to cell contact. The failure of WASp-deficient Tregs to form synapses with effector T cells may explain their decreased function.",
"   </p>",
"   <p>",
"    WASp-deficient myeloid lineage cells exhibit impaired phagocytosis and chemotaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In addition, monocytes, macrophages and dendritic cells from WASp-deficient patients and mice demonstrate almost completely abrogated assembly of podosomes define [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]; the formation of filopodia and lamellipodia define at the migrating edge of macrophages and dendritic cells is defective; and chemotaxis to specific chemoattractants is impaired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/20,22,23\">",
"     20,22,23",
"    </a>",
"    ]. Defective migration and homing of several cell lineages may be a significant pathogenic mechanism in WAS.",
"   </p>",
"   <p>",
"    Thrombocytopenia is caused by ineffective thrombocytopoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/19\">",
"     19",
"    </a>",
"    ], reduced platelet survival due to intrinsic platelet abnormalities, or immune-mediated mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanisms for the high incidence of autoimmunity in WAS include inadequate Treg cell function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], B cell-intrinsic loss of tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/26\">",
"     26",
"    </a>",
"    ], impaired Fas-mediated apoptosis of self-reactive lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/27\">",
"     27",
"    </a>",
"    ], and defective phagocytosis of apoptotic cells resulting in chronic inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194150\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of the",
"    <em>",
"     WAS",
"    </em>",
"    gene on the X chromosome (",
"    <a class=\"graphic graphic_figure graphicRef66996 \" href=\"mobipreview.htm?7/39/7793\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58264 \" href=\"mobipreview.htm?6/38/6767\">",
"     figure 2",
"    </a>",
"    ) are responsible not only for classic WAS, but also for X-linked thrombocytopenia (XLT) and in rare instances, congenital X-linked neutropenia (XLN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Homozygous mutations of the",
"    <em>",
"     WIPF1",
"    </em>",
"    gene on chromosome 2 that encodes WASp-interacting protein (WIP), a cytoplasmic protein required to stabilize WASp, can also cause a WAS phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2410341\">",
"     'WIP deficiency'",
"    </a>",
"    <span class=\"nowrap\">",
"     below.)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5483899\">",
"    <span class=\"h2\">",
"     Molecular basis",
"    </span>",
"    &nbsp;&mdash;&nbsp;WAS/XLT/XLN",
"    have in common mutations in the",
"    <em>",
"     WAS",
"    </em>",
"    gene located on the short arm of the X chromosome. The",
"    <em>",
"     WAS",
"    </em>",
"    gene consists of 12 exons spanning approximately 9 kb of genomic DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/29\">",
"     29",
"    </a>",
"    ] and encodes a 502 amino acid protein, designated WAS protein (WASp), expressed exclusively in the cytoplasm of hematopoietic cells.",
"   </p>",
"   <p>",
"    WASp is a member of a distinct family of proteins that link signaling pathways to actin cytoskeleton reorganization by activating",
"    <span class=\"nowrap\">",
"     Arp2/3-mediated",
"    </span>",
"    actin polymerization. The WASp family of proteins is characterized by a C-terminal domain containing a common actin monomer-binding motif, the verprolin homology domain, and a central acidic region that is capable of activating the actin-related protein (Arp)",
"    <span class=\"nowrap\">",
"     2/3",
"    </span>",
"    complex, a potent nucleator of actin polymerization (",
"    <a class=\"graphic graphic_figure graphicRef66996 \" href=\"mobipreview.htm?7/39/7793\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A proline-rich region in exon 10, required for optimal actin polymerization activity, is indispensible for effective recruitment of WASp to the immunologic synapse in T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/35\">",
"     35",
"    </a>",
"    ], and provides binding sites for multiple SH3-domain containing proteins, including the adaptor proteins Nck, Grb2, P47",
"    <sup>",
"     phox",
"    </sup>",
"    , Fyn, and several protein tyrosine kinases including Btk, Tec, PLC-&gamma;1, and Itk that directly activate WASp by means of tyrosine phosphorylation.",
"   </p>",
"   <p>",
"    The N-terminal region of WASp allows recruitment of WASp-interacting protein (WIP). In resting lymphocytes, WASp constitutively associates and is almost completely complexed with WIP, stabilizing the inactive conformation of WASp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. WIP is phosphorylated following engagement of the T cell antigen receptor, resulting in disengagement of WASp from the",
"    <span class=\"nowrap\">",
"     WIP/WASp",
"    </span>",
"    complex. This allows WASp activation by Cdc42, which leads to actin polymerization and stabilization of actin filaments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Cdc42-binding domain, encoded by exons 7 and 8 of the",
"    <em>",
"     WAS",
"    </em>",
"    gene, allows the association of WASp with Cdc42, a member of the Rho family of GTPases which regulate the formation of filopodia and control cell polarity and chemotaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/39\">",
"     39",
"    </a>",
"    ]. WASp recognizes the GTP-bound, but not the GDP-bound, form of Cdc42 and binds to Cdc42-GTP with a 500-fold greater affinity than to Cdc42-GDP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The autoinhibitory contact between the Cdc42-binding domain and the carboxy-terminal region of WASp can be released by the activated (GTP) form of Cdc42 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/41\">",
"     41",
"    </a>",
"    ]. This demonstrates the profound effect of the Cdc42-binding domain on actin polymerization by controlling the interaction of the C-terminus of WASp with the",
"    <span class=\"nowrap\">",
"     Arp2/3",
"    </span>",
"    actin nucleating complex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5483906\">",
"    <span class=\"h2\">",
"     Spectrum of WAS gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different",
"    <em>",
"     WAS",
"    </em>",
"    gene mutations can cause WAS, although several mutational hotspots have been identified (",
"    <a class=\"graphic graphic_figure graphicRef66996 \" href=\"mobipreview.htm?7/39/7793\">",
"     figure 1",
"    </a>",
"    ). Certain types of mutations at particular locations are more likely to cause XLT than classic WAS (",
"    <a class=\"graphic graphic_figure graphicRef58264 \" href=\"mobipreview.htm?6/38/6767\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The analysis of affected members of 270 unrelated WAS families from three large referral centers (United States, Italy, Japan) revealed a total of 158 unique",
"    <em>",
"     WAS",
"    </em>",
"    gene mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Most common were missense mutations, followed by splice-site mutations, short deletions, and nonsense mutations. Insertions, complex mutations, and large deletions were less frequent. Most deletions and insertions involved fewer than 10 nucleotides, resulting in frame shift and early termination of transcription. Amino acid substitutions are typically located in exons 1 to 4.",
"   </p>",
"   <p>",
"    Splice-site mutations occur predominantly in the downstream half of the",
"    <em>",
"     WAS",
"    </em>",
"    gene (exons 6 to 12) (",
"    <a class=\"graphic graphic_figure graphicRef66996 \" href=\"mobipreview.htm?7/39/7793\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58264 \" href=\"mobipreview.htm?6/38/6767\">",
"     figure 2",
"    </a>",
"    ). Mutations affecting variant splice-sites may result in multiple splicing products which often include normal amounts of",
"    <em>",
"     WAS",
"    </em>",
"    gene cDNA (eg, IVS6+5g&gt;a).",
"   </p>",
"   <p>",
"    Six mutational hotspots, defined as occurring in &gt;2.5 percent of the population have been identified. Three of these hotspots represent point mutations (T45M;",
"    <span class=\"nowrap\">",
"     R86C/H/L/S;",
"    </span>",
"    R211X) within the coding regions, whereas the other three involve splice-sites (IVS6+5g&gt;a; IVS8+1g&gt;n; IVS8+1 to 6del gtga) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/44\">",
"     44",
"    </a>",
"    ]. These six hotspot mutations account for 25.6 percent of the entire cohort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194157\">",
"    <span class=\"h1\">",
"     CLINICAL PHENOTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;WAS has a variable clinical phenotype that correlates with the type of mutation in the",
"    <em>",
"     WAS",
"    </em>",
"    gene and its effect on WASp expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Affected patients are categorized into three major groups: classic WAS, XLT, and XLN.",
"   </p>",
"   <p>",
"    A WAS disease severity scoring system (",
"    <a class=\"graphic graphic_table graphicRef69089 \" href=\"mobipreview.htm?20/11/20669\">",
"     table 1",
"    </a>",
"    ) facilitates the clinical categorization of patients and may be useful in predicting disease severity and outcome of hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/45\">",
"     45",
"    </a>",
"    ]. A score of 1 or 2 defines patients with XLT, a score of 3 to 4 identifies patients with classic WAS, and a score of 5 is reserved for patients with either XLT or WAS who develop autoimmunity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    malignancies.",
"   </p>",
"   <p>",
"    The clinical phenotype of the disease evolves over time and is often incomplete in boys younger than two years of age. Thus, WAS scores should not be used to predict disease severity in infancy. Progression of the disease can occur even at a later age, therefore some patients originally diagnosed with XLT (score of 1 to 2) may develop autoimmunity or cancer later in life (score of 5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The WAS score reflects the severity of the clinical phenotype without taking into account the type of mutation or whether WASp is expressed. However, most patients with missense mutations in exon 1, 2, and 3 of the WAS gene express mutated, nonfunctional WASp, often in decreased amounts, and tend to have a milder disease phenotype (",
"    <a class=\"graphic graphic_figure graphicRef66996 \" href=\"mobipreview.htm?7/39/7793\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58264 \" href=\"mobipreview.htm?6/38/6767\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/42,43,46\">",
"     42,43,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194164\">",
"    <span class=\"h2\">",
"     Classic Wiskott-Aldrich syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenotype originally described by Wiskott is often referred to as classic WAS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/1\">",
"     1",
"    </a>",
"    ]. Affected boys present in early childhood with a hemorrhagic diathesis due to thrombocytopenia; recurrent bacterial, viral and fungal infections; and extensive eczema.",
"   </p>",
"   <p>",
"    Patients with classic WAS tend to develop autoimmune disorders and lymphoma or other malignancies, often leading to early death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T and B cell numbers decline over the years. In vitro proliferation of T cells to specific antigens and to anti-CD3 is reduced. IgA and IgE serum levels may be increased, IgM levels are decreased, and antibody responses to T cell-independent antigens such as bacterial polysaccharide antigens and certain T cell-dependent protein antigens may be impaired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194171\">",
"    <span class=\"h2\">",
"     X-linked thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;This mild variant of WAS presents with congenital thrombocytopenia, sometimes intermittently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/48\">",
"     48",
"    </a>",
"    ], and mild, if any, eczema. These patients have generally a benign disease course and good long-term survival, although they still carry an increased risk for severe events such as life-threatening infections (especially post-splenectomy), serious hemorrhages, autoimmune complications, and cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/46\">",
"     46",
"    </a>",
"    ]. XLT must be differentiated from immune (idiopathic) thrombocytopenic purpura (ITP), which does not have an increased risk of malignancies and autoimmunity. Any male with thrombocytopenia and small platelets should be evaluated for WASp expression and",
"    <em>",
"     WAS",
"    </em>",
"    gene mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194178\">",
"    <span class=\"h2\">",
"     X-linked neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whereas \"loss of function\" mutations in the",
"    <em>",
"     WAS",
"    </em>",
"    gene cause either XLT or WAS, unique \"gain of function\" missense mutations in the GTPase (Cdc42)-binding domain of WASp impair the autoinhibitory conformation of the molecule and lead to increased actin polymerization, resulting in congenital neutropenia (XLN). Patients with XLN present with infections characteristic for neutropenia, but may also develop infections associated with lymphocyte dysfunction, suggested by reduced in vitro-lymphocyte proliferation in response to anti-CD3, and are at increased risk for myelodysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22657800\">",
"    <span class=\"h2\">",
"     Genotype-phenotype correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most consistent",
"    <span class=\"nowrap\">",
"     phenotype/genotype",
"    </span>",
"    correlation is observed when patients are divided into two categories: WASp",
"    <sup>",
"     +",
"    </sup>",
"    for patients whose mutated, nonfunctional protein is expressed, although often in reduced quantities, and of normal size, and WASp",
"    <sup>",
"     -",
"    </sup>",
"    for patients whose mutated protein is absent or truncated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Patients with mutations that allow the expression of normal-sized mutated protein develop the XLT phenotype, with few exceptions (",
"    <a class=\"graphic graphic_figure graphicRef58264 \" href=\"mobipreview.htm?6/38/6767\">",
"     figure 2",
"    </a>",
"    ). In contrast, patients with lymphocytes that do not express WASp or express only truncated WASp are more likely to have the classic WAS phenotype.",
"   </p>",
"   <p>",
"    There are, however, exceptions, making it difficult in individual cases to accurately predict the clinical course based solely on the type of mutations of the",
"    <em>",
"     WAS",
"    </em>",
"    gene. The somatic reversions and mosaicism observed in approximately 10 percent of patients with classic WAS usually affect differentiated T cell subsets, most often CD8",
"    <sup>",
"     +",
"    </sup>",
"    T cells and NK cells, and do not seem to influence the clinical phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27997019\">",
"    <span class=\"h1\">",
"     SPECIFIC CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22660986\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost 90 percent of patients have manifestations of thrombocytopenia at the time of diagnosis. Thrombocytopenia is present at birth. Thus, affected patients may present in the first days of life with petechiae,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged bleeding from the umbilical stump or after circumcision. Other manifestations may include purpura, hematemesis, melena, epistaxis, hematuria, and such life-threatening symptoms as oral, gastrointestinal, and intracranial bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194185\">",
"    <span class=\"h2\">",
"     Immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphadenopathy is frequently present, especially in those WAS patients with chronic eczema, and hepatosplenomegaly is common. In contrast, adenoid tissue on lateral neck radiographs is often absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/54\">",
"     54",
"    </a>",
"    ]. The severity of the immune deficiency in patients with WAS depends largely upon the mutation and its effect on protein expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Patients with severe WAS phenotype may have recurrent infections in early infancy, but in most patients with WAS the frequency of infections increases with age.",
"   </p>",
"   <p>",
"    Patients are particularly susceptible to such organisms as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Manifestations include otitis media, sinusitis, colitis, pneumonia, meningitis, and sepsis. Splenectomy, which is occasionally performed to decrease the risk of bleeding, further increases the risk of severe infections and sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Opportunistic infections with Pneumocystis jiroveci (carinii), Molluscum contagiosum, as well as systemic varicella and cytomegalovirus infection, are also common. Fungal infections are relatively rare (10 percent), consisting primarily of infection due to Candida albicans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22661080\">",
"    <span class=\"h2\">",
"     Eczema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eczema of varying severity, often with superinfection, develops in approximately one-half of WAS patients during the first year of life and resembles classical atopic dermatitis (",
"    <a class=\"graphic graphic_picture graphicRef71280 \" href=\"mobipreview.htm?36/30/37359\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194199\">",
"    <span class=\"h2\">",
"     Autoimmune manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune diseases have been reported in 40 to 70 percent of WAS patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/47,56\">",
"     47,56",
"    </a>",
"    ] and include hemolytic anemia, neutropenia, vasculitis involving both small and large vessels, inflammatory bowel disease, and renal diseases. Autoimmune complications in XLT are less frequent, being reported by 12 percent of XLT patients in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194206\">",
"    <span class=\"h2\">",
"     Malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancies can occur during childhood, but are most frequently observed in adolescent and young adult males with the classic WAS phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/47\">",
"     47",
"    </a>",
"    ]. B cell lymphoma (often Epstein-Barr virus-positive) and leukemia are common. Malignancies have been reported in patients with the XLT phenotype, but the incidence is lower than in classic WAS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22657971\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22657979\">",
"    <span class=\"h2\">",
"     Immunology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal immunologic findings in patients with WAS include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased number and function of T cells",
"     </li>",
"     <li>",
"      Abnormal immunoglobulin isotypes, notably low to normal IgG and IgM and high IgA and IgE",
"     </li>",
"     <li>",
"      Defective antibody responses to some vaccine antigens",
"     </li>",
"     <li>",
"      Normal to increased natural killer (NK) cell numbers, but reduced cytotoxicity",
"     </li>",
"     <li>",
"      Decreased function of regulatory T (Treg) cells",
"     </li>",
"     <li>",
"      Impaired chemotaxis of phagocytic cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Absolute lymphocyte counts are usually normal during infancy, but they decrease later in life in patients with classic WAS. Decreased lymphocyte proliferation in response to nonspecific mitogens occurs in approximately 50 percent of patients, and delayed-type hypersensitivity skin testing is abnormal in 90 percent of affected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/47\">",
"     47",
"    </a>",
"    ]. Morphologically, WAS lymphocytes are relatively devoid of microvillus projections (",
"    <a class=\"graphic graphic_picture graphicRef57509 \" href=\"mobipreview.htm?42/20/43331\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/57\">",
"     57",
"    </a>",
"    ]. Upon in vitro activation with an anti-CD3 antibody, patient lymphocytes proliferate poorly and fail to undergo normal cytoskeleton rearrangements, producing very long filopodial projections instead [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variations in the levels of immunoglobulin have been described, including normal levels of serum IgG, decreased levels of IgM, and elevated levels of IgA and IgE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Consistent findings in WAS patients are low isohemagglutinin titers, decreased antibody responses to polysaccharide antigens and the T-dependent antigen bacteriophage &Phi;X174, and rapid IgG catabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/19,61\">",
"     19,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number and phagocytic activity of neutrophils are normal. However, chemotactic responses are defective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22660816\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal findings in lymphoreticular tissue are commonly observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients have different degrees of T cell zone depletion in lymph nodes and spleen, as well as decreased number of follicles and abnormal follicular formation devoid of marginal zone, and regressive or \"burned out\" germinal centers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/62-64\">",
"       62-64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormalities observed in thymus vary from small thymus with normal architecture and corticomedullary differentiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/65\">",
"       65",
"      </a>",
"      ] to completely atrophic thymus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22658193\">",
"    <span class=\"h2\">",
"     Thrombocytopenia and platelet abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia associated with small platelet volume is a consistent finding in patients with WAS gene mutations, except for those with missense mutations within the Cdc42-binding domain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/31\">",
"     31",
"    </a>",
"    ]. Platelet counts are generally 20,000 to",
"    <span class=\"nowrap\">",
"     50,000/mm3",
"    </span>",
"    but may drop below",
"    <span class=\"nowrap\">",
"     10,000/mm3.",
"    </span>",
"    Intermittent thrombocytopenia has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/48\">",
"     48",
"    </a>",
"    ]. The mean platelet volume is 3.8 to 5.0 fl compared with 7.1 to 10.5 fl in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194227\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF WAS/XLT/XLN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis",
"    <span class=\"nowrap\">",
"     WAS/XLT",
"    </span>",
"    should be considered in any male patient presenting with petechiae, bruises, and congenital or early onset thrombocytopenia associated with small platelet size (",
"    <a class=\"graphic graphic_table graphicRef78822 \" href=\"mobipreview.htm?26/61/27612\">",
"     table 2",
"    </a>",
"    ). Presence of mild or severe eczema supports the diagnosis. Infections and immunologic abnormalities may be absent, mild or severe. Autoimmune diseases and malignancies develop more often in patients with classic WAS than in those with XLT.",
"   </p>",
"   <p>",
"    Screening for WASp mutations can be performed by flow cytometry using an anti-WASp antibody; this may miss patients with expression of mutated WASp. Sequence analysis of the",
"    <em>",
"     WAS",
"    </em>",
"    gene is essential to confirm the diagnosis. A combination of these two methods may aid in estimating the severity of the disease and long-term outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/42,43,46\">",
"     42,43,46",
"    </a>",
"    ]. Male infants with congenital neutropenia may have missense mutations in the Cdc42 binding domain (exon 7 to 8). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=see_link&amp;anchor=H7730525#H7730525\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\", section on 'Wiskott-Aldrich syndrome (WAS)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194234\">",
"    <span class=\"h2\">",
"     WAS/XLT in females",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few symptomatic female patients have been identified who are heterozygous for mutations of the",
"    <em>",
"     WAS",
"    </em>",
"    gene. They presented with either a classic WAS phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/67\">",
"     67",
"    </a>",
"    ] or an XLT phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. In all cases, the symptomatic females were found to have markedly skewed X chromosome inactivation in favor of the X chromosome with the",
"    <em>",
"     WAS",
"    </em>",
"    gene mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2410341\">",
"    <span class=\"h2\">",
"     WIP deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A female infant presenting with typical WAS symptoms and laboratory findings was found to have a homozygous nonsense mutation in",
"    <em>",
"     WIPF1",
"    </em>",
"    that encodes WASp-interacting protein (WIP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/33\">",
"     33",
"    </a>",
"    ]. The patient presented at 11 days of age with eczema, vesicular and ulcerative lesions of the skin and mucosa, poor weight gain, and thrombocytopenia (but with normal platelet volume). Family history was notable for a female sibling who had vesicular and ulcerative skin lesions and died of sepsis at four months of age. The patient was found to have an immune deficiency, including defective chemotaxis, lack of T cell proliferation in response to anti-CD3 crosslinking, and abnormal NK cell function. Her IgE was mildly elevated. She continued to have failure to thrive and developed chronic infections. Thus, she underwent hematopoietic cell transplantation at 4.5 months of age.",
"   </p>",
"   <p>",
"    Analysis of the",
"    <em>",
"     WIPF1",
"    </em>",
"    gene revealed a homozygous nonsense mutation in exon 6 (S434X) located upstream of the region encoding the WASp&ndash;binding domain of WIP. Both parents, who are consanguineous, were heterozygous for this mutation. Both WIP and WASp were absent in the patient&rsquo;s leukocytes. This case illustrates that WAS cannot be diagnosed solely on the basis of lack of WASp expression, but may require sequence analysis of",
"    <em>",
"     WAS",
"    </em>",
"    . WIP deficiency should be suspected in patients with features of WAS in whom WASp is absent, but",
"    <em>",
"     WAS",
"    </em>",
"    sequence and mRNA levels are normal. The diagnosis of WIP deficiency is confirmed by sequencing",
"    <em>",
"     WIPF1",
"    </em>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194241\">",
"    <span class=\"h2\">",
"     Carrier detection and prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carrier females can be identified with certainty by mutation analysis if the",
"    <em>",
"     WAS",
"    </em>",
"    gene mutation is known. Prenatal diagnosis of a male fetus at risk for WAS or XLT can be performed by DNA analysis with chorionic villi sampling or cultured amniocytes as the source of genomic DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194248\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several syndromes presenting with eczema, elevated serum IgE, and susceptibility to infections may resemble",
"    <span class=\"nowrap\">",
"     WAS/XLT.",
"    </span>",
"    These include WIP deficiency, Omenn syndrome due to hypomorphic mutations in genes associated with severe combined immunodeficiency (SCID), eg,",
"    <span class=\"nowrap\">",
"     <em>",
"      RAG1/2,",
"     </em>",
"    </span>",
"    ADA, IL-7R, Artemis, IL-2R&gamma;; RMRP;",
"    immune dysregulation, polyendocrinopathy, X-Linked (IPEX) due to mutations in",
"    <em>",
"     FOXP3",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/72\">",
"     72",
"    </a>",
"    ]; Netherton syndrome due to mutations of",
"    <em>",
"     SPINK5",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/73\">",
"     73",
"    </a>",
"    ]; Hyper IgE syndrome due to heterozygous",
"    <em>",
"     STAT3",
"    </em>",
"    mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/74\">",
"     74",
"    </a>",
"    ]; DOCK8 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/75\">",
"     75",
"    </a>",
"    ]; and atopic dermatitis. (See",
"    <a class=\"local\" href=\"#H2410341\">",
"     'WIP deficiency'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25850?source=see_link\">",
"     \"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32153?source=see_link\">",
"     \"Hyperimmunoglobulin E syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link&amp;anchor=H31#H31\">",
"     \"Combined immunodeficiencies\", section on 'Dedicator of cytokinesis 8 (DOCK8) deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ITP is a frequent misdiagnosis of patients with XLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/76\">",
"     76",
"    </a>",
"    ]. The fact that",
"    <span class=\"nowrap\">",
"     WAS/XLT",
"    </span>",
"    platelets are consistently small and ITP platelets are large is useful for differentiating these two conditions. Automated platelet counting, unfortunately, does not pick up very small platelets and the platelet size difference is less impressive.",
"   </p>",
"   <p>",
"    The neutropenia associated with",
"    <em>",
"     WAS",
"    </em>",
"    gene mutations (XLN) is congenital and has to be differentiated from cyclic neutropenia due to",
"    <em>",
"     ELA2",
"    </em>",
"    mutations, severe congenital neutropenia due to",
"    <em>",
"     HAX1",
"    </em>",
"    mutation (Kostmann disease) or",
"    <em>",
"     ELA2",
"    </em>",
"    mutations, WHIM (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) syndrome due to mutations in the",
"    <em>",
"     CXCR4",
"    </em>",
"    gene, Hermansky-Pudlak syndrome due to mutations in",
"    <em>",
"     AP3B1",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/77\">",
"     77",
"    </a>",
"    ], or due to mutations in the G-CSF receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42966?source=see_link\">",
"     \"Cyclic neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link&amp;anchor=H28#H28\">",
"     \"Combined immunodeficiencies\", section on 'Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=see_link\">",
"     \"Congenital and acquired disorders of platelet function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194255\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194262\">",
"    <span class=\"h2\">",
"     Conventional treatment and supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional treatment and supportive care includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prophylactic antibiotics, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      sulfamethoxazole, to prevent pneumocystis jirovecii (carinii) pneumonia",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      to prevent recurrent herpes simplex infection",
"     </li>",
"     <li>",
"      Platelet transfusions to treat major bleeding episodes such as acute central nervous system hemorrhage or gastrointestinal bleeding, or to prevent excessive blood loss during surgery (platelet transfusions are not recommended as routine prophylaxis nor for minor hemorrhages)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blood products should be irradiated and tested for cytomegalovirus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194269\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG) therapy is indicated in patients with significant antibody deficiency. The dose is usually higher than that used for other primary immunodeficiencies due to an increased catabolic rate observed in WAS patients (eg, 400 to 600 mg every three weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/61\">",
"     61",
"    </a>",
"    ]. Immune globulin may also be given subcutaneously. However, this route of administration must be used with caution in this patient population because of bleeding tendency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194276\">",
"    <span class=\"h2\">",
"     Immunosuppressive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive treatment may be required for autoimmune manifestations. Autoimmune cytopenias often respond to a monoclonal antibody targeting the B cell&ndash;specific CD20 antigen (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ), which is relatively safe for those patients already being treated with IVIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22662060\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective splenectomy has been advocated in selected patients with",
"    <span class=\"nowrap\">",
"     WAS/XLT",
"    </span>",
"    to reverse the thrombocytopenia and arrest the bleeding tendency by increasing the number of circulating platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/55\">",
"     55",
"    </a>",
"    ]. Splenectomy markedly increases the risk of septicemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/46\">",
"     46",
"    </a>",
"    ] and is not routinely recommended, especially not for those patients who might undergo hematopoietic cell transplantation.",
"    <span class=\"nowrap\">",
"     WAS/XLT",
"    </span>",
"    patients who undergo splenectomy require lifelong antibiotic prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194283\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) is at present the only curative treatment, with excellent results for patients with HLA-matched family or unrelated donors or partially matched cord-blood donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/79-83\">",
"     79-83",
"    </a>",
"    ]. Outcomes have been less satisfactory for other donor types, although a retrospective study reports improved survival for recipients of mismatched related donor marrow transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reduced intensity conditioning, although associated with a reduction in adverse and chronic events, is not recommended in patients with WAS because this approach may result in graft rejection or lead to mixed chimerism that is often associated with an increased incidence of autoimmune manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/82\">",
"     82",
"    </a>",
"    ]. Mixed chimerism affecting the myeloid compartment may result in persistent thrombocytopenia. Thus, allogeneic HCT from an HLA-genotypically identical sibling, a",
"    <span class=\"nowrap\">",
"     9/10",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     10/10",
"    </span>",
"    allele-matched unrelated donor (URD), or a",
"    <span class=\"nowrap\">",
"     4-6/6",
"    </span>",
"    cord blood is the standard of care for any WAS patient with clinically significant disease (score 3 to 5) or with absent WASp expression.",
"   </p>",
"   <p>",
"    The decision to perform HCT in patient with XLT is less urgent because these patients have a more favorable long-term outcome with only supportive treatment, but should be considered if an HLA identical sibling is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/46\">",
"     46",
"    </a>",
"    ]. The outcomes of 20 XLT patients identified worldwide who have undergone HCT are under study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Of the four posttransplant deaths reported, two were attributed to sepsis related to pretransplant splenectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194290\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene therapy is an alternative, potentially curative, therapy under investigation for WAS. A normal",
"    <em>",
"     WAS",
"    </em>",
"    gene copy is introduced into hematopoietic CD34+ stem cells isolated from a patient with WAS. These manipulated cells are then reinfused into the same patient after conditioning with sub-myeloablative doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33590?source=see_link\">",
"     \"Gene therapy for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first retroviral-based gene therapy trial is underway and the outcome of the first two gene treated patients has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/87\">",
"     87",
"    </a>",
"    ]. Sustained expression of WASp in hematopoietic stem cells, lymphocytes, myeloid cells, and platelets was observed. T, B, and NK cells and monocytes were all functionally corrected. Both patients' condition markedly improved, with resolution of hemorrhagic diathesis, eczema, autoimmunity, and predisposition to severe infection. As of January 2012, a total of 10 WAS patients have undergone retroviral-based gene therapy at a single site (Hannover, Germany). One patient with insufficient gene-treated cells failed to respond and underwent successful HCT. Three of the remaining nine successfully corrected patients developed leukemia (T-ALL), with two patients showing uncontrolled proliferation of T cells caused by deregulated expression of the oncogene",
"    <em>",
"     LM02",
"    </em>",
"    resulting from the integration of the vector in the",
"    <em>",
"     LMO2",
"    </em>",
"    gene region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several clinical trials using improved lentiviral vectors are planned or already underway. Long-term follow-up is necessary to determine if this experimental therapy is safe and will result in long-term cure as is the case for HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27996912\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life expectancy of patients with classic WAS is reduced, with premature death resulting from infections, hemorrhage, autoimmune disease and malignancies. Bleeding is the main cause of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/47\">",
"     47",
"    </a>",
"    ]. Malignancies in patients with classic WAS are often fatal. In one study, only 1 of 21 patients who developed a malignancy was alive more than two years after diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, life expectancy of patients with XLT is close to that of the normal male population in a developed country [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36313/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564072\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wiskott-Aldrich Syndrome (WAS) is defined as an X-linked hereditary disorder associated with adaptive and innate immune deficiency, microthrombocytopenia, eczema, and an increased risk of autoimmune disorders and malignancy. (See",
"      <a class=\"local\" href=\"#H24194143\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      WAS protein (WASp) is a member of a distinct family of proteins that link signaling pathways to actin cytoskeleton reorganization. &ldquo;Loss of function&rdquo; mutations of the",
"      <em>",
"       WAS",
"      </em>",
"      gene are responsible not only for classic WAS, but also for X-linked thrombocytopenia (XLT) (",
"      <a class=\"graphic graphic_figure graphicRef66996 \" href=\"mobipreview.htm?7/39/7793\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef58264 \" href=\"mobipreview.htm?6/38/6767\">",
"       figure 2",
"      </a>",
"      ). More rarely, &ldquo;gain of function&rdquo; mutations result in congenital X-linked neutropenia (XLN). (See",
"      <a class=\"local\" href=\"#H24194150\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The phenotype originally described by Wiskott is often referred to as classic WAS. Affected boys present in early childhood with hemorrhagic diathesis due to thrombocytopenia; recurrent bacterial, viral and fungal infections; and extensive eczema. Patients with classic WAS tend to develop autoimmune disorders and lymphoma or other malignancies, leading to early death. (See",
"      <a class=\"local\" href=\"#H24194164\">",
"       'Classic Wiskott-Aldrich syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27997019\">",
"       'Specific clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22657971\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      X-linked thrombocytopenia is a mild variant of WAS that presents with congenital thrombocytopenia, sometimes intermittently, and mild, if any, eczema. The disease course is generally benign, although these patients still carry an increased risk for severe events such as life-threatening infections (especially post-splenectomy), serious hemorrhage, autoimmunity, and cancer. (See",
"      <a class=\"local\" href=\"#H24194171\">",
"       'X-linked thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with X-linked neutropenia (XLN, congenital neutropenia) present with infections characteristic for neutropenia, but may also develop infections associated with lymphocyte dysfunction and are at increased risk for myelodysplasia. (See",
"      <a class=\"local\" href=\"#H24194178\">",
"       'X-linked neutropenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis",
"      <span class=\"nowrap\">",
"       WAS/XLT",
"      </span>",
"      should be considered in any male patient presenting with petechiae, bruises, and congenital or early onset thrombocytopenia associated with small platelet size (",
"      <a class=\"graphic graphic_table graphicRef78822 \" href=\"mobipreview.htm?26/61/27612\">",
"       table 2",
"      </a>",
"      ). Screening for WASp expression is performed by flow cytometry using an anti-WASp antibody, but may miss patients with expression of mutated WASp. Sequence analysis of the",
"      <em>",
"       WAS",
"      </em>",
"      gene is essential to confirm the diagnosis. (See",
"      <a class=\"local\" href=\"#H24194227\">",
"       'Diagnosis of WAS/XLT/XLN'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conventional treatment and supportive care include the use of prophylactic antimicrobials and platelet transfusions to stop life-threatening hemorrhages. Intravenous immune globulin (IVIG) therapy is indicated in patients with significant antibody deficiency. Immunosuppressive treatment may be required for autoimmune manifestations. Hematopoietic cell transplantation is presently the only available curative treatment, but gene therapy is under investigation. (See",
"      <a class=\"local\" href=\"#H24194255\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Life expectancy of patients with classic WAS is reduced, with premature death resulting from infections, hemorrhage, autoimmune disease, and malignancies. In contrast, life expectancy of patients with XLT is near normal. (See",
"      <a class=\"local\" href=\"#H27996912\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/1\">",
"      Wiskott A. Familiarer, angeborener Morbus Werlhofii? Mschr. Kinderheilk 1937; 68:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/2\">",
"      ALDRICH RA, STEINBERG AG, CAMPBELL DC. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics 1954; 13:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/3\">",
"      Stray-Pedersen A, Abrahamsen TG, Fr&oslash;land SS. Primary immunodeficiency diseases in Norway. J Clin Immunol 2000; 20:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/4\">",
"      Blundell MP, Worth A, Bouma G, Thrasher AJ. The Wiskott-Aldrich syndrome: The actin cytoskeleton and immune cell function. Dis Markers 2010; 29:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/5\">",
"      Dupr&eacute; L, Aiuti A, Trifari S, et al. Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity 2002; 17:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/6\">",
"      Meyer-Bahlburg A, Becker-Herman S, Humblet-Baron S, et al. Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired peripheral homeostasis. Blood 2008; 112:4158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/7\">",
"      Westerberg LS, de la Fuente MA, Wermeling F, et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood 2008; 112:4139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/8\">",
"      Rengan R, Ochs HD, Sweet LI, et al. Actin cytoskeletal function is spared, but apoptosis is increased, in WAS patient hematopoietic cells. Blood 2000; 95:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/9\">",
"      Orange JS, Ramesh N, Remold-O'Donnell E, et al. Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A 2002; 99:11351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/10\">",
"      Gismondi A, Cifaldi L, Mazza C, et al. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood 2004; 104:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/11\">",
"      Orange JS, Roy-Ghanta S, Mace EM, et al. IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function. J Clin Invest 2011; 121:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/12\">",
"      Locci M, Draghici E, Marangoni F, et al. The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. J Exp Med 2009; 206:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/13\">",
"      Astrakhan A, Ochs HD, Rawlings DJ. Wiskott-Aldrich syndrome protein is required for homeostasis and function of invariant NKT cells. J Immunol 2009; 182:7370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/14\">",
"      Maillard MH, Cotta-de-Almeida V, Takeshima F, et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells. J Exp Med 2007; 204:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/15\">",
"      Humblet-Baron S, Sather B, Anover S, et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest 2007; 117:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/16\">",
"      Marangoni F, Trifari S, Scaramuzza S, et al. WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. J Exp Med 2007; 204:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/17\">",
"      Adriani M, Aoki J, Horai R, et al. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. Clin Immunol 2007; 124:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/18\">",
"      Lorenzi R, Brickell PM, Katz DR, et al. Wiskott-Aldrich syndrome protein is necessary for efficient IgG-mediated phagocytosis. Blood 2000; 95:2943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/19\">",
"      Ochs HD, Slichter SJ, Harker LA, et al. The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood 1980; 55:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/20\">",
"      Burns S, Thrasher AJ, Blundell MP, et al. Configuration of human dendritic cell cytoskeleton by Rho GTPases, the WAS protein, and differentiation. Blood 2001; 98:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/21\">",
"      Calle Y, Chou HC, Thrasher AJ, Jones GE. Wiskott-Aldrich syndrome protein and the cytoskeletal dynamics of dendritic cells. J Pathol 2004; 204:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/22\">",
"      Zicha D, Allen WE, Brickell PM, et al. Chemotaxis of macrophages is abolished in the Wiskott-Aldrich syndrome. Br J Haematol 1998; 101:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/23\">",
"      Badolato R, Sozzani S, Malacarne F, et al. Monocytes from Wiskott-Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein-1 and formyl-methionyl-leucyl-phenylalanine. J Immunol 1998; 161:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/24\">",
"      Shcherbina A, Rosen FS, Remold-O'Donnell E. Pathological events in platelets of Wiskott-Aldrich syndrome patients. Br J Haematol 1999; 106:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/25\">",
"      Marathe BM, Prislovsky A, Astrakhan A, et al. Antiplatelet antibodies in WASP(-) mice correlate with evidence of increased in vivo platelet consumption. Exp Hematol 2009; 37:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/26\">",
"      Becker-Herman S, Meyer-Bahlburg A, Schwartz MA, et al. WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med 2011; 208:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/27\">",
"      Nikolov NP, Shimizu M, Cleland S, et al. Systemic autoimmunity and defective Fas ligand secretion in the absence of the Wiskott-Aldrich syndrome protein. Blood 2010; 116:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/28\">",
"      Leverrier Y, Lorenzi R, Blundell MP, et al. Cutting edge: the Wiskott-Aldrich syndrome protein is required for efficient phagocytosis of apoptotic cells. J Immunol 2001; 166:4831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/29\">",
"      Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994; 79:following 922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/30\">",
"      Villa A, Notarangelo L, Macchi P, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet 1995; 9:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/31\">",
"      Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001; 27:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/32\">",
"      Gul&aacute;csy V, Freiberger T, Shcherbina A, et al. Genetic characteristics of eighty-seven patients with the Wiskott-Aldrich syndrome. Mol Immunol 2011; 48:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/33\">",
"      Lanzi G, Moratto D, Vairo D, et al. A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. J Exp Med 2012; 209:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/34\">",
"      Welch MD, Mullins RD. Cellular control of actin nucleation. Annu Rev Cell Dev Biol 2002; 18:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/35\">",
"      Badour K, Zhang J, Shi F, et al. The Wiskott-Aldrich syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological synapse. Immunity 2003; 18:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/36\">",
"      Sasahara Y, Rachid R, Byrne MJ, et al. Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol Cell 2002; 10:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/37\">",
"      de la Fuente MA, Sasahara Y, Calamito M, et al. WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc Natl Acad Sci U S A 2007; 104:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/38\">",
"      Volkman BF, Prehoda KE, Scott JA, et al. Structure of the N-WASP EVH1 domain-WIP complex: insight into the molecular basis of Wiskott-Aldrich Syndrome. Cell 2002; 111:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/39\">",
"      Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/40\">",
"      Rudolph MG, Bayer P, Abo A, et al. The Cdc42/Rac interactive binding region motif of the Wiskott Aldrich syndrome protein (WASP) is necessary but not sufficient for tight binding to Cdc42 and structure formation. J Biol Chem 1998; 273:18067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/41\">",
"      Kim AS, Kakalis LT, Abdul-Manan N, et al. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 2000; 404:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/42\">",
"      Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood 2004; 104:4010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/43\">",
"      Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004; 103:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/44\">",
"      Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006; 117:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/45\">",
"      Albert MH, Notarangelo LD, Ochs HD. Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. Current Opinion in Hematology 2011; 18:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/46\">",
"      Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010; 115:3231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/47\">",
"      Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994; 125:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/48\">",
"      Notarangelo LD, Mazza C, Giliani S, et al. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood 2002; 99:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/49\">",
"      Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 2006; 108:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/50\">",
"      Beel K, Cotter MM, Blatny J, et al. A large kindred with X-linked neutropenia with an I294T mutation of the Wiskott-Aldrich syndrome gene. Br J Haematol 2009; 144:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/51\">",
"      Lutskiy MI, Beardsley DS, Rosen FS, Remold-O'Donnell E. Mosaicism of NK cells in a patient with Wiskott-Aldrich syndrome. Blood 2005; 106:2815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/52\">",
"      Stewart DM, Candotti F, Nelson DL. The phenomenon of spontaneous genetic reversions in the Wiskott-Aldrich syndrome: a report of the workshop of the ESID Genetics Working Party at the XIIth Meeting of the European Society for Immunodeficiencies (ESID). Budapest, Hungary October 4-7, 2006. J Clin Immunol 2007; 27:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/53\">",
"      Davis BR, Yan Q, Bui JH, et al. Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants. Clin Immunol 2010; 135:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/54\">",
"      BAKER DH, PARMER EA, WOLFF JA. Roentgen manifestation of the Aldrich syndrome. Am J Roentgenol Radium Ther Nucl Med 1962; 88:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/55\">",
"      Mullen CA, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. Blood 1993; 82:2961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/56\">",
"      Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003; 111:e622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/57\">",
"      Kenney D, Cairns L, Remold-O'Donnell E, et al. Morphological abnormalities in the lymphocytes of patients with the Wiskott-Aldrich syndrome. Blood 1986; 68:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/58\">",
"      Gallego MD, Santamar&iacute;a M, Pe&ntilde;a J, Molina IJ. Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation. Blood 1997; 90:3089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/59\">",
"      Blaese RM, Strober W, Brown RS, Waldmann TA. The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition. Lancet 1968; 1:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/60\">",
"      Ozcan E, Notarangelo LD, Geha RS. Primary immune deficiencies with aberrant IgE production. J Allergy Clin Immunol 2008; 122:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/61\">",
"      Blaese RM, Strober W, Levy AL, Waldmann TA. Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism. J Clin Invest 1971; 50:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/62\">",
"      Snover DC, Frizzera G, Spector BD, et al. Wiskott-Aldrich syndrome: histopathologic findings in the lymph nodes and spleens of 15 patients. Hum Pathol 1981; 12:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/63\">",
"      Gerwin N, Friedrich C, Perez-Atayde A, et al. Multiple antigens are altered on T and B lymphocytes from peripheral blood and spleen of patients with Wiskott-Aldrich syndrome. Clin Exp Immunol 1996; 106:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/64\">",
"      Vermi W, Blanzuoli L, Kraus MD, et al. The spleen in the Wiskott-Aldrich syndrome: histopathologic abnormalities of the white pulp correlate with the clinical phenotype of the disease. Am J Surg Pathol 1999; 23:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/65\">",
"      Cooper MD, Chae HP, Lowman JT, et al. Wiskott-Aldrich syndrome. An immunologic deficiency disease involving the afferent limb of immunity. Am J Med 1968; 44:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/66\">",
"      Wolff JA. Wiskott-Aldrich syndrome: clinical, immunologic, and pathologic observations. J Pediatr 1967; 70:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/67\">",
"      Parolini O, Ressmann G, Haas OA, et al. X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med 1998; 338:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/68\">",
"      Inoue H, Kurosawa H, Nonoyama S, et al. X-linked thrombocytopenia in a girl. Br J Haematol 2002; 118:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/69\">",
"      Lutskiy MI, Sasahara Y, Kenney DM, et al. Wiskott-Aldrich syndrome in a female. Blood 2002; 100:2763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/70\">",
"      Zhu Q, Christie JR, Tyler EO, et al. X-chromosome inactivation in symptomatic carrier females of X-linked thrombocytopenia. Clin Immunol 2002; 103:S129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/71\">",
"      Giliani S, Fiorini M, Mella P, et al. Prenatal molecular diagnosis of Wiskott-Aldrich syndrome by direct mutation analysis. Prenat Diagn 1999; 19:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/72\">",
"      Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/73\">",
"      Renner ED, Hartl D, Rylaarsdam S, et al. Com&egrave;l-Netherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol 2009; 124:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/74\">",
"      Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/75\">",
"      Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009; 361:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/76\">",
"      Bryant N, Watts R. Thrombocytopenic syndromes masquerading as childhood immune thrombocytopenic purpura. Clin Pediatr (Phila) 2011; 50:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/77\">",
"      International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies, Notarangelo LD, Fischer A, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol 2009; 124:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/78\">",
"      Beel K, Vandenberghe P. G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. Haematologica 2009; 94:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/79\">",
"      Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 2001; 97:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/80\">",
"      Kobayashi R, Ariga T, Nonoyama S, et al. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol 2006; 135:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/81\">",
"      Pai SY, DeMartiis D, Forino C, et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant 2006; 38:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/82\">",
"      Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008; 111:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/83\">",
"      Friedrich W, Sch&uuml;tz C, Schulz A, et al. Results and long-term outcome in 39 patients with Wiskott-Aldrich syndrome transplanted from HLA-matched and -mismatched donors. Immunol Res 2009; 44:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/84\">",
"      Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011; 118:1675.",
"     </a>",
"    </li>",
"    <li>",
"     Oshima K, Kyoto University, 2012, personal communication.",
"    </li>",
"    <li>",
"     Albert M, Ludwig-Maximilian University, 2012, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36313/abstract/87\">",
"      Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363:1918.",
"     </a>",
"    </li>",
"    <li>",
"     Klein C, Ludwig Maximilian University, 2012, personal communication.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3953 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36313=[""].join("\n");
var outline_f35_29_36313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H564072\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24194143\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6866590\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22657964\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24194150\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5483899\">",
"      Molecular basis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5483906\">",
"      Spectrum of WAS gene mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24194157\">",
"      CLINICAL PHENOTYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194164\">",
"      Classic Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194171\">",
"      X-linked thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194178\">",
"      X-linked neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22657800\">",
"      Genotype-phenotype correlation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27997019\">",
"      SPECIFIC CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22660986\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194185\">",
"      Immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22661080\">",
"      Eczema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194199\">",
"      Autoimmune manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194206\">",
"      Malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22657971\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22657979\">",
"      Immunology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22660816\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22658193\">",
"      Thrombocytopenia and platelet abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24194227\">",
"      DIAGNOSIS OF WAS/XLT/XLN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194234\">",
"      WAS/XLT in females",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2410341\">",
"      WIP deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194241\">",
"      Carrier detection and prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194248\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24194255\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194262\">",
"      Conventional treatment and supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194269\">",
"      Intravenous immune globulin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194276\">",
"      Immunosuppressive treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22662060\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194283\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194290\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27996912\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564072\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3953\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3953|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/39/7793\" title=\"figure 1\">",
"      Mutations in the Wiskott-Aldrich syndrome - WAS gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/38/6767\" title=\"figure 2\">",
"      Mutations in the WAS gene causing X-linked thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3953|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/30/37359\" title=\"picture 1\">",
"      Skin findings Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/20/43331\" title=\"picture 2\">",
"      Blood lymphocyte - Normal and Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3953|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/11/20669\" title=\"table 1\">",
"      WAS disease severity scoring system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/61/27612\" title=\"table 2\">",
"      Diagnosis of Wiskott Aldrich",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42966?source=related_link\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=related_link\">",
"      Flow cytometry for the diagnosis of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33590?source=related_link\">",
"      Gene therapy for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25850?source=related_link\">",
"      IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_29_36314="Choice of therapy in primary (essential) hypertension: Recommendations";
var content_f35_29_36314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Choice of therapy in primary (essential) hypertension: Recommendations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36314/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36314/contributors\">",
"     Johannes FE Mann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36314/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36314/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36314/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/29/36314/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/29/36314/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/29/36314/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no uniform agreement as to which antihypertensive drugs should be given for initial therapy. The major options are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thiazide-type diuretics",
"     </li>",
"     <li>",
"      Angiotensin-converting enzyme (ACE)",
"      <span class=\"nowrap\">",
"       inhibitors/angiotensin",
"      </span>",
"      II receptor blockers (ARBs)",
"     </li>",
"     <li>",
"      Calcium channel blockers",
"     </li>",
"     <li>",
"      Beta blockers, which are now used less often for initial therapy in the absence of a specific indication for their use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations concerning the use of particular agents for the initial treatment of hypertension will be presented here. The efficacy of these agents, the clinical trials that examined their effects upon patient outcomes, particularly cardiovascular morbidity and mortality, and the indications for initiating antihypertensive therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RELATIVE EFFICACY OF ANTIHYPERTENSIVE DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the antihypertensive agents is roughly equally effective in lowering the blood pressure, producing a good antihypertensive response in 30 to 50 percent of patients (",
"    <a class=\"graphic graphic_figure graphicRef77960 \" href=\"mobipreview.htm?2/36/2638\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65117 \" href=\"mobipreview.htm?37/22/38253\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. There is, however, wide interpatient variability as many patients will respond well to one drug but not to another. In addition, there are few clinical parameters that reliably predict individual responses to one drug or another. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Initial monotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Importance of attained blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses published in 2008 and 2009, the 2007 American Heart Association statement on the treatment of blood pressure in ischemic heart disease, and the 2010 European Society of",
"    <span class=\"nowrap\">",
"     Hypertension/European",
"    </span>",
"    Society of Cardiology guidelines on the management of hypertension all concluded that the amount of blood pressure reduction is the major determinant of reduction in cardiovascular risk in both younger and older patients with hypertension,",
"    <strong>",
"     not",
"    </strong>",
"    the choice of antihypertensive drug (assuming that the patient does not have an indication for a particular drug, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , or a beta blocker for rate control in atrial fibrillation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/1,2,6,7\">",
"     1,2,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This conclusion was based upon the finding in a number of large randomized trials that, at the same level of blood pressure control, most antihypertensive drugs provide the same degree of cardiovascular protection. As an example, the CAPPP, STOP-Hypertension-2, NORDIL, UKPDS, and INSIGHT trials found little overall difference in outcomes between older (such as diuretics and beta blockers) and newer antihypertensive drugs (such as ACE inhibitors and calcium channel blockers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/3,8\">",
"     3,8",
"    </a>",
"    ], and the CAMELOT trial found no significant difference in outcomes with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    , two newer antihypertensive drug classes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar conclusions have been reached in the subgroup of patients at increased cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link&amp;anchor=H21#H21\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'High cardiovascular risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When differences in outcomes have been noted in trials comparing different antihypertensive drugs, the drug producing better outcomes had better blood pressure control. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ASCOT trial found a lower rate of cardiovascular disease and death with a calcium channel blocker (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      ) compared with a beta blocker (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      ). However, patients in the amlodipine arm had a significantly lower mean blood pressure at the end of the study",
"      <span class=\"nowrap\">",
"       (3/2",
"      </span>",
"      mmHg) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       Ramipril",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/32/22024?source=see_link\">",
"       perindopril",
"      </a>",
"      produced better outcomes than placebo in the HOPE and EUROPA trials of patients at increased cardiovascular risk, but the blood pressure was significantly lower in the treated patients:",
"      <span class=\"nowrap\">",
"       3.3/1.4",
"      </span>",
"      mmHg (with a greater difference overnight) in HOPE and",
"      <span class=\"nowrap\">",
"       5/2",
"      </span>",
"      mmHg in EUROPA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the VALUE trial of over 15,000 patients who had either prior atherosclerotic cardiovascular disease or at least one cardiovascular risk factor,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      produced better outcomes than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/4/31815?source=see_link\">",
"       valsartan",
"      </a>",
"      but also greater blood pressure reduction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/13\">",
"       13",
"      </a>",
"      ]. When 5000 pairs were matched exactly for systolic blood pressure and other risk factors, the two groups had nearly identical rates of cardiovascular events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible exceptions to these general findings were thought to come from the ALLHAT trial of monotherapy and from the ACCOMPLISH trial of combination therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     ALLHAT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ALLHAT trial randomly assigned over 41,000 hypertensive patients (mean blood pressure",
"    <span class=\"nowrap\">",
"     146/84",
"    </span>",
"    mmHg) with at least one other coronary risk factor to one of four initial regimens:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    (12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    ; the doxazosin arm was prematurely terminated due to an increased risk of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/15\">",
"     15",
"    </a>",
"    ]. At a mean follow-up of 4.9 years, the primary outcome (fatal coronary heart disease or nonfatal myocardial infarction) was the same in the three arms (",
"    <a class=\"graphic graphic_figure graphicRef82432 \" href=\"mobipreview.htm?6/63/7166\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the chlorthalidone arm had a significantly lower rate of heart failure than amlodipine and lisinopril (",
"    <a class=\"graphic graphic_figure graphicRef68780 \" href=\"mobipreview.htm?39/59/40893\">",
"     figure 4",
"    </a>",
"    ) and a significantly lower rate of combined cardiovascular disease outcomes than lisinopril (",
"    <a class=\"graphic graphic_figure graphicRef61612 \" href=\"mobipreview.htm?39/18/40237\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link&amp;anchor=H9#H9\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ALLHAT trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It seems likely that the benefits seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    were due at least in part to an earlier and greater degree of blood pressure reduction, similar to the findings with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    in the VALUE trial described in the preceding section [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/14\">",
"     14",
"    </a>",
"    ]. Chlorthalidone was associated with a small but significantly lower systolic pressure over the course of the study than amlodipine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    (133.9 versus 134.7 and 135.9 mmHg, respectively) and a higher proportion of patients who attained the blood pressure goal of less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg (68.2 versus 66.3 and 61.2 percent, respectively). The difference in mean systolic blood pressure was most pronounced in the first two years (136.4 versus 137.8 and 139.2 mmHg, respectively).",
"   </p>",
"   <p>",
"    Twenty-four-hour blood pressure monitoring was not obtained in ALLHAT, which may have been important, since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    is long-acting, while the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    may diminish toward the end of the day, especially at doses of 10",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    The findings in ALLHAT led the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), which was published in 2003, and others to conclude that low-dose thiazides (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    at 12.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    should be used in the initial drug treatment of most patients with uncomplicated hypertension, unless there is a specific indication for a drug from another class (",
"    <a class=\"graphic graphic_table graphicRef63628 \" href=\"mobipreview.htm?10/53/11101\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Indications for specific drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One cannot exclude the possibility that the observed benefits with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    in ALLHAT were due at least in part to the lower attained blood pressure, which is in keeping with the findings in other trials cited in the preceding section.",
"   </p>",
"   <p>",
"    Looking at the data in another way, there was no difference in the primary end point among the three treated groups (",
"    <a class=\"graphic graphic_figure graphicRef82432 \" href=\"mobipreview.htm?6/63/7166\">",
"     figure 3",
"    </a>",
"    ), despite the lower attained blood pressure with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    . This raises the possibility that thiazide diuretics may actually be associated with worse outcomes at the same attained blood pressure. Although this may seem to represent manipulation of the data, it is an important consideration given the findings in the ACCOMPLISH trial in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    was associated with worse cardiovascular outcomes than benazepril plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    , despite a trend toward lower 24-hour average blood pressure in the benazepril plus hydrochlorothiazide group. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'ACCOMPLISH trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chlorthalidone versus hydrochlorothiazide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     Chlorthalidone",
"    </a>",
"    at the same dose is approximately 1.5 to 2.0 times as potent as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Thus, 12.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of chlorthalidone is equivalent to 19 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of hydrochlorothiazide. This may not be so important for efficacy since the dose-response curve for thiazide diuretics in the treatment of primary hypertension (formerly called essential hypertension) is relatively flat (",
"    <a class=\"graphic graphic_figure graphicRef61248 \" href=\"mobipreview.htm?18/24/18829\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/2,22,23\">",
"     2,22,23",
"    </a>",
"    ]. However, metabolic complications, such as hypokalemia, glucose intolerance, and hyperuricemia increase with dose (",
"    <a class=\"graphic graphic_figure graphicRef69912 \" href=\"mobipreview.htm?37/49/38685\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/2,22,23\">",
"     2,22,23",
"    </a>",
"    ]. In two major trials of low-dose chlorthalidone (12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    treatment for hypokalemia was required in 7 to 8 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/15,24\">",
"     15,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15350?source=see_link\">",
"     \"Use of thiazide diuretics in patients with primary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=see_link&amp;anchor=H27627359#H27627359\">",
"     \"Causes of hypokalemia\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possibly more important difference than potency is the longer duration of action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    (24 to 72 hours versus 6 to 12 hours with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. This may not affect office blood pressure if the medication is taken in the morning but may result in a greater fall in nighttime blood pressure with chlorthalidone compared to baseline (eg, -13.5 mmHg with 12.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [force titrated to 25",
"    <span class=\"nowrap\">",
"     mg/day]",
"    </span>",
"    versus -6.4 mmHg with 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [force titrated to 50",
"    <span class=\"nowrap\">",
"     mg/day]",
"    </span>",
"    of hydrochlorothiazide in a small randomized, crossover trial) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lesser efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    throughout the day was also demonstrated in a study in which 24-hour ambulatory monitoring was performed in 228 patients with primary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/25\">",
"     25",
"    </a>",
"    ]. The mean fall in blood pressure with ambulatory monitoring after four weeks of therapy with hydrochlorothiazide 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was significantly greater with office blood pressures compared with 24-hour ambulatory measurements (14.3 versus 9.5 mmHg).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24743126\">",
"    <span class=\"h3\">",
"     Efficacy in preventing cardiovascular events",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that directly compare outcomes in hypertensive patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    . In the absence of such head-to-head trials, a multiple treatment (network) meta-analysis of nine trials including 50,946 patients was conducted in which hydrochlorothiazide and chlorthalidone were indirectly compared by evaluating their efficacy against common comparator drugs (eg, ACE inhibitors were compared with hydrochlorothiazide in ANBP2 and with chlorthalidone in ALLHAT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/26\">",
"     26",
"    </a>",
"    ]. The major findings of this meta-analysis were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      significantly reduced the risk of cardiovascular events (relative risk 0.79, 95% CI 0.72 to 0.88) and heart failure (relative risk 0.77, 95% CI 0.61 to 0.98). The authors calculated that 27 patients would need to be treated with chlorthalidone instead of hydrochlorothiazide over five years to prevent one cardiovascular event.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       Chlorthalidone",
"      </a>",
"      remained superior to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      even after the meta-analysis was controlled for achieved office systolic blood pressure (relative risk for cardiovascular events 0.82, 95% CI 0.70 to 0.97). This finding may reflect the longer duration of action and lower nocturnal blood pressure associated with chlorthalidone described above, or to other effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of this meta-analysis are consistent with observational data from the Multiple Risk Factor Intervention Trial (MRFIT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/27\">",
"     27",
"    </a>",
"    ]. Among hypertensive men in MRFIT, 2392 were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    and 4049 were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    . During six years of follow-up, cardiovascular events (defined as myocardial infarction, stroke, coronary artery bypass surgery, heart failure, left ventricular hypertrophy, peripheral artery disease, or angina) were significantly less common with chlorthalidone compared with hydrochlorothiazide (hazard ratio 0.79, 95% CI 0.68 to 0.92). Through the course of the study, systolic blood pressure and LDL cholesterol levels were also lower with chlorthalidone compared with hydrochlorothiazide.",
"   </p>",
"   <p>",
"    In contrast, another observational study performed among 29,873 older adults (66 years and older) found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    was not associated with a reduced risk of death or cardiovascular hospitalization (hazard ratio 0.93, 95% CI 0.81 to 1.06) compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , but was associated with an increased risk of hospitalization for hypokalemia (hazard ratio 3.06, 95% CI 2.04 to 4.58) and hyponatremia (hazard ratio 1.68, 95% CI 1.24 to 2.28) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/28\">",
"     28",
"    </a>",
"    ]. Nevertheless, the trial evidence supporting the efficacy of low-dose thiazide diuretics in the management of hypertension comes primarily from those using chlorthalidone, such as ALLHAT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/15\">",
"     15",
"    </a>",
"    ]. There is little if any trial evidence that hydrochlorothiazide alone in a dose of 12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    reduces cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], and the blood pressure may not be as well controlled overnight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/19,32\">",
"     19,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Choice of thiazide diuretic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above observations, we and other experts suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    (12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is the thiazide diuretic of choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/20,29-31,33\">",
"     20,29-31,33",
"    </a>",
"    ]. However, the choice may vary with the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most patients not previously treated with a thiazide diuretic, we suggest 12.5 to 25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      , rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      . However, among frail older patients who are less than 10 mmHg above goal blood pressure, some consider low-dose hydrochlorothiazide a reasonable alternative.",
"     </li>",
"     <li>",
"      Among patients already treated with low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      , the optimal approach has not been defined. Some experts would switch all patients to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      at their next visit, with the possible exception of those who monitor their blood pressure at home and have values below goal on the first morning measurement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Monitoring for hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     Chlorthalidone",
"    </a>",
"    produced hypokalemia requiring therapy in 7 to 8 percent of patients in large clinical trials including ALLHAT and SHEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/15,24\">",
"     15,24",
"    </a>",
"    ]. It is possible that hypokalemia is more common with chlorthalidone than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/21\">",
"     21",
"    </a>",
"    ], given its longer duration of action. Concurrent use of a low salt diet will both contribute to blood pressure lowering and reduce the risk of hypokalemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=see_link&amp;anchor=H27627359#H27627359\">",
"     \"Causes of hypokalemia\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring for the development of hypokalemia is warranted with all thiazide diuretics. In stable patients on a fixed dose of either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , potassium loss, like other diuretic-induced fluid and electrolyte complications, occurs only during the first two weeks of therapy before a new steady state is established (",
"    <a class=\"graphic graphic_figure graphicRef74940 \" href=\"mobipreview.htm?15/33/15901\">",
"     figure 8",
"    </a>",
"    ). Thus, a stable patient with a normal serum potassium concentration at three weeks is not at risk of late hypokalemia unless the diuretic dose is increased, extrarenal potassium losses increase, or dietary potassium intake is reduced. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11018?source=see_link&amp;anchor=H838162389#H838162389\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'The steady state'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6868?source=see_link\">",
"     \"Time course of loop and thiazide diuretic-induced electrolyte complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Issues with chlorthalidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recognize that most clinicians, particularly in the United States, have limited, if any, experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    . The basic principles of monitoring for hypokalemia with chlorthalidone are identical to those with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , as described in the preceding section.",
"   </p>",
"   <p>",
"    There are three other potential limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is not available in all formularies and pharmacies.",
"     </li>",
"     <li>",
"      There is no 12.5 mg tablet. Thus, 25 mg tablets of generic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      need to be cut in half. There is a more expensive 15 mg brand name preparation (Thalitone&reg;). This preparation has greater bioavailability than generic chlorthalidone, and clinical studies suggest that its antihypertensive efficacy is closer to 25 mg of generic chlorthalidone.",
"     </li>",
"     <li>",
"      In patients who require combination therapy, fixed dose combination pills of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      with ACE inhibitors, angiotensin II receptor blockers, and long-acting calcium channel blockers are not available (in contrast to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Combination therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     ACCOMPLISH trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only one major trial, ACCOMPLISH, directly compared different combination regimens in hypertensive patients who require two drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/36\">",
"     36",
"    </a>",
"    ]. The results of ACCOMPLISH are discussed in detail elsewhere but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link&amp;anchor=H17#H17\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ACCOMPLISH trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ACCOMPLISH trial included 11,506 patients with hypertension who were at high risk for a cardiovascular event and, despite prior antihypertensive therapy in 97 percent (most requiring two or more drugs), had a mean baseline blood pressure of",
"    <span class=\"nowrap\">",
"     145/80",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/37\">",
"     37",
"    </a>",
"    ]. The patients were randomly assigned to initial combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    (12.5",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Benazepril was increased to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in both groups at one month. If goal blood pressure was not attained, the amlodipine dose was increased to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and the hydrochlorothiazide dose to 25",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    The primary end point was measured as the time to the first event, which was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac death or coronary revascularization. The trial was terminated early upon recommendation of the Data Safety Monitoring Board at a mean follow-up of 36 months when a substantial disadvantage associated with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    arm was noted and the prespecified stopping rule was exceeded.",
"   </p>",
"   <p>",
"    The primary end point was achieved significantly less often in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    group (9.6 versus 11.8 percent, hazard ratio 0.80, 95% CI 0.72-0.90). However, in a prespecified, post-hoc analysis, the superiority of amlodipine-based therapy was most pronounced in nonobese individuals; both combinations produced similar outcomes among obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     Benazepril",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    therapy led to a similar reduction in the secondary end point of cardiovascular death or nonfatal myocardial infarction or stroke (5.0 versus 6.3 percent, hazard ratio 0.79). These benefits increased progressively over the duration of the trial. The development of chronic kidney disease (mostly defined as doubling of the serum creatinine) was also less common with benazepril-amlodipine (2.0 versus 3.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean office blood pressure was slightly (about 1 mmHg) but significantly lower in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    group",
"    <span class=\"nowrap\">",
"     (131.6/73.3",
"    </span>",
"    compared to",
"    <span class=\"nowrap\">",
"     132.5/74.4",
"    </span>",
"    mmHg). However, in contrast to all other major randomized trials that compared the outcomes with different antihypertensive drugs, ACCOMPLISH included 24-hour blood pressure monitoring in a subset of 573 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/40\">",
"     40",
"    </a>",
"    ]. The 24-hour average blood pressure was nonsignificantly higher",
"    <span class=\"nowrap\">",
"     (1.6/0.3",
"    </span>",
"    mmHg) in the benazepril-amlodipine group. Similar trends were noted with daytime and nighttime average blood pressures.",
"   </p>",
"   <p>",
"    Thus, the clinical benefits with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    combination cannot be explained by better blood pressure control. The difference in outcome can be explained in one or both of two ways: there is a beneficial effect of benazepril-amlodipine or an adverse effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19767?source=see_link\">",
"     benazepril-hydrochlorothiazide",
"    </a>",
"    . There is no way to distinguish between these possibilities. In addition, it is not known if amlodipine plus benazepril is associated with better outcomes than other combinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Implications for practice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACCOMPLISH trial was large, well designed, and without apparent flaws. In addition, it compared combination regimens using the three classes of antihypertensive drugs that are preferred for initial monotherapy in the absence of a specific indication for a particular drug class. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Initial monotherapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Indications for specific drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some have suggested that confirmatory trials are required before practice recommendations are changed. However, such information is unlikely to be available for many years.",
"   </p>",
"   <p>",
"    We and our peer reviewers feel that the results of ACCOMPLISH should not be ignored and that they raise the following questions about the use of a long-acting ACE",
"    <span class=\"nowrap\">",
"     inhibitor/ARB",
"    </span>",
"    and a long-acting dihydropyridine calcium channel blocker",
"    <span class=\"nowrap\">",
"     (A/dC):",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the",
"      <span class=\"nowrap\">",
"       A/dC",
"      </span>",
"      combination the preferred regimen in previously untreated patients who require two drugs because they are more than",
"      <span class=\"nowrap\">",
"       20/10",
"      </span>",
"      mmHg above goal?",
"     </li>",
"     <li>",
"      Should patients being treated with the combination of an ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      and a thiazide diuretic who are at goal and doing well be switched to",
"      <span class=\"nowrap\">",
"       A/dC?",
"      </span>",
"      Approximately 75 percent of patients in ACCOMPLISH had previously been treated with two or more antihypertensive drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients being treated with and having responded to a thiazide diuretic who require a second antihypertensive drug, should the thiazide be discontinued and the patient started on",
"      <span class=\"nowrap\">",
"       A/dC?",
"      </span>",
"     </li>",
"     <li>",
"      Does ACCOMPLISH affect the choice of monotherapy, with a long-acting ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      or a long-acting dihydropyridine calcium channel blocker being preferred so that the second class can be added if the patient responds but does not reach goal with the initial drug?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues will be discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Combination therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H28\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INITIAL MONOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of antihypertensive therapy in most patients below the age of 80 years with uncomplicated combined systolic and diastolic hypertension is a blood pressure of less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg. There is evidence supporting lower goals in patients with atherosclerotic cardiovascular disease, diabetes mellitus, and proteinuric chronic kidney disease. The supportive data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with isolated systolic hypertension, the goal systolic pressure is less than 140 mmHg, but many authorities recommend not to reduce the diastolic blood pressure below certain levels to attain the target systolic pressure. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial monotherapy is successful in most patients with mild primary (formerly called essential) hypertension. However, single drug therapy is unlikely to attain goal blood pressure in patients whose blood pressures are more than",
"    <span class=\"nowrap\">",
"     20/10",
"    </span>",
"    mmHg above goal. In such patients, initial combination therapy using two drugs is recommended. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'First-line combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the antihypertensive agents is roughly equally effective in lowering the blood pressure, producing a good antihypertensive response in 30 to 50 percent of patients (",
"    <a class=\"graphic graphic_figure graphicRef77960 \" href=\"mobipreview.htm?2/36/2638\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65117 \" href=\"mobipreview.htm?37/22/38253\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. There is, however, wide interpatient variability as many patients will respond well to one drug but not to another. There are some predictable differences, such as black patients generally responding better to monotherapy with a thiazide diuretic or calcium channel blocker and relatively poorly to an ACE inhibitor or beta blocker (",
"    <a class=\"graphic graphic_figure graphicRef65117 \" href=\"mobipreview.htm?37/22/38253\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Monotherapy based upon age and race'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to these general observations, the following findings were noted in a 2009 meta-analysis of randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defining the standard dose of a class of drugs as the usual maintenance dose in reference pharmacopoeias, the largest reduction in blood pressure was seen at a half standard dose with only modestly greater reductions in systolic and diastolic blood pressures at standard or twice standard doses. As examples, the average fall in systolic blood pressure over 24 hours with half standard, standard, and twice standard doses was 7.1, 9.1, and 10.9 mmHg with data from all classes combined and 7.4, 8.8, and 10.3 mmHg with a thiazide diuretic. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Drug dosing and drug frequency'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      With thiazide diuretics, calcium channel blockers, and beta blockers, the rate of symptomatic and metabolic adverse effects increased significantly with standard or twice standard doses compared to half standard doses. Similar findings have been noted in other studies (",
"      <a class=\"graphic graphic_figure graphicRef69912 \" href=\"mobipreview.htm?37/49/38685\">",
"       figure 7",
"      </a>",
"      ). In contrast, there was a very low rate of side effects with ACE inhibitors and ARBs with no dose dependence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, after the initial dose, going to higher doses produced on average relatively small further reductions in blood pressure at the price of an increasing rate of adverse effects. As a result, we generally limit dose titration to one step with a given antihypertensive drug (eg, 12.5 to 25 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    and 5 to 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These observations suggest that two or even three drugs at half standard doses might have greater antihypertensive efficacy and less toxicity than one drug at standard or twice standard doses and might produce better patient outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/2\">",
"     2",
"    </a>",
"    ]. Randomized trials to validate this hypothesis have not been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have an indication for a specific drug or drugs that is unrelated to primary (formerly called essential) hypertension (eg, a nondihydropyridine calcium channel blocker or beta blocker for rate control in patients with atrial fibrillation). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Indications for specific drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the absence of a specific indication, there are three main classes of drugs that have been used for initial monotherapy: thiazide diuretics, long-acting calcium channel blockers (most often a dihydropyridine), and ACE inhibitors or angiotensin II receptor blockers (ARBs). Each of these classes of drugs has been equally effective in monotherapy trials if the attained blood pressure is similar. Beta blockers are NOT commonly used for initial monotherapy in the absence of a specific indication, since they may have an adverse effect on some cardiovascular outcomes, particularly in older patients. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Indications for specific drugs'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3\">",
"     'Importance of attained blood pressure'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Beta blockers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among patients in whom there is a reasonable likelihood of requiring a second drug (eg, more than",
"    <span class=\"nowrap\">",
"     10/5",
"    </span>",
"    mmHg above goal), some physicians who practice according to the results of the ACCOMPLISH trial prefer initial therapy with a long-acting ACE",
"    <span class=\"nowrap\">",
"     inhibitor/ARB",
"    </span>",
"    or a long-acting dihydropyridine calcium channel blocker, since the second class can be added if additional therapy is required to achieve the desired combination regimen. As described in the next section, the choice between these drug classes may be influenced by age and race. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'ACCOMPLISH trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This is a change from the current practice of many physicians. Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    (12.5 to a maximum of 25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is widely used and, after publication of the ALLHAT trial, was recommended as initial monotherapy in most patients with mild primary hypertension by JNC 7 and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, hydrochlorothiazide appears to be less effective and has a shorter duration of action than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    , and there is little, if any, evidence that low-dose hydrochlorothiazide alone reduces cardiovascular events as opposed to the evidence with chlorthalidone. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Chlorthalidone versus hydrochlorothiazide'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, when a thiazide diuretic is used, we and others suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    (12.5 to a maximum of 25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], which produced the best outcomes in ALLHAT, not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    at the same doses. Chlorthalidone is probably associated with somewhat greater risks of hypokalemia, glucose intolerance, and new onset diabetes mellitus than hydrochlorothiazide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Monotherapy based upon age and race",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of a good response is increased when two simple clinical characteristics, age and race, are utilized to determine drug treatment. The following patients respond best to different types of antihypertensive agents used as monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Younger patients respond best to angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor blockers (ARBs) and beta blockers. However, beta blockers are",
"      <strong>",
"       not",
"      </strong>",
"      commonly used for initial monotherapy in the absence of a specific indication because they appear to provide inferior protection against stroke risk. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Beta blockers'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Support for this differential antihypertensive response in younger patients is supported by a study of 56 young (22 to 51 years) white hypertensive patients who were treated in a crossover rotation with the four main classes of antihypertensive drugs: ACE inhibitor, thiazide diuretic, long-acting dihydropyridine CCB, and beta blocker [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/42\">",
"       42",
"      </a>",
"      ]. Significantly greater responses in both systolic and diastolic blood pressure levels were noted with the ACE inhibitor and beta blocker than with the CCB or diuretic.",
"     </li>",
"     <li>",
"      Black patients (",
"      <a class=\"graphic graphic_figure graphicRef65117 \" href=\"mobipreview.htm?37/22/38253\">",
"       figure 2",
"      </a>",
"      ) and elderly patients often respond best to a thiazide diuretic or long-acting calcium channel blocker [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/5,44\">",
"       5,44",
"      </a>",
"      ]. These different responses may be at least partially related to the baseline plasma renin activity (PRA) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/45\">",
"       45",
"      </a>",
"      ]. Older and black hypertensives usually have lower PRA values than younger and white patients. However, many elderly hypertensive patients have a specific indication for an ACE inhibitor or ARB, including heart failure, prior myocardial infarction, and proteinuric chronic kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/14/15592?source=see_link\">",
"       \"Treatment of hypertension in blacks\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link\">",
"       \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H17\">",
"       'Indications for specific drugs'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sequential monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the recommended first-line agents will normalize the BP in 30 to 50 percent of patients with mild hypertension (",
"    <a class=\"graphic graphic_figure graphicRef77960 \" href=\"mobipreview.htm?2/36/2638\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65117 \" href=\"mobipreview.htm?37/22/38253\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. A patient who is relatively unresponsive to one drug has an almost 50 percent likelihood of becoming normotensive on a second drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, in a patient who has little or no fall in BP after an adequate dose of drug 1, switching to (rather than adding) drug 2 and, if this is ineffective, switching to drug 3 may allow as many as 60 to 80 percent of patients with mild hypertension to initially be controlled with a single agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/42,46\">",
"     42,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no strict guidelines as to how to perform sequential monotherapy. As the dose is increased with most antihypertensive drugs, the antihypertensive response attenuates and side effects become more prominent with the relative exception of ACE inhibitors and ARBs in patients with normal renal function (",
"    <a class=\"graphic graphic_figure graphicRef52852 \" href=\"mobipreview.htm?1/24/1422\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/47\">",
"     47",
"    </a>",
"    ]. As a result, we generally limit dose titration to one step with a given drug (eg, 12.5 to 25 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    and 5 to 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ). Using higher doses may produce a lesser blood pressure response and more toxicity than switching to an initial dose of a second drug. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'General principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This regimen of trying to find the one drug to which the patient is most responsive may minimize side effects, maximize patient compliance, and is as effective as some forms of combination therapy. However, over time, more than one drug will be needed in many patients who are initially controlled. In ALLHAT, for example, the proportion of patients treated with more than one drug increased from 26 to 33 percent at one year to 40 to 43 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Addition of a second drug'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Drug dosing and drug frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although stepped care therapy has emphasized pushing initial therapy, as necessary, to the maximum recommended dose, the steepest part of the dose-response curve is typically seen at lower doses: good responders generally respond to low doses with few side effects, while higher doses produce more side effects often with little further reduction in blood pressure (",
"    <a class=\"graphic graphic_figure graphicRef52852 \" href=\"mobipreview.htm?1/24/1422\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/2,48\">",
"     2,48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'General principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As examples, patients often respond as well to 12.5 or 25 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    (or its equivalent) per day as they do to 50 mg (",
"    <a class=\"graphic graphic_figure graphicRef61248 \" href=\"mobipreview.htm?18/24/18829\">",
"     figure 6",
"    </a>",
"    ), to 50 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    as they do to 100 mg, to 10 to 15 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    as they do to 20 or 40 mg, and to 50 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    as they do to 100 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/22,49-53\">",
"     22,49-53",
"    </a>",
"    ]. In addition to its efficacy, low-dose hydrochlorothiazide is less likely to produce the metabolic abnormalities that are often seen at higher doses (",
"    <a class=\"graphic graphic_figure graphicRef69912 \" href=\"mobipreview.htm?37/49/38685\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15350?source=see_link\">",
"     \"Use of thiazide diuretics in patients with primary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of dose frequency relates to the possible absence of 24-hour efficacy with shorter-acting drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Once daily dosing with such drugs gives a greater peak response, but the BP tends to return toward baseline in the early morning hours, well before the next dose. This is a potential concern, since a greater daily BP load and early morning abrupt elevations in BP can increase cardiovascular risk. Thus, drugs that are longer acting are preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/57\">",
"     57",
"    </a>",
"    ]. Giving one-half the dose twice a day is an alternative that produces a lesser peak effect but a more sustained response; however, patient compliance may be reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/56,58\">",
"     56,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link&amp;anchor=H14#H14\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Influence on therapy of hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Indications for specific drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general recommendations for initial therapy should be amended in patients with specific underlying conditions in whom specific agents might offer particular benefit independent of blood pressure control (",
"    <a class=\"graphic graphic_table graphicRef63628 \" href=\"mobipreview.htm?10/53/11101\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/6,16,59\">",
"     6,16,59",
"    </a>",
"    ]. These indications include the demonstration that ACE inhibitors improve outcomes in a number of high risk settings and that beta blockers improve survival in patients with systolic heart failure or a prior myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/6\">",
"     6",
"    </a>",
"    ]. Further information on specific disorders is available in separate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors are first-line therapy in all patients who have HF or asymptomatic LV dysfunction, in all patients who have had an ST elevation MI, in patients with a non-ST elevation MI who have had an anterior infarct, diabetes, or systolic dysfunction, and in patients with proteinuric chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that ACE inhibitors and ARBs have a cardioprotective effect independent of blood pressure lowering in patients at high risk for a cardiovascular event. However, as mentioned above and described in detail elsewhere, the available evidence suggests that the attained blood pressure, not the drug used, is of primary importance in such patients. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Importance of attained blood pressure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Angiotensin II receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific indications for and efficacy of angiotensin II receptor blockers (ARBs) are similar to those with ACE inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is at least one setting in which ARBs have specific benefit and in which similar trials have not been performed with ACE inhibitors: severe hypertension with ECG evidence of left ventricular hypertrophy in LIFE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/49\">",
"     49",
"    </a>",
"    ]. An ARB can be used instead of an ACE inhibitor in such patients, although it is highly likely that an ACE inhibitor is equally effective. We would not switch such a patient who is already receiving and tolerating an ACE inhibitor to an ARB.",
"   </p>",
"   <p>",
"    An ARB is particularly indicated in patients who do not tolerate ACE inhibitors (mostly because of cough). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/14/19685?source=see_link\">",
"     \"Differences between angiotensin converting enzyme inhibitors and receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Thiazide diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred thiazide diuretic in patients with primary hypertension (formerly called essential hypertension) is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    (12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    since major trials such as ALLHAT have shown benefit with this regimen. There is little, if any, evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    at this dose improves cardiovascular outcomes. Hydrochlorothiazide is both less potent and shorter acting than chlorthalidone. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Chlorthalidone versus hydrochlorothiazide'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Initial monotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    One problem with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    is that there is no 12.5 mg tablet. Thus, 25 mg tablets of generic chlorthalidone need to be cut in half. There is a more expensive 15 mg brand name preparation (Thalitone&reg;). This preparation has greater bioavailability than generic chlorthalidone, and clinical studies suggest that its antihypertensive efficacy is closer to 25 mg of generic chlorthalidone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/60\">",
"     60",
"    </a>",
"    ]. Another problem with chlorthalidone compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    is the current lack of availability of fixed dose combination pills with ACE inhibitors, angiotensin II receptor blockers, and long-acting calcium channel blockers.",
"   </p>",
"   <p>",
"    Diuretics should also be given for volume control in patients with heart failure or chronic kidney disease, with or without nephrotic syndrome; these settings usually require loop diuretics. In addition, an aldosterone antagonist (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) is indicated in patients with HF who have relatively preserved renal function and for the prevention or treatment of hypokalemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no absolute indications for calcium channel blockers in hypertensive patients. Long-acting dihydropyridines are most commonly used. Like beta blockers, the non-dihydropyridine calcium channel blockers (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ) can be given for rate control in patients with atrial fibrillation or for control of angina. Calcium channel blockers also may be preferred in patients with obstructive airways disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2021?source=see_link\">",
"     \"Treatment of hypertension in asthma and COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A beta blocker without intrinsic sympathomimetic activity should be given after an acute myocardial infarction and to stable patients with heart failure or asymptomatic left ventricular dysfunction (beginning with very low doses to minimize the risk and degree of initial worsening of myocardial function). The use of beta blockers in these settings is in addition to the recommendations for ACE inhibitors in these disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta blockers are also given for rate control in patients with atrial fibrillation, for control of angina, and for symptom control in a number of other disorders (",
"    <a class=\"graphic graphic_table graphicRef63628 \" href=\"mobipreview.htm?10/53/11101\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the absence of such indications, we and others (including the 2010 update of the European Society of",
"    <span class=\"nowrap\">",
"     Hypertension/European",
"    </span>",
"    Society of Cardiology guidelines) recommends that beta blockers",
"    <strong>",
"     not",
"    </strong>",
"    be used as first line therapy, particularly in patients over age 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/7,41,61,62\">",
"     7,41,61,62",
"    </a>",
"    ]. Compared to other antihypertensive drugs in the primary treatment of hypertension, beta blockers (not all trials used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ) may be associated with inferior protection against stroke risk (particularly among smokers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/63,64\">",
"     63,64",
"    </a>",
"    ], and perhaps, with atenolol, a small increase in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/65\">",
"     65",
"    </a>",
"    ]. These effects are primarily seen in patients over age 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/64,66,67\">",
"     64,66,67",
"    </a>",
"    ]. Beta blockers are also associated with impaired glucose tolerance and an increased risk of new onset diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/41\">",
"     41",
"    </a>",
"    ], with the exception of vasodilating beta blockers such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/34/32295?source=see_link\">",
"     nebivolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The data supporting these conclusions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link&amp;anchor=H18#H18\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'Beta blockers as initial therapy?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Alpha blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ALLHAT trial cited above included a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    arm that was terminated prematurely because of a significantly increased risk of heart failure compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    (relative risk 2.0 after adjusting for a 3 mmHg higher in-trial systolic pressure with doxazosin) noted during an interim analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/70\">",
"     70",
"    </a>",
"    ] and a higher rate of cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/71\">",
"     71",
"    </a>",
"    ]. Thus, an alpha blocker is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for initial monotherapy, with the possible exception of older men with symptoms of prostatism, particularly if they are not at high cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMBINATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two issues related to combination therapy: use as first-line therapy; and addition of a second drug when the goal blood pressure is not achieved with monotherapy. The following discussion assumes that the patient does not have an indication for the use of specific drugs. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Indications for specific drugs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Recommendations for combination therapy were made in the 2003 JNC 7 report, the 2004 British Hypertension Society guidelines, and the 2010 European Societies of Hypertension and Cardiology guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/16,43,72\">",
"     16,43,72",
"    </a>",
"    ]. However, the guidelines were published well before the ACCOMPLISH trial, which we feel provides the best evidence for combination therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     First-line combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administering two drugs as initial therapy should be considered when the blood pressure is more than",
"    <span class=\"nowrap\">",
"     20/10",
"    </span>",
"    mmHg above goal, as recommended in the JNC 7 report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/16\">",
"     16",
"    </a>",
"    ]. This strategy may increase the likelihood that target blood pressures are achieved in a reasonable time period. Fixed-dose combination preparations are available that may improve patient compliance, blood pressure control, and, if both drugs are given at lower doses, reduce side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/2,47,73-76\">",
"     2,47,73-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supine and standing pressures should be measured prior to the initiation of combination therapy in patients at increased risk for orthostatic (postural) hypotension, such as elderly patients and those with diabetes. Orthostatic hypotension is diagnosed when, within two to five minutes of quiet standing, one or more of the following is present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At least a 20 mmHg fall in systolic pressure",
"     </li>",
"     <li>",
"      At least a 10 mmHg fall in diastolic pressure",
"     </li>",
"     <li>",
"      Symptoms of cerebral hypoperfusion, such as dizziness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/41/12951?source=see_link\">",
"     \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the results of the ACCOMPLISH trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/36\">",
"     36",
"    </a>",
"    ], we recommend the use of a long-acting dihydropyridine calcium channel blocker plus a long-acting ACE",
"    <span class=\"nowrap\">",
"     inhibitor/ARB",
"    </span>",
"    (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    as used in ACCOMPLISH). In addition, in nonobese patients already being treated with and doing well on the combination of a thiazide diuretic and a long-acting angiotensin inhibitor, we suggest replacing the thiazide diuretic with a long-acting dihydropyridine calcium channel blocker. In obese patients, the combination of a thiazide diuretic and a long-acting angiotensin inhibitor can be continued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'ACCOMPLISH trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Addition of a second drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, each of the recommended first line agents will normalize the BP in up to 30 to 50 percent of patients with mild hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/5\">",
"     5",
"    </a>",
"    ]. In the patient who is relatively unresponsive to one drug, sequentially trying different agents may allow 60 to 80 percent of patients with mild hypertension to be initially controlled with a single agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/42,46\">",
"     42,46",
"    </a>",
"    ]. These issues are discussed in detail above. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Initial monotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We generally limit dose titration to one step with a given drug (eg, 12.5 to 25 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    or 5 to 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ). Using higher doses generally produces a lesser blood pressure response and more toxicity than switching to an initial dose of a second drug (",
"    <a class=\"graphic graphic_figure graphicRef52852 \" href=\"mobipreview.htm?1/24/1422\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/5,47,77\">",
"     5,47,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over time, more than one drug will be needed in many patients who are initially controlled. In ALLHAT, for example, the proportion of patients treated with more than one drug increased from 26 to 33 percent at one year to 40 to 43 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the results of the ACCOMPLISH trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/36\">",
"     36",
"    </a>",
"    ], we suggest that combination therapy consist of a long-acting dihydropyridine calcium channel blocker plus a long-acting ACE",
"    <span class=\"nowrap\">",
"     inhibitor/ARB",
"    </span>",
"    (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    ). Thus, if the patient is being treated with one of the drugs, add the other. In patients being treated with a thiazide diuretic, we suggest discontinuing the thiazide and starting combination therapy. Approximately 75 percent of patients in ACCOMPLISH had previously been treated with two or more antihypertensive drugs. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'ACCOMPLISH trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Beta blockers are now used less often as initial therapy except for patients with another indication for their use. The preferred second drugs in patients who are treated with a beta blocker are a thiazide diuretic or a dihydropyridine calcium channel blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/59\">",
"     59",
"    </a>",
"    ]. An alpha blocker would be chosen only if there is another reason for its use, such as symptomatic benign prostatic hyperplasia.",
"   </p>",
"   <p>",
"    An ACE inhibitor or ARB is likely to be less effective in patients treated with a beta blocker, since beta blockers reduce renin secretion and therefore angiotensin II formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/78\">",
"     78",
"    </a>",
"    ], and a beta blocker should be used with caution in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and to a lesser degree",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    . These drugs can potentiate the cardiac depressant effect of the beta blocker, possibly leading to or exacerbating bradycardia or heart block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12238489\">",
"    <span class=\"h1\">",
"     BEDTIME VERSUS MORNING DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average nocturnal blood pressure is approximately 15 percent lower than daytime values. Failure of the blood pressure to fall by at least 10 percent during sleep is called \"nondipping,\" and is a stronger predictor of adverse cardiovascular outcomes than daytime blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link&amp;anchor=H10#H10\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\", section on 'Nocturnal blood pressure and nondippers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shifting at least one antihypertensive medication from the morning to the evening both restores the normal nocturnal blood pressure dip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/79-81\">",
"     79-81",
"    </a>",
"    ], and reduces 24-hour mean blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nocturnal antihypertensive therapy also appears to reduce the incidence of cardiovascular disease, as was demonstrated in an open-label trial of 2156 hypertensive patients who were randomly assigned to take all antihypertensive medications in the morning or to take at least one (non-diuretic) at bedtime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/83\">",
"     83",
"    </a>",
"    ]. At baseline, the two groups had similar mean ambulatory blood pressure",
"    <span class=\"nowrap\">",
"     (131/78",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     130/79",
"    </span>",
"    mmHg) and proportion of nondippers (55 versus 53 percent).",
"   </p>",
"   <p>",
"    The following findings were noted at 5.6 years follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/83\">",
"     83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean ambulatory blood pressure remained similar between the groups and there was no change in nocturnal blood pressure or the proportion of nondippers in patients who continued to take all antihypertensive drugs in the morning. In contrast, patients assigned to take at least one medication at bedtime had significant reductions in both nocturnal blood pressure (from",
"      <span class=\"nowrap\">",
"       123/71",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       111/63",
"      </span>",
"      mmHg) and the proportion of nondippers (from 53 to 34 percent, respectively).",
"     </li>",
"     <li>",
"      Taking at least one medication at bedtime significantly reduced all-cause mortality (1.1 versus 2.6 percent) and the incidence of total cardiovascular events (2.8 versus 6.8 percent) and cardiovascular death (0.3 versus 1.3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar observations have been made in patients with chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H3128354#H3128354\">",
"     \"Overview of hypertension in acute and chronic kidney disease\", section on 'Possible benefit from nocturnal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serious concerns about this trial include its open label design and small number of events. In addition, the effect size (a 67 percent reduction in the relative risk of myocardial infarction, stroke, or cardiovascular death) is considerably larger than the true effects of most rigorously studied interventions. As an example, treating hypertensive patients with antihypertensive medications reduces the relative risk of cardiovascular events by 20 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/1\">",
"     1",
"    </a>",
"    ]. Provided that bedtime dosing does not impair compliance with therapy, there seems to be little downside to taking at least one (non-diuretic) antihypertensive medication at night while awaiting additional data to confirm the clinical benefit of nocturnal therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23828?source=see_link&amp;anchor=H4#H4\">",
"     \"Patient adherence and the treatment of hypertension\", section on 'Treatment characteristics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other trials also employed nocturnal therapy, although they were",
"    <strong>",
"     not",
"    </strong>",
"    specifically designed to compare bedtime versus morning dosing of antihypertensive therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the HOPE and EUROPA trials, ACE inhibitor therapy given at bedtime reduced the incidence of cardiovascular events as compared with placebo. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H7#H7\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Trials demonstrating benefit'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the CONVINCE trial, sustained release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      (given at bedtime) did",
"      <strong>",
"       not",
"      </strong>",
"      reduce cardiovascular events compared with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      (given in the morning). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link&amp;anchor=H18#H18\">",
"       \"Choice of therapy in essential hypertension: Clinical trials\", section on 'Beta blockers as initial therapy?'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=see_link\">",
"       \"Patient information: Medicines for heart failure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"       \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"       \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 American Heart Association statement on the treatment of blood pressure in ischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/6\">",
"     6",
"    </a>",
"    ], the 2010 European Society of",
"    <span class=\"nowrap\">",
"     Hypertension/European",
"    </span>",
"    Society of Cardiology guidelines on the management of hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/7\">",
"     7",
"    </a>",
"    ] and meta-analyses published in 2008 and 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/29/36314/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. All concluded that the amount of blood pressure reduction is the major determinant of reduction in cardiovascular risk in both younger and older patients with hypertension, NOT the choice of antihypertensive drug. This conclusion also applies to patients at increased cardiovascular risk as shown in the ALLHAT, VALUE, and CAMELOT trials. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Importance of attained blood pressure'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'ALLHAT trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, this may not apply to combination therapy. In the ACCOMPLISH trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    was associated with a 20 percent lower rate of cardiovascular events compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    plus benazepril, despite slightly higher 24-hour blood pressures in the amlodipine arm. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'ACCOMPLISH trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some hypertensive patients have underlying conditions for which specific antihypertensive drugs might offer particular benefit independent of blood pressure control, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , or a beta blocker for rate control in atrial fibrillation. The following recommendations do NOT apply to such patients. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Indications for specific drugs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertensive patients who are less than",
"    <span class=\"nowrap\">",
"     20/10",
"    </span>",
"    mmHg above goal can initially be treated with monotherapy. Among such patients who do not have an indication for a specific drug, the major classes of drugs that have been used for monotherapy are a low dose thiazide diuretic, long-acting angiotensin-converting enzyme (ACE)",
"    <span class=\"nowrap\">",
"     inhibitor/angiotensin",
"    </span>",
"    II receptor blocker (ARBs), or a long-acting dihydropyridine calcium channel blocker.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the preference for an ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      plus a dihydropyridine calcium channel blocker in patients requiring combination therapy, we suggest use of one of these drug classes as initial therapy so that the other can be added, if necessary (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If this approach is chosen, an ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      may be more effective in younger patients, and a dihydropyridine calcium channel blocker may be more effective in elderly and black patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial monotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Monotherapy based upon age and race'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a thiazide-type diuretic is chosen, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Most clinicians, particularly in the United States, have limited, if any, experience with chlorthalidone, which may be somewhat more likely to induce hypokalemia than hydrochlorothiazide at the same dose. The basic principles of monitoring for hypokalemia with chlorthalidone are identical to those with hydrochlorothiazide. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Choice of thiazide diuretic'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Issues with chlorthalidone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Monitoring for hypokalemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients who have a minimal or no response to the initial antihypertensive drug be treated with sequential monotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Sequential monotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients who have an initial blood pressure more than",
"      <span class=\"nowrap\">",
"       20/10",
"      </span>",
"      mmHg above goal, we recommend therapy with the combination of a long-acting ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      plus a long-acting dihydropyridine calcium channel blocker (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/19/16696?source=see_link\">",
"       benazepril",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      was used in the ACCOMPLISH trial) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'ACCOMPLISH trial'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'First-line combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among nonobese patients who are already being treated with an ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      plus a thiazide diuretic and have attained goal blood pressure, we suggest stopping the thiazide and switching to a long-acting dihydropyridine calcium channel blocker (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Among obese patients, the combination of an ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      plus a thiazide diuretic can be continued. We suggest continuing therapy in patients who are well controlled on combinations other than an ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      plus a thiazide (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among patients being treated with a thiazide diuretic as monotherapy who have responded but have not attained goal blood pressure, we suggest stopping the thiazide and switching to a long-acting ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      plus a long-acting dihydropyridine calcium channel blocker (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12238705\">",
"    <span class=\"h2\">",
"     Bedtime versus morning dosing",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who require antihypertensive therapy, we suggest that at least one medication (but not a diuretic) be taken at bedtime rather than taking all medications in the morning (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12238489\">",
"       'Bedtime versus morning dosing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/1\">",
"      Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/2\">",
"      Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/3\">",
"      Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/4\">",
"      Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/5\">",
"      Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/6\">",
"      Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/7\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/8\">",
"      Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/9\">",
"      Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/10\">",
"      Dahl&ouml;f B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/11\">",
"      Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/12\">",
"      Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/13\">",
"      Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/14\">",
"      Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/15\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/16\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/17\">",
"      Appel LJ. The verdict from ALLHAT--thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002; 288:3039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/18\">",
"      Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/19\">",
"      Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/20\">",
"      Sica DA. Chlorthalidone: has it always been the best thiazide-type diuretic? Hypertension 2006; 47:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/21\">",
"      Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/22\">",
"      Carlsen JE, K&oslash;ber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/23\">",
"      Flack JM, Cushman WC. Evidence for the efficacy of low-dose diuretic monotherapy. Am J Med 1996; 101:53S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/24\">",
"      Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/25\">",
"      Finkielman JD, Schwartz GL, Chapman AB, et al. Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens 2005; 18:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/26\">",
"      Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012; 59:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/27\">",
"      Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/28\">",
"      Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med 2013; 158:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/29\">",
"      Messerli FH, Bangalore S. Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark? Circulation 2009; 119:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/30\">",
"      Ernst ME, Carter BL, Basile JN. All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective. J Clin Hypertens (Greenwich) 2009; 11:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/31\">",
"      A diuretic for initial treatment of hypertension. Med Lett Drugs Ther 2009; 51:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/32\">",
"      Lacourci&egrave;re Y, Poirier L, Lefebvre J, et al. Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension. Am J Hypertens 1995; 8:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/33\">",
"      Kaplan NM. The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide. Hypertension 2009; 54:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/34\">",
"      Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med 1981; 141:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/35\">",
"      Langford HG, Schlundt D, Levine K. Sodium restriction in hypertension. Compr Ther 1984; 10:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/36\">",
"      Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/37\">",
"      Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004; 17:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/38\">",
"      Weber MA, Jamerson K, Bakris GL, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013; 381:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/39\">",
"      Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/40\">",
"      Jamerson KA, Devereux R, Bakris GL, et al. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension 2011; 57:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/41\">",
"      Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008; 117:2706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/42\">",
"      Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/43\">",
"      Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/44\">",
"      Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001; 14:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/45\">",
"      Blaufox MD, Lee HB, Davis B, et al. Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. JAMA 1992; 267:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/46\">",
"      Materson BJ, Reda DJ, Preston RA, et al. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1995; 155:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/47\">",
"      Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996; 156:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/48\">",
"      Kaplan NM. The appropriate goals of antihypertensive therapy: neither too much nor too little. Ann Intern Med 1992; 116:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/49\">",
"      Dahl&ouml;f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/50\">",
"      Lindholm LH, Ibsen H, Dahl&ouml;f B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/51\">",
"      Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1984; 144:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/52\">",
"      Salvetti A, Arzilli F. Chronic dose-response curve of enalapril in essential hypertensives. An Italian multicenter study. Am J Hypertens 1989; 2:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/53\">",
"      Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/54\">",
"      Neutel JM, Schnaper H, Cheung DG, et al. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J 1990; 120:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/55\">",
"      Sarafidis P, Bogojevic Z, Basta E, et al. Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich) 2008; 10:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/56\">",
"      Meredith PA, Donnelly R, Elliott HL, et al. Prediction of the antihypertensive response to enalapril. J Hypertens 1990; 8:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/57\">",
"      Eguchi K, Kario K, Hoshide Y, et al. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. Am J Hypertens 2004; 17:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/58\">",
"      Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261:3273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/59\">",
"      European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/60\">",
"      Vardan S, Mehrotra KG, Mookherjee S, et al. Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study. JAMA 1987; 258:484.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (NICE clinical guideline update). Available at: file://www.nice.org.uk. Accessed January 21, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/62\">",
"      Cutler JA, Davis BR. Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation 2008; 117:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/63\">",
"      Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/64\">",
"      Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992; 304:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/65\">",
"      Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/66\">",
"      Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/67\">",
"      Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/68\">",
"      Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/69\">",
"      Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM 2006; 99:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/70\">",
"      Davis BR, Cutler JA, Furberg CD, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med 2002; 137:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/71\">",
"      Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/72\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/73\">",
"      Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/74\">",
"      Brixner DI, Jackson KC 2nd, Sheng X, et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin 2008; 24:2597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/75\">",
"      Brown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011; 377:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/76\">",
"      Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/77\">",
"      Bakris GL. Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals. J Clin Hypertens (Greenwich) 1999; 1:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/78\">",
"      Pickering TG. The use of angiotensin converting enzyme inhibitors in combination with other antihypertensive agents. Am J Hypertens 1991; 4:73S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/79\">",
"      Minutolo R, Gabbai FB, Borrelli S, et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis 2007; 50:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/80\">",
"      Hermida RC, Calvo C, Ayala DE, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol Int 2005; 22:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/81\">",
"      Hermida RC, Ayala DE, Fern&aacute;ndez JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 2008; 51:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/82\">",
"      Zhao P, Xu P, Wan C, Wang Z. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev 2011; :CD004184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/29/36314/abstract/83\">",
"      Hermida RC, Ayala DE, Moj&oacute;n A, Fern&aacute;ndez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010; 27:1629.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3869 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36314=[""].join("\n");
var outline_f35_29_36314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RELATIVE EFFICACY OF ANTIHYPERTENSIVE DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Importance of attained blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ALLHAT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chlorthalidone versus hydrochlorothiazide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24743126\">",
"      - Efficacy in preventing cardiovascular events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Choice of thiazide diuretic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Monitoring for hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Issues with chlorthalidone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ACCOMPLISH trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Implications for practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INITIAL MONOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Monotherapy based upon age and race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sequential monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drug dosing and drug frequency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Indications for specific drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Thiazide diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Alpha blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMBINATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      First-line combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Addition of a second drug",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12238489\">",
"      BEDTIME VERSUS MORNING DOSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12238705\">",
"      Bedtime versus morning dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3869\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3869|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/36/2638\" title=\"figure 1\">",
"      Single drug in whites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/22/38253\" title=\"figure 2\">",
"      Response to antihypertensives in blacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/63/7166\" title=\"figure 3\">",
"      AHT drug and outcome ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/59/40893\" title=\"figure 4\">",
"      AHT drug and HF ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/18/40237\" title=\"figure 5\">",
"      AHT drug and stroke ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/24/18829\" title=\"figure 6\">",
"      Antihypertensive dose-response to thiazide therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/49/38685\" title=\"figure 7\">",
"      Thiazide side effects and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/33/15901\" title=\"figure 8\">",
"      Time course of diuretic action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/24/1422\" title=\"figure 9\">",
"      Dose response curves in HTN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3869|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/53/11101\" title=\"table 1\">",
"      Treatment of HTN by underlying disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=related_link\">",
"      Choice of therapy in essential hypertension: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/14/19685?source=related_link\">",
"      Differences between angiotensin converting enzyme inhibitors and receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23828?source=related_link\">",
"      Patient adherence and the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=related_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/45/6868?source=related_link\">",
"      Time course of loop and thiazide diuretic-induced electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2021?source=related_link\">",
"      Treatment of hypertension in asthma and COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/14/15592?source=related_link\">",
"      Treatment of hypertension in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15350?source=related_link\">",
"      Use of thiazide diuretics in patients with primary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_29_36315="Tests to be considered in patients with selective IgM deficiency";
var content_f35_29_36315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F52719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F52719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Further evaluation of the patient with selective IgM deficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other studies of specific antibody production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isohemagglutinins (antibody to blood group antigens A and B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Response to neoantigens (bacteriophage fX174 or keyhole limpet hemocyanin)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunoglobulin G subclass levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgG 1,2,3 and 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        B and T lymphocyte evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Immunophenotyping of B cells*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        CD19+/CD20+/sIgM+ (immature B cell)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        CD19+/CD20+/sIgM+/sIgD+ (mature B cell)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        CD19+/CD20+/sIgM+/sIgD+/CD27+ (memory B cell)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        In vitro lymphocyte responses*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        B cell proliferation response to SAC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        IgM production by B cells in response to SAC and BCDF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Suppressor activity of B cells specific for IgM",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SAC: staphylococcus aureus cowan strain 1; BCDF: B cell differentiation factor.",
"     <br/>",
"     * May only be available in specialized centers and research laboratories.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36315=[""].join("\n");
var outline_f35_29_36315=null;
var title_f35_29_36316="Rapid sequence intubation induction agents";
var content_f35_29_36316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid sequence intubation induction agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Benefits",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Notes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etomidate",
"       </td>",
"       <td>",
"        Imidazole derivative",
"       </td>",
"       <td>",
"        Excellent sedation with little hypotension",
"       </td>",
"       <td>",
"        Known to suppress adrenal cortisol production",
"       </td>",
"       <td>",
"        Use cautiously if patient has sepsis; initial dose of glucocorticoid may be needed",
"       </td>",
"       <td>",
"        0.3 mg/kg",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Ketamine",
"       </td>",
"       <td>",
"        Phencyclidine derivative, dissociative anesthetic",
"       </td>",
"       <td>",
"        <p>",
"         Stimulates catecholamine release",
"        </p>",
"        <p>",
"         Bronchodilation",
"        </p>",
"       </td>",
"       <td>",
"        Use in patients with elevated ICP or elevated blood pressure is controversial",
"       </td>",
"       <td>",
"        May be an excellent induction agent for patients with bronchospasm, septic shock,",
"        <strong>",
"         AND",
"        </strong>",
"        hemodynamic compromise",
"       </td>",
"       <td>",
"        1 to 2 mg/kg",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Midazolam",
"       </td>",
"       <td>",
"        Benzodiazepines",
"       </td>",
"       <td>",
"        Potent dose-related amnesic properties",
"       </td>",
"       <td>",
"        Dose-related myocardial depression can result in hypotension",
"       </td>",
"       <td>",
"        Frequently underdosed",
"       </td>",
"       <td>",
"        0.2 to 0.3 mg/kg",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Propofol",
"       </td>",
"       <td rowspan=\"2\">",
"        Alkylphenol derivative",
"       </td>",
"       <td rowspan=\"2\">",
"        Bronchodilation",
"       </td>",
"       <td>",
"        No absolute contraindications",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        1.5 to 3 mg/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dose-related hypotension",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Thiopental sodium",
"       </td>",
"       <td rowspan=\"3\">",
"        Ultrashort-acting barbiturate",
"       </td>",
"       <td rowspan=\"3\">",
"        Cerebroprotective and anti-convulsive properties",
"       </td>",
"       <td>",
"        Potent venodilator and myocardial depressant; can cause hypotension",
"       </td>",
"       <td rowspan=\"3\">",
"        May not be commercially available",
"       </td>",
"       <td rowspan=\"3\">",
"        3 to 5 mg/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relatively contraindicated in reactive airway disease due to histamine release",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute intermittent and variegate porphyrias",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Methohexital",
"       </td>",
"       <td>",
"        Barbiturate",
"       </td>",
"       <td>",
"        Cerebroprotective",
"       </td>",
"       <td>",
"        Acute intermittent and variegate porphyrias",
"       </td>",
"       <td>",
"        Rarely used",
"       </td>",
"       <td>",
"        1 to 3 mg/kg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36316=[""].join("\n");
var outline_f35_29_36316=null;
var title_f35_29_36317="Contents: Acne and rosacea";
var content_f35_29_36317=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?2/59/3006\">",
"       Dermatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Acne and rosacea",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Acne and rosacea",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acne",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/35/44599\">",
"           Hormonal therapy for women with acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/54/33639\">",
"           Light-based, adjunctive, and other therapies for acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/42/22184\">",
"           Oral isotretinoin therapy for acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/20/6474\">",
"           Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/9/44183\">",
"           Postadolescent acne in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/28/39370\">",
"           Treatment of acne vulgaris",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Perioral dermatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/55/9081\">",
"           Perioral (periorificial) dermatitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rosacea",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/24/29066\">",
"           Management of rosacea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/60/34761\">",
"           Ocular rosacea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/46/36584\">",
"           Rosacea: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-6022E1B79A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_29_36317=[""].join("\n");
var outline_f35_29_36317=null;
var title_f35_29_36318="Ascending aorta in Kawasaki disease";
var content_f35_29_36318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/65317/asaogkaw_conv.mp4?title=Ascending+aorta+in+Kawasaki+disease\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coronary artery aneurysms in Kawasaki's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The aortogram in a left anterior oblique projection shows large aneurysms of both the left and right coronary arteries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36318=[""].join("\n");
var outline_f35_29_36318=null;
var title_f35_29_36319="Diabetic foot ulcer 2 PI";
var content_f35_29_36319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F64087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F64087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wagner grade 2 ulcer and claw toe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Foot from a diabetic patient with a penetrating neuropathic ulcer that is not associated with abscess formation or bone involvement (Wagner grade 2). The toes have been pulled anteriorly because the anterior tibial muscles are unopposed due to motor neuropathy-induced weakness of the intrinsic foot muscles. This promotes subluxation of the proximal interphalangeal-metatarsal joints, resulting in a claw toe appearance (arrow) and in increased pressure on the metatarsal heads, predisposing to ulcer formation at this site.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David McCulloch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_29_36319=[""].join("\n");
var outline_f35_29_36319=null;
